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With the invention of Sanger sequencing (also known as the first generation of 
sequencing) in 1977, the landscape of the DNA sequencing changed forever [1-3]. 
The Sanger sequencing works by selective incorporation of chain-terminating 
dideoxynucleotides using DNA polymerase during in vitro DNA replication. For 
nearly three decades, Sanger sequencing was the go to method for sequencing [4]. 
One of the biggest application of Sanger sequencing was in the Human Genome 
Project (HGP). For the very first time, the code that makes us human was not a 
secret anymore. Though the HGP was a great success, the time (~13 years), money 
($2.7 billion), and the manpower (numerous researchers and technicians from 20 
institutions across the globe) it required was overwhelming 
[https://www.genome.gov/human-genome-project/Completion-FAQ]. 
The challenges in Sanger sequencing paved the way for next-generation sequencing 
(NGS) and they came into existence with the onset of the twenty-first century. NGS 
addressed the limitations of Sanger sequencing such as time and cost, sequencing 
only short pieces of DNA (300-1000 bases), the poor quality of first and last 15 to 
40 bases [5], and the quality degrades for longer sequences. The NGS technologies 
could sequence large fragments, made comparatively fewer errors, were faster and 
cheaper, and could sequence multiple samples in one go. The size of data 
generated by a single run of NGS can range from a few Gbs to thousands of Gbs 
(NovaSeq 6000; output range of 4800 - 6000 Gb) and all of this can be achieved in 
few hours to few days [https://www.illumina.com/systems/sequencing-
platforms/novaseq.html]. The projection for genomics data storage stands at 2–40 
EB/year (1 EB = 1018 bytes or 1 billion gigabytes) by 2025 [6]. 
Besides all the knowledge which was achieved with the commencement of the 
HGP, one important piece of theory, “one gene-one enzyme”, as proposed by 
George Beadle and Edward Tatum in 1941 [7] did not hold true anymore. The 
number of genes in humans was established to be ~20000 while the number of 
proteins was found to be much higher. Uniprot, one of the most popular protein 
database, houses 20,368 manually annotated and 171,915 computationally 
annotated human proteins (assessed on 29/07/2020) [8]. Similarly, Ensembl houses 
249,740 transcripts for human (GRCh38.p13) (assessed on 29/07/2020) [9]. The 






be accredited to alternative splicing, single amino acid polymorphisms (SAPs) 
arising from nonsynonymous single-nucleotide polymorphisms (nsSNPs), and 
posttranslational modifications (PTMs) [10, 11]; as many as 100 different proteins 
can potentially be produced from a single gene. 
The transcriptome comprises of all types of RNA transcripts. The transcriptomic 
landscape goes under tremendous changes owing to different growth phases, 
diseases, lifestyle, environmental factors, etc. The identification and quantification 
of the various types of transcripts can provide specific signatures for diseases and 
treatment. A detailed classification of the transcripts, adapted from Ensembl 
transcript classification 
(https://vega.archive.ensembl.org/info/about/gene_and_transcript_types.html), 
is presented below. 
1. Protein coding: The transcripts that are translated into a functional protein and are 
further classified as follows: 
a. Known protein coding: The transcripts that are 100% identical to a RefSeq NP 
(curated non-redundant sequence database of genomes, transcripts, and proteins) 
[12] or Swiss-Prot entry (manually annotated and reviewed Uniprot entry). 
b. Novel protein coding: The transcripts that share more than 60% length with known 
coding sequence from a RefSeq or Swiss-Prot or have cross-species/family support 
or domain evidence. 
c. Putative protein coding: The transcripts that share less than 60% length with known 
coding sequence from a RefSeq or Swiss-Prot, or have an alternative first or last 
coding exon. 
d. Nonsense mediated decay (NMD): The coding sequence of a transcript carrying a 
premature termination codon (PTC) that finishes more than 50 base pairs (bp) from 
a downstream splice site. The transcripts with PTC are a result of nonsense or 
frameshift mutations in endogenous genes, pseudogenes, or intron retention or 
inclusion of PTC-containing exons from alternative splicing [13-15]. NMD 
transcripts are recognized and subsequently degraded to avoid deleterious effects 
for the organism [16]. 
e. Nonstop decay (NSD): Transcripts that have polyadenylation (polyA) features 
without an in-frame stop codon, i.e. a non-genomic polyA tail attached directly to 
the CDS without 3' untranslated region (UTR). NSD transcripts are formed when 
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transcription aborts abruptly, polyadenylation occurs prematurely, or through 
point mutations that disrupt the stop codon [17]. These transcripts are subject to 
degradation. 
2. Processed transcripts: The transcripts that do not contain an open reading frame 
(ORF) and are further divided into three major categories. 
a. Long non-coding RNA (lncRNA): The transcripts that do not code for proteins and 
have a length of more than 200 nucleotides. They are sub-classified into one of the 
following types: 
i. 3-prime overlapping ncRNA: The transcripts that have di-tag and/or published 
experimental data which strongly support the existence of long non-coding 
transcripts that overlaps the 3' UTR of a protein-coding locus on the same strand. 
ii. Antisense: The transcripts that overlap the genomic span (i.e. exon or introns) of a 
protein-coding locus on the opposite strand. They are complementary to a protein 
coding messenger RNA (mRNA) and are known to play an important role in the 
regulation of gene expression [18]. 
iii. lincRNA (long interspersed ncRNA): The long intervening/intergenic non-coding 
RNAs that do not overlap protein-coding genes. They lack coding potential and may 
not be conserved between species. Some known functions of lincRNA are 
remodeling chromatin and genome architecture, RNA stabilization, and 
transcription regulation, including enhancer-associated activity [19]. 
iv. Retained intron: An alternatively spliced transcript that has an intronic sequence 
relative to other coding variants. 
v. Sense intronic: A long non-coding transcript in introns of a coding gene that does 
not overlap any exons. 
vi. Sense overlapping: A long non-coding transcript that contains a coding gene in its 
intron on the same strand. 
vii. Macro lncRNA: Un-spliced lncRNAs that are several kb in size. They are particularly 
found in imprinted gene clusters and have been shown to silence various cis-genes 
in imprinted gene clusters [20]. 
b. ncRNA (non-coding RNA): A RNA molecule that is not translated into a protein and 






i. miRNA (microRNA): These are small ncRNA with a size of ~22 nucleotides. Their role 
in gene silencing and translational repression by binding to target mRNAs has 
presented them as potential therapeutic targets [21]. Lately, their significance in 
biological processes, development, and progression of various diseases in 
thoroughly investigated [22, 23]. 
ii. piRNA (piwi-interacting RNA): The small ncRNA that binds to the piwi-subfamily 
Argonaute proteins and has a size of 26-31 nucleotides. They are crucial for genome 
defense, and it is achieved by transcriptional and posttranscriptional silencing of 
the transposable elements [24]. 
iii. siRNA (small interfering RNA): They are double-stranded non-coding RNA 
molecules, typically 20-27 base pairs in length. They are also known as short 
interfering RNA or silencing RNA. They are a powerful tool for the regulation of gene 
expression and has been utilized as a therapeutic agent against various diseases 
[25]. It binds to the complementary mRNA and induces mRNA cleavage, hence 
preventing translation [26]. 
iv. snRNA (small nuclear RNA): In eukaryotic cells, small RNA molecules found within 
the splicing speckles and Cajal bodies of the cell nucleus are snRNA. They have an 
average length of ~150 nucleotides. They are always associated with a set of 
specific proteins, and the complexes hence formed are referred to as small nuclear 
ribonucleoproteins (snRNP, pronounced as "snurps"). They are subunits of the 
spliceosome, involved in catalyzing the pre-mRNA splicing [27]. 
v. snoRNA (small nucleolar RNA): The small ncRNA that guides the chemical 
modifications (methylation and pseudouridylation) of other RNAs, such as 
ribosomal RNAs, transfer RNAs, and small nuclear RNAs [28, 29].  
vi. tRNA (transfer RNA): An adaptor molecule composed of RNA, having a length of 76-
90 nucleotides. It acts as the physical link between the mRNA and the amino acid 
sequence of proteins. 
vii. vaultRNA: The short non-coding RNAs, ~100 nucleotides long, that form part of the 
vault ribonucleoprotein complex. They are shown to be involved in 
nucleocytoplasmic transport [30], riboregulation [31], and drug-resistance [32]. 
c. rRNA (ribsosomal RNA): rRNA is a ribozyme that is the primary component of 
ribosomes and carries out protein synthesis. The ribosomes are made of two 
subunits: the large ribosomal subunit (60S) and the small ribosomal subunit (40S). 
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The large subunit consists of three rRNA molecules (5S: 121 nucleotides, 5.8S: 156 
nucleotides, 28S : 5070 nucleotides) and the small subunit is composed of a single 
rRNA molecule (40S) of size 1869 nucleotides [33]. The ribosome binds to both 
mRNA and tRNA to facilitate the translation of codons in the mRNA into amino 
acids. A polysome is formed when a single mRNA molecule is translated 
simultaneously by multiple ribosomes, creating multiple copies of the protein [34]. 
3. Pseudogene: A paralogous gene that has one or more of the further listed 
characteristics: missing promoter, start codon, or introns, frameshift, premature 
stop codon, and partial deletion. Sometimes these entries have an intact coding 
sequence or a truncated ORF, in which case there is other evidence used (for 
example genomic polyA stretches at the 3' end) to classify them as a pseudogene. 
These can be further classified as follows: 
a. Processed pseudogene: Pseudogene that appears to have been produced by the 
integration of a reverse transcribed mRNA into the genome. 
b. Unprocessed pseudogene: Pseudogene that shows evidence of loss of function, but 
has a exon-intron structure. 
c. Polymorphic pseudogene. Pseudogene owing to a single nucleotide polymorphism, 
a deletion, or an insertion polymorphism but in other individuals / haplotypes / 
strains the gene is translated. 
d. Unitary pseudogene: A species-specific unprocessed pseudogene without a parent 
gene, as it has an active orthologue in another species. 
e. IG pseudogene: An inactivated immunoglobulin gene. 
Though the presence of various types of transcripts is well established, the research 
community is primarily focused on studying gene expression. The gene-based 
analyses are an ideal choice to study gene regulation, gene expression, genetic 
networks, gene fusions, and genetic mutations. However, while assessing the 
functional capacity of the biological systems, the gene-based analysis has limited 
applicability due to its capacity to code for several protein coding and non-coding 
transcripts. The gene expression is an ensemble of expression of various transcripts 
that originate from the given gene (Figure 1). If the expression of one transcript is 
decreased and another increased by the same magnitude, the global gene 
expression might seem unperturbed. A gene-expression based study masks the 







Figure 1: Illustration of gene and transcript expression. The contigs obtained from sequencing 
are mapped to the regions corresponding to different transcripts. The summation of these 
contigs give the transcript expression, the contigs that are shared between different 
transcripts are resolved using various techniques. These transcripts can be protein coding or 
non-coding. From the transcript expression, then the gene expression is obtained by the 
accumulation of expression of all transcripts for that gene. 
 
The vast repertoire of transcripts found in almost all living systems can be 
attributed to various transcription start sites (TSS) [35] and alternative splicing (AS) 
[36]. The presence of multiple transcription start sites explain the pervasive 
transcription and may lead to translational differences [35, 37]. Consecutively, a 
large chunk of transcript repertoire is attributed to AS. Through AS, from one pre-
mRNA multiple spliced mature mRNA can be produced. AS functions by inserting 
and deleting important functional domains that are encoded by alternatively 
spliced exons [36]. 
 
Omnipresence of gene-based analyses 
There are multiple reasons why gene expression based analyses in transcriptomics 
studies are preferred, the main arguments being non-exhaustive transcript 
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identification, the unknown function of the transcripts, and the prevalence of gene 
based biological databases and tools.  
The knowledge of the existence of different transcripts is known for long; however, 
there is still a lot to be learned about their structure, functions, and origin. Over the 
last five decades, we have not yet managed to identify and enumerate all 
transcripts for any species, let alone humans. However, with the introduction of 
NGS technologies and advancements in bioinformatics, the discovery of the 
transcripts has gained pace in the last two decades [38, 39]. Large-scale genomics 
and transcriptomics studies have added immense knowledge to our understanding 
of transcripts in recent years. Nearly 250k transcripts in humans have been 
identified so far [9], yet there are more that are still to be found. 
For many protein coding transcripts, the functions and/or ontologies are 
established, however in the case of non-coding transcripts limited or no knowledge 
of their function is available. From transcriptomics data analyses highly perturbed 
transcripts can be identified, however, if they cannot be connected to phenotypes, 
diseases, or molecular dysregulations, conclusions cannot be derived on functional 
changes. The biological databases, most of them, if not all, focus on genes and 
proteins. Due to the over-simplistic notion of “one gene one protein one function”, 
it is more convenient to show the pathways (KEGG [40], Reactome [41] or, BioCyc 
[42]), ontologies (Gene ontology resource [43]), functions (Entrez-gene [44], 
Uniprot [8]), and AOPs (adverse outcome pathways OECD knowledgebase [45]) in 
terms of proteins or genes. Similar is the case with tools that are used to analyze 
transcriptomics data. 
However, through an application programming interface (APIs) and additional on-
web functionality some tools, web applications or databases allow performing 
transcript-based analysis such as Biomart [46], Uniprot. Nevertheless, in all the 
cases, the loss of data is inevitable and the conflicting cases of 1:many and 1:none 
identifier mappings across databases cannot be resolved. Many tools developed for 
gene expression analyses can be used for transcript expression by first converting 
the identifiers (for instance, using Biomart) but it requires some basic programming 
skills. 
Besides APIs and identifier conversions, work has been done to analyze the 
transcript expression data and present the results in the form of the genes by 






to achieve this are: selecting the longest protein coding transcript or APPRIS 
defined principal isoform. APPRIS (short for annotating principal splice isoforms) 
takes into account protein structural and functional features and information from 
cross-species conservation to select the principal isoform for the gene [47]. 
Selecting one transcript from a gene results in overlooking other transcripts from 
the given gene; however, close to 95% of human multi-exon genes undergo 
alternative splicing [48] and may hold important biological signals. Thus, 
emphasizing the importance of analyzing all transcripts rather than selecting one 
representative of the gene. 
With the increase in our knowledge about transcripts, novel methods and tools to 
analyze, and knowledgebase of the transcriptomics data have been developed. 
GRO-seq is a method developed to measure nascent RNA and to study the function 
and mechanism of action of non-coding RNAs [49]. TumorFusions is a database of 
cancer-associated transcript fusions [50]. A novel approach to calculate the 
capacity of a transcript that it exerts in a cell as an enzyme or a protein function 
after being translated [51]. However, multiple new applications have been 
developed around the transcripts and their expression; there is a fundamental 
problem in transcript level expression data analyses. 
 
The limitation with transcript-based analyses 
Certain challenges with the transcript-based analyses have already been discussed 
in the previous section however, there is also a fundamental problem associated 
with analyzing transcript expression data. As already mentioned, one protein 
coding transcript will code for a single type of protein, barring the posttranslational 
modifications. However, different transcripts can code for similar proteins, owing 
to codon degeneracy. While such transcripts have a similar coding sequence (CDS), 
they differ from each other in terms of 3’ or 5’ UTR, introns, and transcription start 
sites [52, 53]. On certain occasions, they may be formed due to premature 
transcription termination [54]. 
 




A careful look at the data from Ensembl highlights that different protein coding 
transcripts from a gene are mapped to the same Uniprot identifier and have high 






































































































































































































transcripts overlap and others did not.  In the case of the gene ZFP64 (Zinc finger 
protein 64) (Figure 2), six protein coding transcripts are mapped to the same 
Uniprot Identifier (Q9NTW7). ZFP64-205 spans over the longest chromosomal 
stretch among the six transcripts, from 51693496 to 51705190. The other five 
transcripts: ZFP64-201, ZFP64-202, ZFP64-203, ZFP64-204, and ZFP64-206, all 
overlap certain regions of the ZFP63 transcript. The ZFP64-206 transcript is mapped 
to a different region on the chromosome than ZFP64-201, ZFP64-202, and ZFP64-
204, however, they are all mapped to the same Uniprot identifier implying that they 
have a similar function(s). Similar trends can be observed across different genes – 
transcripts from different genes mapping to the same Uniprot identifier. Through 
this observation, it can be implied that the transcripts coding for the same/similar 
proteins may originate from the same or different genes. A preliminary analysis of 
the Ensembl and Uniprot identifier mapping revealed that in ~40k instances, two 
or more transcripts originating from the same or different Ensembl genes mapped 
to the same Uniprot identifier. 
Multiple different transcripts are capable enough to code for the same proteins and 
hence they should be analyzed together as one entity rather than considering all 
transcripts individually. To achieve this, identification of transcripts that may code 
for the same/similar proteins has to be done thoroughly. Studying the protein 
structure can help in identifying proteins that have similar functions. Through the 
structure of the proteins, structural and functional domains can be identified, as 
well as various binding sites (major and minor grooves) can be located. Using this 
information, the similarity of the protein functions can be predicted. However, due 
to the scarcity of high-quality protein structure data – PDB lists a total of 48783 
human protein structures, of which only 17.9K with a resolution below 2 Å are 
present [55] and the inefficiency of the in silico approaches to predict the 3D 
structure of proteins correctly [56], limits our ability to compare the protein 3D 
structures. Analyzing amino acid sequences and secondary structures of the 
proteins can be a practical option to provide a function-based comparison. 
The omics, protein sequence, and structural data have accumulated into 
gargantuan amounts of data; resulting in the handling and analysis of the data 
overwhelming. However, the advances in the field of machine learning over the 
past decade have provided great promise. 
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Machine learning and its applications 
Any set of techniques that enable computers to mimic human behavior are termed 
as artificial intelligence (AI) and the specific branch of AI that uses data to train the 
computers to learn and identify the patterns, and infer decisions without (or with 
least) human intervention are termed as machine learning (ML). Interest in 
machine learning has gained attention due to the growing volumes and varieties of 
data, cheaper and more powerful computational processing, and affordable data 
storage. Now it has become possible to create models quickly and automatically 
which can analyze bigger and complex data and produce faster and accurate 
results. 
Primarily machine learning approaches can be divided into two categories: 
supervised and unsupervised. In supervised learning, the patterns are learned from 
the “labeled” data and in case of unsupervised learning from the “unlabeled” data. 
The labeled data has defined categories, for instance, healthy and diseased. To 
generate the models using the supervised algorithms, the knowledge of the 
categories of the data is used. Supervised learning algorithms are further split into 
classification and regression; and unsupervised learning into clustering and 
association, based on the type of tasks they perform. In classification, the given 
data is categorized into predefined groups, e.g. if a drug is toxic or non-toxic. The 
classification can be binary or multiclass depending on the number of categories 
into which the algorithm divides the data. Regression finds application in predicting 
the future value of a variable based on the knowledge that has been acquired from 
data, for instance, given the expression of a gene for time points tn, tn+1, and tn+2; 
the expression of the gene at tn+3 can be predicted. Clustering is similar to 
classification as it also categorizes the data into different categories except that the 
categories are not predefined (unlabeled data). One of the most popular examples 
of clustering in omics data studies is of principal component analysis (PCA) plots. 
PCA tries to find a dimension that can separate the data into various clusters. Lastly, 
the association is used to look for rules to establish relationships amongst various 
variables in unlabeled data, for example, building network graphs from gene or 
transcript expression data. The association helps in discovering new relationships 
between the variables. 
ML algorithms are capable of handling huge amounts of data, limited only by the 
computational power and time. Owing to ML’s ability to handle huge data, learn 






unsupervised algorithms have been applied to a vast array of biomedical data with 
great success. One of the major application has been improvements in the 
underlying processes of drug discovery such as target identification and validation 
[57, 58], and small-molecule design and optimization [58, 59]. In a recent initiative, 
the sensitivity of the drugs was also predicted using ML on a cohort of genomics, 
epigenomics, and proteomics profiling data sets measured in human breast cancer 
cell lines [60]. Moreover, our understanding of the transcriptome landscape is 
attributed to ML’s ability to accurately predict alternative splicing signals [61]. 
Image analyses for abnormal tissue detection, patient stratification, and disease 
diagnosis or prediction has also been done with great accuracy using ML [58]. 
Another major aspect of disease diagnosis where recent novel findings are all 
attributed to the ML algorithm is the identification of biomarkers [62-65]. 
 
Biomarkers 
Biomarkers (short for biological marker) are defined as distinctive and measurable 
biological characteristics that can be used to evaluate normal or pathogenic 
biological processes [66], A biomarker must be accurately measurable by some 
technology and should be reproducible [67]. Many molecules can be used as 
biomarkers, such as nucleic acids (DNA and RNA), proteins, peptides, lipids, 
antibodies, several metabolites, and other small molecules [66, 68, 69]. These 
biomolecules can be detected and quantified using various techniques from the 
tissues and/or bio-fluids. The biomarkers can be classified as predisposition, 
diagnostic, prognostic, and predictive, based on the clinical information they 
provide [69-72] (Figure 3). Though discovery of novel and potent biomarkers has 
gained momentum with the evolution of omics, the discovery of the biomarkers is 
not limited to NGS data. 
For instance, various assays were performed to discover the predisposition 
biomarkers for formaldehyde exposure. Formaldehyde is a carcinogen and its 
exposure is both environmental and occupational. An increased risk for cancer 
development among workers exposed to formaldehyde has been revealed by 
several epidemiological studies [73-75]. It has been shown that there were 
alterations in the percentage of T-cytotoxic lymphocytes, NK cells, and B-
lymphocytes between control and test groups. Moreover, polymorphisms in 
CYP2E1, GSTP1, and FANCA genes were demonstrated to be associated with an 
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increased genetic damage [75]. Similarly, the search for predisposition biomarkers 
in case of developing leukopenia (white blood-cell deficiency) was studied in 
northeast Brazil using Maximum likelihood on data from several assays. It was 
extrapolated that GSTT1 and/or GSTM1 can be used as susceptibility biomarkers 
for leukopenia [76]. 
 
Figure 3: Different types of biomarkers. Four types of biomarkers, based on the type of clinical 
information they provide, namely predisposition, diagnostic, prognostic, and predictive 
biomarkers. 
 
Many less studied genes/proteins, for which the functions might not be known, can 
be projected as potent biomarkers when transcriptomics data is used. As in the case 
of colorectal cancer, the integration of multi-platform transcriptomics data 
together with several ML algorithms allowed the discovery and validation of 
diagnostic biomarkers. While poor disease-free survival was shown with the 
overexpression of TGFBI and S100A2, the down-regulation of NR5A2, SLC4A4, and 
CD177 was linked to the worse overall survival of the patients [77]. In another 
study, several ML algorithms and different feature selection techniques were used 
to predict biomarkers from multi-platform transcriptomics data. Three genes, 
namely, FCN3, CLEC1B, and PRC1 were identified as hepatocellular carcinoma 
prognostic indicators for various types of survival of HCC patients [78]. There are 
also some examples where both, the transcriptomics data and various assays were 
used. One such example is the discovery of novel diagnostic markers, prognostic 






Numerous studies have been conducted in search of novel biomarkers for various 
diseases and conditions using ML algorithms [80-83]. A common feature among all 
these studies is their focus on finding the “gene” biomarkers. However, as 
discussed before, gene expression can be misleading at times, and hence the 
homogeneous transcript expression should be a preferred choice for biomarker 
discovery. Some recent work has highlighted the added advantage of using 
transcripts as biomarkers with respect to increased prediction accuracy. In a study 
to identify novel biomarkers for increased risk to develop metabolic disorders, a set 
of transcript-based biomarkers indicative of a predisposition to metabolic 
syndrome-related alterations were identified in rats models. Among different 
biomarkers found in the study, NPC1 was further validated in humans due to its 
involvement in both lipid and glucose metabolism, as well as insulin sensitivity. 
Decreased NPC1 transcript levels in peripheral blood cells were observed and it was 
projected as a candidate biomarker of increased risk for impaired metabolic health 
in humans [84]. In another study, in an attempt to find better biomarkers to 
measure the effects downstream of FGFR pathway inhibition, four transcripts were 
identified from the genes: DUSP6, ETV5, YPEL2, and EGR1 [85]. It was demonstrated 
that these transcript biomarkers were more robustly modulated by FGFR inhibition 
than some conventional downstream signaling protein biomarkers. 
The identification of biomarkers aid in timely prognosis of deviant behavior of the 
system. However, to investigate probable reasons for the development of the 
diseases, the knowledge of the cohort of binding partners of the perturbed protein 
is pertinent. The binding partners can potentially form protein complexes that may 
be involved in several functions. Once the binding partners and functions are 
identified, the information might allow looking for techniques and approaches to 
manipulate the binding by pharmacological inhibitors to help cure the disease [86]. 
 
Protein complexes – the molecular machinery 
The intracellular environment is crowded and all different types of biomolecules 
come in close physical contact with each other [87, 88]. The frequency, specificity, 
affinity, and duration of these interactions are highly variable [86]; based on these 
factors the complexes can be divided into stable (or permanent) and transient 
complexes (Figure 4). The stable complexes demonstrate assemblies that have a 
long half-life, bigger interaction interface, and the interactions are found in the 
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molar range (M range) [89, 90]. Such complexes have been identified by 
experimental characterization and have well-defined molecular functions. On the 
other hand, transient complexes are short-lived and are usually weak (µM range). 
They arise as a result of posttranslational modification of one or both proteins 
involved in the interaction [89, 90]. The transient complexes have important 
functions in cellular signaling [91, 92]. In a transient protein-protein interaction, 
one or both proteins in the interaction undergo conformational changes, often to 
reveal a binding site for the next interacting protein [86]. However, there are some 
of the other transient complexes that have little biological relevance and are 
formed mostly due to intracellular crowding [93, 94]. 
 
 
Figure 4: Different types of protein-protein interactions based on their binding affinities. 
 
The protein complexes can also be divided based on the types of subunits they 
consist of: homomeric or heteromeric [95]. As the name suggests, homomeric 
complexes are made up of the same subunits and heteromeric complexes from 
different subunits. Most known protein complex structures are homomeric [96, 
97], however, this observation could be strongly biased due to the inclination 
towards studying individual proteins [98]. 
Currently, there are four main experimental methods for the detection of protein 
complexes: X-ray crystallography, nuclear magnetic resonance (NMR), various 






mobility, and protein microarray. Besides these experimental methods, there are 
also various computational methods for protein complex prediction (Table 1). All 
computational methods take advantage of the information on the structure and 
topology of the given protein-protein interaction network (PPIN) [99]. Some of the 
computational methods make use of the unweighted PPIN whereas others employ 
weighted PPINs to model dense subnetworks as complexes. The discussion on the 
application, advantages, and limitations of experimental and in silico approaches is 
beyond the scope of this thesis and can be reviewed elsewhere [99]. 
 
Table 1: Various computational methods available for protein complex prediction. Adapted 
from Zahiri J, et al, 2019 [99]. 





Divides the PPIN into smaller 
networks and then search for 
protein complexes 
Friedel et al. [100] 
Pu et al. [101] 
MCL [102] 
Agglomerative methods 
Takes the PPIN as a whole and 
then tries to find the complexes 










Tries to find the core proteins and 
then add other proteins that are 






Functional information based Zhang et al. [113] 
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Adds information of protein 
functions to find the proteins 









Adds information on the proteins 
from various organisms; 




Hirsh et al. [121] 
Sharan et al. [122] 
Sharan et al. [123] 





Using PPIN, dense interactions 
are taken and complexes are 
searched however, some 
complexes are spared and need 





To find the protein complexes of 




Ruan et al. [130] 
 
Many databases for protein complexes exist, however, most of them are either 
non-functional or have not been updated in at least the last two years. 
Nevertheless, there are two manually annotated and regularly updated protein 






the protein complexes based on various sets of evidence. For instance, CORUM, 
lists five levels of evidence that is based on the quality of confidence: experimental 
evidence, evidence from literature like reviews, known mammalian homolog, high-
throughput experiment, and predicted function. Similarly, Complex portal uses six 
evidence levels: physical interaction evidence (ECO:0000353), experimental 
evidence from mixed species (ECO:0005543), homology evidence (ECO:0005610), 
orthology evidence (ECO:0005544), paralogy evidence (ECO:0005546), and 
inference from background scientific knowledge (ECO:0005547); given with their 
corresponding evidence and conclusion ontology [133]. Both databases also 
provide information on the stoichiometry of the complexes. 
The subunits of a protein complex and their respective stoichiometry define one 
aspect of the protein complexes, the assembly of protein complexes is the other. 
The identification of the order of assembly is currently done using electrospray 
mass spectrometry (mass spectrometry using electrospray ionization), which can 
identify different intermediate states simultaneously. Through the knowledge 
gained from these studies, it has been discovered that most complexes follow an 
ordered assembly pathway [134]. Though highly regulated, a misassembled or 
disordered assembly can happen and may lead to disastrous consequences [135], 
such as aggregation and protein complex dysfunction [136]. Disordered assembly 
can occur due to, but not limited to, unfavorable environmental conditions such as 
unfavorable pH or temperature, mutations in genes for the protein subunits, and 
error in the folding process. 
Aberrant changes in the pH and temperature of the body affect the folding of the 
proteins and under extreme conditions, protein denaturation can also occur. The 
deviant protein structure influences the interactions between different proteins 
and hence the formation of the complexes. Among the different attraction 
interactions, pH affects notably the salt bridges and hydrogen bonding. Disruption 
of these forces results in unfolded, misfolded, or differently folded protein. 
Nitrophorin 4 (NP4) protein releases nitric oxide (NO) in a pH-sensitive manner. At 
pH 5.5 NP4 is in a closed conformation where NO is tightly bound, while at pH 7.5 
Asp30 becomes deprotonated, causing the conformation to change to an open 
state from which NO can easily escape [137]. However, it has been demonstrated 
that many macromolecules can tolerate small pH fluctuations that are inevitable 
with cellular functions [138]. 
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Many misfolded proteins involved in diseases contain one or more mutations that 
destabilize the correct fold and/or stabilize a misfolded state [139]. When forming 
complexes, such mutations can result in perturbed inter-subunit interactions, 
dominant-negative mechanism, and stoichiometric imbalances [95]. Perturbation 
of the inter-subunit interaction can be witnessed in the case of acetyl-CoA 
dehydrogenase that causes the metabolic disorder. A missense mutation in the 
homo-tetrameric medium-chain of acetyl-CoA dehydrogenase results in the 
disruption of ionic bonds and water bridges. The substitution of a positively charged 
Lys to the negatively charged Glu at the homomeric interface affects the assembly 
of a functioning tetramer [140]. The dominant-negative mechanism arises when 
there is a mutation in one allele of a protein-coding gene and the complex is formed 
from the mix of wild and mutant proteins and the function is obstructed by the 
mutant protein [95]. The dominant-negative effect has been observed in STAT3 
that belongs to the signal transducer and activator of transcription family. In the 
DNA binding domain of STAT3, five distinct mutations were noted. The STAT3 
protein expression was unperturbed, phosphorylation, and dimerization capability 
were unchanged from the wild type. However, the STAT3 dimers that contained at 
least one mutant monomer presented severely reduced DNA-binding ability and 
resulted in hyper-IgE syndrome [141]. Stoichiometric imbalances can be observed 
in heteromeric complexes when one of the subunits is increased or decreased. Such 
imbalances are caused by either heterozygous mutations in individual protein-
coding genes that decrease or knock out the expression of the allele or from larger 
scale copy number variations or aneuploidy [142]. 
Lastly, the protein folding machinery, though intricate, can still make errors, 
resulting in misfolded proteins, hence affecting the complex formation. Recently, it 
has been illustrated that subunits of many protein complexes start assembling 
before all the subunits are formed [143, 144]. The protein complex assembly occurs 
co-translationally and translation, folding, and assembly of protein complexes are 
integrated processes in eukaryotes [143]. The information of co-translational 
assembly of the proteins can be used to model an in silico approach taking the 
transcriptomics data across several time points. Emphasizing that the expression of 
the transcripts for the respective protein subunits in the complex peak when they 







The idea behind this thesis is that using the transcript expression would generate 
better inferences from RNA-Seq data. To validate this hypothesis we identified gaps 
in gene expression analyses and developed approaches to study transcript 
expression data. Furthermore, novel applications of the transcript expression are 
presented: assessing functional changes, identifying of biomarkers, and studying 
protein complexes. The novel approaches developed in this thesis were applied to 
liver transcriptomics data because the liver is involved in numerous functions and 
is prone to several diseases. 
 
Liver – the organ of choice 
To develop novel data analyzing methods aiming at proposing a solution for all 
these gaps identified in the current state of the art procedures, a single organ was 
chosen – the liver. The liver was selected owing to multiple reasons, such as the 
number of various functions it is involved in (discussed below), its significance in 
toxicological and drug safety studies, the amount of transcriptomics dataset 
available in the public domain, and the data generated in the EU-ToxRisk project 
(c.f. chapter 2). The liver plays a vital role in numerous functions in the body, 
ranging from digestion to metabolism and storage of various biomolecules to 
removing toxins from the body to maintaining homeostasis. 
The liver plays a significant role in digestion, mainly of fats and carbohydrates. Bile, 
a dark-green-to-yellowish-brown fluid that is secreted from the liver and then 
stored and concentrated in the gall bladder, which is a key element in the digestion 
of fats. During digestion in the small intestine, bile is released into the duodenum 
where it breaks down the fats for further digestion and absorption [145]. It also 
helps in the absorption of fat-soluble vitamins such as A, D, E, and K [146]. The liver 
is also involved in controlling carbohydrate metabolism and maintains glucose 
concentrations in the normal range by tightly regulating the system of enzymes and 
kinases. The liver controls both, glucose breakdown and synthesis in hepatocytes. 
This process is under the control of glucoregulatory mediators among which insulin 
plays a key role [147]. 
The liver plays an equally important part in detoxification that it accomplishes by 
breaking down and removing harmful substances. It neutralizes a wide range of 
toxic chemicals, produced within the body or coming from the environment. These 
include, but are not limited to, alcohol [148], drugs [149], bile salts [150], and 
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bilirubin [151]. The liver achieves the task of detoxification of the system in 
different ways, as listed: removing large toxins from the blood, excreting 
cholesterol and other fat-soluble toxins in the bile, and finally breaking down and 
neutralizing the toxins. The breakdown is achieved in three steps termed as phase 
I, II, and III metabolism. Phase I involves functionalization reactions, phase II is a 
conjugation reaction, and phase III refers to the transporter-mediated elimination 
of drugs and/or metabolites from the body normally via liver, gut, kidney, or lung 
[149]. 
The liver is also an important immune tissue and is a part of the mononuclear 
phagocyte system. It houses the largest population of resident tissue macrophages 
in the body, Kupffer cells, which are responsible for phagocytosis [152]. The liver is 
capable of detecting the pathogens such as bacteria, viruses, and macromolecules 
entering the body via the gut. The liver aims at establishing a balance between 
being anti-inflammatory or immunotolerant (to allow food particles to pass) and 
exhibiting an immune response (to detect, capture, and eliminate the harmful 
pathogens). In the absence of infection, excessive inflammation may lead to sterile 
liver injury, tissue damage, and remodeling. On the other hand, insufficient 
immunity can result in chronic infection and cancer [153]. 
Liver stores and regulates the level of glycogen, iron, copper, and vitamin A in the 
body. After a meal, when there is excess sugar in the blood, the liver removes it 
from the system via the blood in the portal vein and stores it in the form of 
glycogen. When blood sugar levels fall, the stored glycogen is released back into 
the system by breaking it down as glucose [154]. The excess iron released from the 
breakdown of the red blood cells (RBCs) is stored in the hepatocytes and the liver 
acts as a regulator of iron homeostasis in the body as well [155]. Similarly, copper 
is also stored in the liver and it plays a protective role against copper-induced 
cytotoxicity [156]. The liver also stores a significant amount of vitamin A. From the 
circulation, vitamin A is taken up by the hepatocytes and ~80 % of it is stored in 
hepatic stellate cells [157]. 
Moreover, the liver is the body's chemical "factory." It can synthesize several 
chemicals needed by the body to function, using the raw materials absorbed by the 
intestine. Various chemicals synthesized by the liver are listed ahead with their 
functions. Albumin is required to transport fatty acids and steroid hormones as well 
as maintaining oncotic pressure [158]. Angiotensinogen is a component of the 






[159]. Coagulation factors help in achieving hemostasis [160]. Complement factors 
are part of the complement system [161]. Haptoglobin binds to free plasma 
hemoglobin and allows degradative enzymes to destroy it [162]. Caeruloplasmin is 
responsible for oxidation of Fe2+ into Fe3+ [163]. Lastly, transferrin binds to iron and 
transports it throughout the body [164]. 
Owing to the multitude of functions that the liver is involved in, it is continuously 
exposed to various toxic substances from within the body and outside (gut). This 
makes the liver highly susceptible to injury, infection, and diseases. One of the most 
common liver diseases is hepatitis, which is usually caused by viruses like hepatitis 
A, B, and C [165, 166]. Hepatitis can also be caused by non-infectious causes 
including, drugs, allergic reactions, heavy drinking, or obesity [167-169]. Long-term 
liver damage from any causes can result in permanent scarring and loss of function, 
such a condition is referred to as cirrhosis [170]. The liver is also prone to various 
types of cancer, namely hepatocellular carcinoma (HCC) [171], intrahepatic 
cholangiocarcinoma (bile duct cancer) [172], angiosarcoma (cancers beginning in 
cells lining the blood vessels of the liver) [173], and hepatoblastoma (liver cancer in 
children) [174]. Of all, HCC is the most common liver cancer and accounts for ~80% 
of liver cancers [175]. Liver cancers usually occur after long-term hepatitis B or C 
infection and/or cirrhosis [176, 177]. Some other less frequently occurring liver 
diseases include ascites (leakage of liver fluid into the belly) [178], gallstones (stuck 
gallstone in the bile duct) [179], hemochromatosis (high iron deposit in the liver) 
[180], primary sclerosing cholangitis (inflammation and scarring in the bile ducts) 
[181], primary biliary cirrhosis (slowly destroys the bile ducts) [182], and liver failure 
[183]. 
 
Aims, objective, and outline of the thesis 
Several liver cell models ranging from cancer cell models to iPSC derived cell models 
to liver cancer slices were made available through the EU-ToxRisk project were 
sequenced in-house. All cell models were at baseline. An investigation to find which 
cell model closely mimics the liver biopsies, an exhaustive comparison of these cell 
models was done using transcriptomics data. Besides finding the most similar liver 
cell model to in vivo liver, the differences in the gene-based and transcript-based 
analyses were highlighted. In Chapter 2, the similarity of the liver cell models to in 
vivo liver and the advantages of using transcript expression over gene expression 
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analyses are discussed in detail. Liver comparison results are provided as 
differentially expressed genes, differential transcript usage, and their coverage on 
human KEGG pathways. 
From the knowledge gained in the previous chapter on the transcripts, especially 
the protein coding transcripts, it was realized that there are a significant number of 
protein coding transcripts, originating from the same or different genes, that code 
for similar proteins. Coding for similar protein would imply a similar function, and 
if such transcripts were studied individually, the functional characteristics might be 
masked. To address the concern of different transcripts that code for the same 
protein, FuSe (Functional grouping of transcripts for RNA-Seq analyses) was 
developed. Chapter 3 discusses the development of FuSe and its application on 
liver transcriptomics data. The transcriptomics data was obtained for liver cell 
models exposed to toxic and therapeutic APAP doses, along with untreated and 
DMSO control. 
Furthermore, in Chapter 4, the ability of machine learning (ML) in finding novel 
biomarkers using transcriptomics data is investigated. Using various machine 
learning algorithms and approaches, a novel methodology to search for better 
disease biomarkers is developed. To illustrate the applicability of the methodology, 
transcriptomics data for several cell models of hepatocellular carcinoma (HCC) and 
healthy liver biopsies were taken. For the identification of the biomarkers, 
transcript expression rather than gene expression was used and it is illustrated that 
transcript biomarkers give high accuracy in differentiating the healthy and HCC cell 
models. 
Through transcript expression comparison a list of perturbed transcripts is 
obtained, however, the knowledge of their binding partners can further aid in 
better understanding the changes in the biological system. These binding partners 
might form protein complexes and perform specific functions. In Chapter 5, time-
series transcriptomics data from untreated liver cell models were taken to first 
devise an approach to calculate protein complex expression and then to predict the 
order of assembly of the protein complexes. Along with transcript expression data, 
stoichiometry was used to calculate the protein complex expression and for the 
prediction of the order of assembly, dynamic Bayesian networks were used. The 







In Chapter 6, a discussion on the overall conclusions derived from this thesis is 
presented and further ideas to explore are debated. Starting with liver cell model 
comparison, illustrating the exhaustive pathway mapping data generated for 
several cell models and its applicability in selecting a cell model for a study. 
Furthermore, the advantages of using transcript expression over gene expression 
for transcriptomics data analyses are discussed. Then moving to the tool, namely 
FuSe, which is developed to analyze mRNA transcripts that code for similar 
proteins. The opportunities for the improvement of FuSe and the addition of new 
features like non-coding transcripts are presented. Furthermore, the interesting 
findings from the application of ML to transcriptomics data in the quest of finding 
novel transcript biomarkers in HCC cell models are given. Its intended use for other 
diseases and on non-invasive transcriptomics data is discussed. Finally, results from 
the protein complex expression and assembly order prediction are discussed. 
Lastly, under impact, a scrutiny of the outcomes from chapters 2 to 5 are presented 
with arguments on its impact and practicality. 
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Abstract 
The liver plays an important role in xenobiotic metabolism and represents a primary 
target for toxic substances. Many different in vitro cell models have been 
developed in the past decades. In this study, we used RNA-sequencing (RNA-Seq) 
to analyze the following human in vitro liver cell models in comparison to human 
liver tissue: cancer derived cell lines (HepG2, HepaRG 3D), induced pluripotent stem 
cell derived hepatocyte-like cells (iPSC-HLCs), cancerous human liver derived assays 
(hPCLiS, human precision cut liver slices), non-cancerous human liver derived 
assays (PHH, primary human hepatocytes) and 3D liver microtissues. First, using 
CellNet, we analyzed whether these liver in vitro cell models were indeed classified 
as liver, based on their baseline expression profile and gene regulatory networks 
(GRN). More comprehensive analyses using non-differentially expressed genes 
(non-DEGs) and differential transcript usage (DTU) were applied to assess the 
coverage for important liver pathways. Through different analyses, we noticed that 
3D liver microtissues exhibited a high similarity with in vivo liver, in terms of CellNet 
(C/T score: 0.98), non-DEGs (10363) and pathway coverage (highest for 19 out of 
20 liver specific pathways shown) at the beginning of the incubation period (0h) 
followed by a decrease during long-term incubation for 168 and 336h. PHH also 
showed a high degree of similarity with human liver tissue and allowed stable 
conditions for a short-term cultivation period of 24h. Using the same metrics, 
HepG2 cells illustrated the lowest similarity (C/T: 0.51, non-DEGs: 5623, and 
pathways coverage: least for 7 out of 20) with human liver tissue. The HepG2 are 
widely used in hepatotoxicity studies, however, due to their lower similarity, they 
should be used with caution. HepaRG models, iPSC-HLCs, and hPCLiS ranged clearly 
behind microtissues and PHH but showed higher similarity to human liver tissue 
than HepG2 cells. In conclusion, this study offers a resource of RNA-Seq data of 
several biological replicates of human liver cell models in vitro compared to human 







The liver plays a central role in metabolizing exogenous substances. After oral 
uptake xenobiotics pass through the digestive tract and enter the liver via the portal 
vein, where metabolism by phase I and II enzymes take place [1]. Xenobiotics or 
their metabolites may damage the liver with fatal consequences for the individual 
[2]. Therefore, it is important to identify compounds that cause hepatotoxic effects 
to avoid exposure to humans. 
While the use of animal models has proven to be of great importance in biological 
research [3-6], it remains challenging to translate the results to humans. Many 
drugs that showed great promise in animal testing failed safety assessment in 
clinical trials, e.g., emicizumab, zydelig, JCAR014, JCAR015, and Ad-RTS-hIL-12. To 
overcome these limitations human cell models have emerged as a viable alternative 
for efficacy, safety, and toxicity testing [7, 8]. These in vitro models do not just 
eliminate the species-specific variations but also have other advantages such as the 
requirement of only small amounts of the substance, relatively short testing 
periods, and the technically easy possibility to study mechanisms of toxicity, 
enzyme kinetics, and concentration-response relationships [7, 9]. Limitations using 
in vitro cell models are that differences between cells in vitro and in vivo may exist; 
moreover, relatively complex techniques are required to extrapolate from test 
compound concentrations in the culture medium in vitro to blood concentrations 
or doses in vivo [10, 11]. 
Several human liver cell models have been developed with an aim to resemble the 
in vivo situation as closely as possible[12]. HepaRG cells may be used for xenobiotic 
metabolism, toxicity studies, cytochrome P450 induction studies, and for analyzing 
genotoxic compounds [13, 14]. Primary human hepatocytes are still considered to 
represent a gold standard for hepatic biotransformation studies [15, 16], whereas 
HepG2 cells have been reported to represent a useful tool to study the regulation 
of drug-metabolizing enzymes [17]. In a review of different in vitro liver cell models, 
the advantages and disadvantages of the in vitro liver cell models have also been 
discussed [18]. Though informative, these studies only give a superficial comparison 
as they are based on selected processes and components, whereas next-generation 
sequencing (NGS) technologies can be used to obtain an unbiased, holistic view. 
The evolution of NGS over the years has revolutionized genomics and 
transcriptomics research [19] making it affordable, fast, and precise. With NGS 
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based RNA sequencing (RNA-Seq), it has now become possible to both identify and 
quantify RNA transcripts [20], even in the absence of any prior genomic knowledge 
[19, 21]. Quantification of the transcript level, known as gene expression, can be 
analyzed in many different ways [7, 22-24] depending on the type of biological 
questions that need to be addressed. RNA-Seq provides the exhaustive expression 
profile of all genes expressed in the cell and is not limited to a set of genes widely 
studied. 
In this study, we compared healthy human liver tissue, further referred to as “in 
vivo liver” with in vitro liver cell lines often used in toxicology studies. For the 
bioinformatics analysis, we used CellNet [25] which is a network biology-based 
computational platform to assess RNA-Seq expression data. In CellNet, consensus 
expression profiles of specific cells or tissue types were generated. For the ease of 
use, the authors have created transcriptome indices and annotation files of some 
cells/tissues by congregating publicly available RNA-Seq data for humans. We used 
these human indices and annotation files for comparing the liver in vitro cell 
models. Comparing the consensus expression data with the test cell models 
objectifies their similarity with different cells/tissues. CellNet also creates gene 
regulatory networks (GRN) that are derived from the expression profile. GRN is a 
network of genes that interact with each other to control specific cell functions 
[26]. GRNs can also be used to analyze similarities as they are specific for 
development, differentiation, and response to environmental cues [22]. 
In order to study each component (genes and/or transcripts) individually with equal 
weight, we also analyzed non-differentially expressed genes (non-DEGs). Usually, 
differentially expressed genes (DEGs) between samples are analyzed to describe 
the differences between cell types, exposures, time-points, or other influences 
[22]. Here, also the non-DEGs were analyzed to focus on the similarities between 
in vitro liver cell models and in vivo liver. The higher the number of non-DEGs the 
higher the similarity an in vitro model and the liver. 
Gene expression levels from RNA-Seq data are usually obtained by summing the 
reads attributed to all transcript (or isoforms) variants for each given gene so that 
the change in the amount of expression of individual isoforms is not apparent. A 
previous consensus has been that the majority of genes are regulated through their 
mRNA levels but NGS has shown that also the selection of individual spliced variants 
may change while the sum of all isoforms remains unchanged. Moreover, the 






genes undergo alternative splicing [27] to form the gene transcripts. Gene 
transcripts are mRNAs that have different transcription start sites (TSSs), protein 
coding DNA sequences (CDSs), and/or untranslated regions (UTRs) but all are 
expressed from the same locus. Ensembl [28] provides an extensive list of transcript 
types broadly categorized as protein coding, nonsense mediated decay, non-stop 
decay, and long as well as small non-coding RNA 
(http://www.ensembl.org/info/genome/genebuild/biotypes.html). By RNA-Seq, 
quantified information of different transcripts of a gene can be obtained [19] and 
changes in the fraction of each transcript, known as differential transcript usage 
(DTU), can be studied to provide insights. These differences in the ratio of the 
expression of the transcripts can potentially alter the gene function and the mRNA 
regulation, stability, and localization [29, 30]. 
To our knowledge, previous studies have compared genome-wide expression only 
of individual cell models, such as e.g. PHH and iPSC derived human hepatocyte-like 
cells [16, 31]; however, a systematic comparison of the most frequently applied in 
vitro liver cell models to human liver tissue has not yet been performed. Here, we 
studied different in vitro liver cell models at baseline conditions, i.e. without any 
compound exposure: liver models derived from cancer cells (HepG2, HepaRG 3D), 
iPSC (induced pluripotent stem cells) derived hepatocyte like cells, cancerous 
human liver derived (hPCLiS, human precision cut liver slices), and non-cancerous 
human liver derived cultivated primary human hepatocytes (PHH) and 3D liver 
microtissues. These cell models were compared to healthy in vivo liver assessed by 
NGS data. 
 
Materials and methods 
An overview of the analyzed samples, human liver tissue specimens in vivo and in 
vitro liver cell models is given in Table 1, detailed information on samples and 
protocols is available in Suppl. methods 1a-g, and details on samples selected after 
each filtration step are provided in Suppl. Table 1. For PHH, hPCLiS, and 3D liver 




Beyond Gene Expression 
 40 
Table 1: Overview of in vitro liver cell models used in this study. 
Cell line Cultivation 
period 
(in hours) 
No of replicates (biological/technical) Protocol and 







to in vivo 
healthy liver) 
In vivo liver NA 27 24# 24 Suppl. 
methods 
1(a) 
PHH 0* 6 6 3 Suppl. 
methods 
1(b) 
24 6 6 3 





0* 3 2 2 Suppl. 
methods 
1(d) 
168 3 3 3 
336 3 3 3 
HepG2 0* 7 7 3 Suppl. 
methods 
1(e) 
HepaRG 3D 0* 4 3 3 Suppl. 
methods 1(f) 
hPCLiS 0* 4 4 3 Suppl. 
methods 
1(g) 
24 4 4 3 
*Timepoint 0 hours is time post-seeding 
**Donor 1 (SBAD2) → 4 replicates; Donor 2 (SBAD3) → 2 replicates 
#3 samples from infants or children were removed  
 
RNA sequencing 
All samples from the in vitro liver cell models were analyzed by a standardized 
working pipeline that included the immediate transfer of cells and tissues into 
TRIzol™ after the cultivation periods as indicated in Table 1. RNA was extracted 
from these cell samples with a Qiagen miRNeasy Mini Kit (Cat # 217004). 
Additionally, DNase digest was performed with a Qiagen RNase-Free DNase Set (Cat 
# 79254) to remove unwanted DNA. RNA quantity and quality were assessed by 
Qubit™ RNA HS Assay Kit (Cat # Q32855) and Agilent RNA 6000 Nano Kit (Cat #5067-
1511) respectively and prepared for sequencing with the Lexogen SENSE mRNA-Seq 






quality of the libraries was checked on an Agilent 2200 TapeStation using an Agilent 
High Sensitivity D5000 ScreenTape (Cat # 5067-5592) and library concentration was 
determined by Qubit™ dsDNA HS Assay Kit (Cat # Q32854) before proceeding to 
sequencing. While the healthy liver tissue samples were sequenced (paired-end, 
150bp) on an Illumina NovaSeq 6000® using a single S2 flowcell, the in vitro cell 
models were sequenced (paired-end, 100bp) on Illumina HiSeq2000®. 
 
Data pre-processing 
The quality of the RNA-Seq raw data (fastq files) was analyzed using the Fastqc 
(version 0.10.1) [32] and after considering the quality of the sequences, tails of the 
sequences were trimmed of the bad quality of the sequences (twelve nucleotides) 
using Trimmomatic (version 0.33) [33]. The sequences were mapped onto the 
Ensembl [28] human genome (version 84) using Bowtie2, (version 2.2.6) [32], and 
gene and isoform (transcript) expression were calculated using RSEM (version 
1.2.28) [34]. Using the sorted genome bam files from RSEM, annotation of the 
mapped reads was assessed by applying ALFA [35].  
The gene read counts, isoform read counts and isoform percentage from all in vivo 
and in vitro samples were taken.  Gene read counts were used for finding the non-
DEGs, then isoform count and percentage were used to analyze DTU. Calculation of 
non-DEGs and DTU is done for each cell model and all timepoints, individually. 
 
CellNet analyses 
The fastq files were used for CellNet analysis. All the subsequent steps were 
performed locally as explained in the CellNet protocol paper [36]. We used the 
‘Human Jun_20_2017’ cnProc from the CellNet for analyses. Two types of analyses 
were performed: comparing the consensus expression profile and GRN status. The 
consensus expression profile per cell or tissue type is generated from publicly 
available RNA-Seq data and classification scores for the test samples are obtained. 
GRN created from the consensus expression profile give the GRN status when 
samples are compared against them. These are calculated by first computing the 
raw GRN status as the mean z-score of all genes in a C/T (cell/tissue) GRN, weighted 
by their importance to the associated C/T classifier. The raw GRN status is then 
Beyond Gene Expression 
 42 




A different number of replicates (technical or biological) were present for all cell 
models. To eliminate this possible source of bias, we selected three replicates from 
each cell model which presented the highest similarity with the healthy in vivo liver 
(Table 1, Suppl. Table 1) based on the number of non-DEGs. In the case of 3D liver 
microtissues, only two replicates were taken instead of three because the third 
replicate had very low coverage and was discarded at the sequencing depth 
filtration. These selected replicates were then used to calculate non-DEGs, DEGs, 
DTU, and other further analyses. 
 
Non-DEGs 
The data were normalized by defining in vivo liver as one dataset and each in vitro 
liver model for each time point as an individual dataset (best three replicates were 
taken as explained above). Then each in vitro dataset was compared individually to 
the in vivo dataset for calculating the non-DEGs using the ‘DESeq’ function from 
DESeq2 R-package [38]. The list of non-DEGs is obtained by filtering the results for 
q-value (padj) > 0.05 and basemean > 10. These non-DEGs were mapped onto KEGG 
pathways [39] using Pathview [40], and in-house developed scripts were used to 
calculate the pathway coverage. 
 
Differential transcript usage (DTU) 
The change in the proportion of the transcripts expressed for a gene represents 
differential transcript usage. Isoform counts and percentages were calculated using 
RSEM. The isoform counts were normalized using DESeq2 as explained for gene 
reads for the selected replicates for each cell model. Considering the number of 
transcripts assessed, multiple filtering steps were applied to remove the low 
expressed transcripts (or noise), and transcripts expressed at a similar level from 







i. Low expression/noise: 
Isoforms that were expressed less than one in a million reads in one dataset (test 
or control) were removed. These isoforms were removed because their expression 
level was not sufficient to be considered above the noise at this sequencing depth. 
This filtration step was performed on isoform counts. 
ii. Similar expression: 
Isoforms that differ less than equal to 10% between the average percentage of in 
vivo and in vitro samples were removed because we were interested in looking for 
the isoforms having sufficient differential usage. This filtration step was performed 
on isoform percentages. 
iii. No expression in some samples: 
The isoforms that were not detected in more than 20% of the samples in any one 
of the datasets (in vivo or in vitro) were discarded, as this would reduce the 
confidence in the samples that showed expression for those isoforms. If the 
number of samples for test or control were less than five, we imposed that the 
transcripts were detected in all samples. This filtration step was performed on 
isoform percentages. 
Isoforms deleted from the counts dataset were removed from the percentages 
dataset and the ones deleted from the percentages were removed from the counts. 
After the filtration steps, the genes left with only one isoform were removed from 
both datasets (counts and percentages). The variance was calculated between the 
test and control samples for all the remaining transcripts using ANOVA in R. Isoform 
percentages were used to find the variance because percentages are linearly 
distributed (contrary to the RNA-Seq read count). It was filtered on p-value < 0.01 
as the calculation at the isoform level has a higher error rate. 
The highest expressed isoform was identified (highest percentage) in the control 
samples for each gene and was compared with its expression profile in test 
samples. The genes with different expression profiles (DTU) were removed from 
the non-DEGs and were named as non-DEGsDTU-. The list of non-DEGsDTU- was 
mapped onto the KEGG pathways and pathway coverage was recalculated. 
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Results 
RNA from totally of 27 liver tissue specimens from donors without liver diseases, 
further named “healthy in vivo liver” and 46 samples from cultivated hepatocytes, 
cell lines, liver slices or iPSC derived hepatocyte-like cells, so-called in vitro cell 
models, were sequenced on the Illumina NovaSeq (PE, 150bp) and the Illumina 
HiSeq 2000 (PE, 100bp), respectively. After removing the samples from children or 
infants for healthy in vivo liver specimens and filtering for sequencing depth 24 in 
vivo cell models, 38 in vitro samples remained for further analysis (Suppl. Table 1). 
Since healthy human liver represents a very valuable resource, we generated 
sequences at very high depth (1.63*108) for community usage. However, to avoid 
coverage bias in our analysis with the in vitro samples (sequenced at a depth of 
33.65*106), only the first 30 million reads of the fastq files obtained from the in vivo 
samples were used. We compared the full coverage and part of the data and found 
that the whole sample and sub-selection had similar distribution (Suppl. Fig. 1). 
 
 
Figure 1: Spearman’s correlation plot. The Spearman’s correlation plot for normalized read 
counts of all in vivo and in vitro samples taken after first sample filtration. For healthy in vivo 






(000/024/168/336 h) and replicate numbers are indicated except iPSC HLC. In the case of iPSC 
HLC the donor id (SABD2/3) and replicate number are given. The color bar indicates the 
Spearman correlation coefficient of each pairwise correlation. 
 
All samples taken after initial filtration passed the ‘per base sequence quality’ 
metric of the Fastqc. The annotation of reads was assessed using ALFA. Median 
protein coding reads were 47.02%, 52.3%, 45.52%, 40.9%, 40.87%, 35.15%, and 
47.16% for healthy liver tissue, 3D liver microtissues, HepaRG, HepG2, hPCLiS, PHH, 
and iPSC-HLC, respectively (Suppl. Fig. 2a and 2b).  The samples that had lower 
protein coding and 3’UTR reads showed an increase in the intergenic and 5’UTR 
reads. Overall, the samples had similar distributions across different regions. 
Furthermore, the global similarity of the cell models was evaluated using pairwise 
Spearman’s correlation for normalized read counts (Fig. 1). The median (and 
standard deviation) of all pairwise correlation coefficients of the healthy liver tissue 
specimens with the samples from 3D liver microtissues, HepaRG, HepG2, hPCLiS, 
PHH, and iPSC-HLC, were 0.87 (0.033), 0.83 (0.008), 0.82 (0.013), 0.86 (0.014), 0.86 
(0.014), and 0.83 (0.01), respectively. The variation coefficients of 3D liver 
microtissues, HepaRG, HepG2, hPCLiS, PHH, and iPSC-HLC, were 3.87, 0.99, 1.57, 
1.65, 1.59, and 1.22, respectively.  Inter-replicate variation was observed 
predominantly in 3D liver microtissues (166_1 and 336_3) and PHH (024_1) cell 
models. It should be considered that interindividual variability contributes to the 
cell models obtained from different donors (healthy liver tissue specimens, 3D liver 
microtissues, hPCLiS, PHH), in contrast to the cell line derived cell models (iPSC-
HLC, HepaRG, HepG2). 
 
CellNet cell/tissue classification scores of RNA-Seq expression profiles  
Since the quality and global distributions of the samples were comparable, we next 
assessed their transcriptome expression to consensus profiles of different cells and 
tissues. Using CellNet on the expression data of our liver in vivo and in vitro samples, 
we calculated classification scores (Fig. 2 and Suppl. Table 2). CellNet classified all 
cell models as liver. We noticed that the iPSC-HLCs present the lowest CellNet 
classification score for the human liver and they still share some resemblance with 
embryonic stem cells (ESC). Among all the cell models, HepaRG 3D had the highest 
classification score for fibroblasts. The cancer cell models (HepG2 and HepaRG 3D) 
also exhibited low classification scores as compared to non-cancerous liver-derived 
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cell models, whereby the classification scores of HepaRG 3D were slightly higher 
compared to HepG2 cells but still much lower than the values for 3D liver 
microtissues, hPCLiS, and iPSC-HLC. The human liver derived models (3D liver 
microtissues, hPCLiS, and iPSC-HLC) did not show major differences among each 
other based on the CellNet classification score. Furthermore, at the level of GRNs 
(status score) (Suppl. Fig. 3) similar results were obtained as for the consensus 
expression comparison (classification score). CellNet results can be used to find the 
extent of similarity and dissimilarity for the cell models but other approaches 
should be used to identify the differences at gene and transcript level. In this study, 
we explored non-differentially expressed genes (non-DEGs) and differential 
transcript usage (DTU) to provide comprehensive comparisons between the cell 
models. However, to remove the bias caused by the different number of replicates 
from each cell model, we performed bootstrap analyses to guarantee that an 
identical number of replicates from each cell model was used (Fig. 3, Suppl. Table 
1). The cell models had differing number of replicates, hence the number of 
combinations of replicates, taken three at a time, also varied across cell models. 
The number of DEGs for 3D liver microtissues were 6315 (0h), 9552 (168h), and 
9478 (336h), for iPSC HLCs it was 12155 (480h), and 11790 for HepaRG 3D. For these 
cell models, only one combination of replicates per time point was obtained. For 
the remaining cell models, where the number of replicates were more than three 
after the initial filtration for quality, the average number of DEGs for PHH were 
~9684 (0h) and ~9508 (24h), for hPCLiS the mean was ~12499 (0h) and ~12815 
(24h), and for HepG2 it was 13070 (0h). From these, the best three replicates were 
selected based on the number of non-DEGs, except for 3D liver microtissues 0h 





































































































































































































































































































































































































































































































In vivo versus in vitro, using non-differentially expressed genes 
Normalized gene expression (mRNA profiles) of the in vitro cell models and in vivo 
liver were used to identify genes that are not differentially expressed (non-DEGs) 
(Fig. 4 and Suppl. Table 3) to characterize which liver-like features the individual cell 
models possess. The numbers of non-DEGs of 3D liver microtissues (0h) before 
cultivation was highest compared to the other cell models but dropped below the 
corresponding numbers of PHH after long-term cultivation for 168 and 336h (Fig. 
3). Similar numbers of non-DEGs were obtained for PHH before and after short-
term cultivation for 24h. The lowest numbers of non-DEGs were obtained for 
HepG2 and hPCLiS, while HepaRG and iPSC-HLC were intermediate. The highest 
overlap of non-DEGs was obtained between PHH before and after the cultivation 
period, illustrating that this system offers a relatively stable number of non-DEGs 
during short-term incubation for 24h (Fig. 3). Moreover, a relatively large overlap 
of non-DEGs was obtained for iPSC-HLC and PHH. 
To understand the effect on the biological processes, we then mapped all non-DEGs 
onto KEGG pathways (Suppl. Table 4a). Pathway mapping data can be used to study 
the specific processes/pathways of interest for each cell model and provide a 
metric of the similarity between liver tissue and the individual in vitro systems. 
Pathway coverage was calculated for the 20 liver pathways [41] illustrated in Fig. 5 
(Suppl. Table 5). Higher pathway coverage by non-DEGs implies higher similarity 
with the human liver. 
3D liver microtissues (0h) before the incubation period showed the highest 
coverage for most pathways but after 168 and 336 h of incubation, the coverage 
systematically dropped. In general, HepaRG 3D and HepG2 demonstrated a much 
lower coverage with HepG2 having the least. Exceptions were the high DNA repair 
functions of both tumor cell lines, with a relatively high coverage seen for base 
excision repair for HepaRG (68%) and nucleotide excision repair for HepG2 (59%). 
PHH showed a relatively high pathway coverage for all pathways and only small 
differences before (0h) and after (24h) after the cultivation period. For the primary 
bile acid biosynthesis pathway, PHH showed an increase during the 24h cultivation 
period. For cytochrome P450 pathways, microtissues, PHH, and hPCLiS 
demonstrated a high coverage (metabolism of xenobiotics: hPCLiS 0h: 71%, 24h: 
79%, PHH 0h: 79%, 24h: 71% and drug metabolism: hPCLiS 0h: 78%, 24h: 94%, PHH 
0h: 89%, 24h: 89%), hence presenting their metabolizing capacities for exogenous 
substances. While the number of pathways for which hPCLiS exhibited a low 
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coverage, was six for 0h and eight for 24h, it also had the highest coverage for two 
pathways for 24h (both cytochrome p450 pathways). IPSC-HLC also showed a high 
coverage for DNA repair pathways with highest on base excision repair (68%) and 
nucleotide excision repair (66%). For other DNA repair pathways, iPSC-HLC also 
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In vivo versus in vitro, using differentially expressed genes 
While the non-DEGs illustrated the similarities between the in vitro cell models and 
the in vivo liver, we also compared the differentially expressed genes (DEGs, q-value 
(padj) < 0.05 & average counts > 10) to highlight the differences. The volcano plots 
demonstrated the extent of perturbation in the genes for all cell models (Figure 6A-
J). The number of DEGs were the highest for HepG2 (9910) and lowest for 3D liver 
microtissues 000 (5169) (Figure 6K, Suppl. Fig. 4). The number of DEGs were also 
high, comparable to HepG2, for hPCLiS both time points (0h: 9837 and 24h: 9890). 
The complete list of DEGs from all cell models is provided in Suppl. Table 6. The 
overlap between the DEGs from all cell models in Suppl. Fig. 4 shows that the 
highest overlap was between all cell models except both time points from PHH. An 
enrichment analyses was performed for the DEGs using GOrilla [42] (Suppl. Table 
7). While iPSC, HepaRG and HepG2 demonstrated the most perturbed GO 
functions, PHH had the least (Fig. 7). The highest overlap (19 GO functions) was 





























































































































































































































































































The DEGs were also mapped onto the pathways to check their coverage (Fig. 8). A 
higher coverage by DEGs means that the cell models share low similarity with 
healthy in vivo liver. It is important to mention here that the pathway coverage for 
the DEGs is not the inverse of the pathway coverage of non-DEGs, this is because 
different genes can make similar proteins. The pathways are proteins interacting 
with each other and due to ambiguity in protein-gene relationships, pathway 
mapping tools, frequently map more than one gene to a protein. The pathway 
coverage of the DEGs illustrated an opposite mapping trend than non-DEGs (Fig. 5) 
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coverage whereas PHH and 3D liver microtissues showed lowest coverage and iPSC 
HLCs had high for some and low coverage for other pathways. Pathway mappings 
on DEGs from all cell models for all human pathways are provided in Suppl. Table 
4b. 
The changes in the expression of genes, differentially expressed genes, can be 
linked to the fluctuations in the expression of different transcription factors (TFs). 
The Network influence score (NIS), defined by the expression of downstream 
regulated genes, for the transcription factors from all the cell models was 
calculated using CellNet (Suppl. Fig. 5a-g). These differences were calculated with 
respect to the cell/tissue profiles of the CellNet. The results show that the 
transcription factor ATF5 had the highest perturbation for all cell models except the 
PHH where it was shown to be the least perturbed. In the case of PHH, NR1H4 was 
the most affected factor. Moreover, in the case of PHH, ATF5 exhibited 
perturbation in the opposite direction than all other cell models. A similar analysis 
using the microarray data for freshly extracted hepatocytes, PHH and hiPSC using 
the microarray data illustrated a different list of TFs being affected. However, 
different types of data used for the two studies (microarray and transcriptomics) 
might be the reason for this difference. 
Furthermore, we also investigated how the cell models behaved over the 
incubation period. Three cell models, namely, PHH, hPCLiS, and 3D liver 
microtissues were incubated for different time durations. We computed the DEGs 
for each cell model over different time points (Fig. 9). PHH and hPCLiS show only 
very small variation in their expression profile over time, with a single gene 
differently expressed for PHH (0h vs 24h) and two DEGs for hPCLiS (0h vs 24h). 3D 
liver microtissues show a more important effect of time, with 684 DEGs between 
0h and 168h, 223 between 0h and 336h and 8 for 168h vs 336h. While 3D liver 
microtissues illustrated comparatively higher number of DEGs, it should also be 
acknowledged that the incubation period for 3D liver microtissues was much longer 
than PHH and hPCLiS. PHH and hPCLiS that had same incubation period showed 























































































































































































































































































































































































































































































































































































In vivo versus in vitro, using differential transcript usage 
In the previous analyses, RNA-Seq data have been analyzed to identify differences 
between in vivo and in vitro cell models for the total gene expression generated by 
all isoforms of a gene. If the proportion of expression changes between different 
isoforms of a gene, total gene expression may remain constant. However, the 
different transcript usage (DTU) may nevertheless be relevant, because DTU may 
generate functionally different gene products. Differences in transcript expression 
(DTU) may be caused by alternative splicing, preference for one transcription start 
site over the other, spatial availability of transcription factors, and other elements. 
In standard RNA-Seq analysis, gene expression is assessed by summing the 
expression of all the transcripts for a given gene, and then it conceals the genes 
regulated at the splicing level. Genes with significant differential usage (p-value < 
0.01) at transcript level were then removed from the list of non-DEGs, giving the 
non-DEGDTU- (Suppl. Table 8). An exhaustive list of DTU for all the cell models can 
also be found in the supplementary (Suppl. Table 9). The gene for which transcripts 
had differential usage (DTU) should be removed from the non-DEGs to fine-tune 
the analyses. This was illustrated for the examples of four genes that were non -
differentially expressed but display DTU for the in vitro cell models (Fig. 10). The 
highest expressed protein coding transcript of POLR2F (DNA-directed RNA 
polymerases I, II, and III subunit RPABC2) was mostly replaced by other protein 
coding transcripts. For GOLGA8B (Golgin subfamily A member 8B) and ARHGAP21 
(Rho GTPase-activating protein 21), it was predominantly replaced by non-coding 
transcripts. HSPA8 (Heat shock cognate 71 kDa protein) exhibited a different 
pattern, where the highest expressed protein coding transcript was replaced by 
other protein coding and non-coding transcripts. The highest expressed protein 
coding transcript in the case of POLR2F (52%) was reduced to <2% in all cell models 
except hPCLiS 0h (9%) while for HSPA8, it was reduced from 65% to <3% for all 
except iPSC HLC (25%). Similar trends can be seen for GOLGA8B and ARHGAP21 
(Fig. 10). 
An investigation at this level revealed major changes in transcript usage for all in 
vitro cell models (Fig. 5). After removing the DTUs from the non-DEGs, termed as 
non-DEGsDTU- (Fig. 3), their count and pathway coverage decreased. As for non-
DEGs, a similar trend can be seen for non-DEGsDTU- in terms of pathway coverage. 
Pathway mapping data of non-DEGsDTU- for each cell model for all KEGG pathways 
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are also provided to investigate queries per cell model and/or pathway (Suppl. 
Table 3b). 
 
Figure 10: Examples of four non-DEGs that show major differential transcript usage (DTU). 
Transcript usage illustrated for four genes that were not differentially expressed at the gene 
level (non-DEGs) but had differential transcript usage (DTU). The most expressed protein 
coding transcript in vivo is replaced by other protein coding and/or non-coding transcripts (A) 
POLR2F, (B) HSPA8, (C) GOLGA8B, and (D) ARHGAP21. 
 
Discussion 
Different in vitro liver cell models have been developed for studying the effects of 
toxic compounds in humans. In the past, these models have been evaluated time 
and again for specific processes and components, giving a limited overview [13, 17, 
18], however, a systematic comparison of RNAseq data is not yet available. We 
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compared these models at baseline gene expression using RNA-Seq. While in vivo 
and in vitro samples were sequenced on different platforms (Illumina NovaSeq 
6000® and HiSeq 2000® respectively), it is important to consider that both samples 
were produced using the same library preparation method, and both Illumina 
sequencers produced comparable results. The in vivo samples were sequenced 
with longer reads (150bp) compared to cell samples (100bp) but this cannot be 
expected to cause larger differences in the data as the read length higher than 50bp 
does not drastically impact the outcome [43, 44]. Once a read’s position can be 
mapped unambiguously, longer reads do not add much value in a quantification-
based analysis [45]. 
As expected, in comparison to the human in vivo liver, the highest pairwise 
spearman’s correlation was shown by the non-cancerous human liver derived cell 
models, such as 3D liver microtissues and PHH. The cancer-derived cell models and 
iPSC-HLCs were still classified liver based on CellNet analysis but obtained the 
lowest classification scores using the human liver as reference. CellNet provides an 
easy and direct way to compare the cell models but it uses single-end (SE) reads for 
building the consensus expression profiles and GRNs[36] to accommodate more 
data available in public domains. However, SE sequences have poor coverage and 
low resolution of the 3' end of the transcripts as compared to paired-end 
sequences. Thus, further approaches besides CellNet are required. 
Therefore, we analyzed non-DEGs to focus on similarities between the in vivo and 
in vitro samples. Based on the number of non-DEGs and pathway coverage, 3D liver 
microtissues initially showed a high similarity with the liver in vivo but during the 
cultivation period of 168 and 336h, the number of non-DEGs decreased. The largest 
deviation from the results obtained by CellNet was obtained with the hPCLiS and 
iPSC-HLC samples. Based on the results of CellNet, hPCLiS showed a high level of 
similarity with in vivo liver but using non-DEGs a relatively low resemblance was 
observed. On the other hand, for iPSC-HLC, CellNet predicted poor similarity but 
non-DEGs demonstrated a higher degree of similarity. The difference between 
results obtained by CellNet and analysis of non-DEGs could be due to differences in 
the level of lowly expressed genes which may gain more weight in the analysis of 
non-DEGs than in CellNet due to downsampling in CellNet [36]. Furthermore, with 
DEGs, the highest similarity was observed for 3D liver microtissues and PHH, and 
lowest for HepG2 and hPCLiS 000 for the enrichment analysis and pathway 
coverage. 
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In addition to non-DEGs and DEGs, we also explored DTU thus highlighting the 
genes which are not differentially expressed on the gene level but exhibited 
significant differential usage of isoforms on the transcript level. The change in the 
amount of expression of the different transcript types in the cell models provided 
another metric to distinguish liver similar and dissimilar cell models. The analysis of 
the DTU first resulted in reduced numbers of non-differentially expressed genes 
(non-DEGsDTU) and hence pathway coverage. While globally the results of pathway 
coverage were similar to non-DEGs, studying the DTUs helped in identifying the 
genes which were differentially spliced between the in vivo liver and the in vitro 
system, notably by having a dominant protein coding or non-coding transcript(s). 
An important point worth mentioning here is that in our methodology, we used a 
stricter p-value cut-off in the case of DTU (0.01) because isoform mapping is known 
to induce a higher false-positive rate [46, 47]. The evaluation of the DTUs aid in 
identifying the regulation control of expression of different protein coding and non-
coding transcripts and conservation of the function of the proteins which otherwise 
remains oblivious at the gene level, as illustrated for the four exemplary genes in 
Fig. 7: These four genes are responsible for the process of transcription to protein 
trafficking and localization. First, POLR2F is a component of RNA polymerases I, II, 
and III which plays an important role in transcription [48] while HSPA8 which is 
involved in a wide variety of cellular processes and also takes care of protein 
folding, transport, and proteolysis [49]. GOLGA8B and ARHGAP21 are responsible 
for maintaining the Golgi apparatus [50, 51] and were shown to be differentially 
expressed at the transcript level. The differential expression of these genes implies 
that the functions of the Golgi (modifying, sorting, and packaging of proteins for 
secretion) may be perturbed. The present results show that the 3D liver 
microtissues (0h) demonstrate a particularly high Spearman correlation, CellNet 
classification score, GRN status, number of non-DEGs, non-DEGsDTU-, and pathway 
coverage. During the cultivation period, these values decrease. It should, however, 
be considered that cultivation periods of 168 and 336h are relatively long and it is 
difficult to maintain in vivo like properties for such long periods. For short term 
incubation of 24h PHH represent an adequate system, since the CellNet 
classification score, GRN status, number of non-DEGs, non-DEGsDTU-, and pathway 
coverage remained almost unchanged during the cultivation period. Therefore, in 
agreement with previous studies [52, 53] cultivated primary hepatocytes seem to 
represent an adequate system for short term experiments to identify genome-wide 
expression changes. Over the incubation period, the non-DEG pathway coverage 
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for primary bile acid biosynthesis increased for PHH. This is in agreement with 
previous studies showing that isolated hepatocytes establish bile canaliculi and 
express bile acid excretion carriers at their apical membranes during the first 24h 
in culture [54, 55]. While the hPCLiS cell models exhibited lower similarity with in 
vivo liver compared to microtissues and PHH, this may be explained by the location 
of extraction of the tissue from the liver cancer patients. 
HepG2 cells lost numerous functions compared to primary hepatocytes. 
Nevertheless, they are used for in vitro studies as they represent a relatively 
inexpensive, easy to handle cell line. These present a higher intermodal variability, 
probably because the cancer cells under uncontrolled cell division accumulate 
mutations over time. The same holds for HepaRG cells that still show slightly more 
non-DEGs than HepG2 cells but are less similar to in vivo liver tissue as PHH or 
microtissues. Several recent studies reported that HepaRG 3D models mimic in vivo 
liver [56-58] but these studies did not perform an RNA-Seq based comparison to 
human liver tissues.  
The use of human iPSCs as a renewable source for the generation of human 
hepatocytes holds great promise as non-transformed hepatocytes from individuals 
with multiple genetic backgrounds could be generated. However, consistent with 
other publications [16, 31, 59], we here found that iPSC-derived hepatocyte-like 
cells still show major differences compared to liver tissue and primary human 
hepatocytes. CellNet analysis of the RNA-seq expression profiles of human-iPSC-
HLCs demonstrated that the iPSC progeny shows a low CellNet classification score 
for the human liver. Moreover, they still share a resemblance with embryonic stem 
cells and exhibit some overlap with the expression profiles of the intestine and 
colon cells/tissue (Suppl. Table 2), as previously described in other studies [31]. 
Additionally, non-DEGs and non-DEGDTU- were identified by comparing the mRNA 
profiles of the iPSC-HLCs with in vivo liver expression data. With around 7118 non-
DEGs and 7087 non-DEGDTU- iPSC-HLCs demonstrated an even higher similarity to 
human liver tissue than hPCLiS, HepaRG, and HepG2 but ranged clearly behind 
microtissues and PHH. However, when mapping onto liver pathways selected from 
KEGG, the iPSC HLCs showed only a relatively low pathway coverage. Taken 
together, the results illustrate that iPSC-derived cells performed better than the 
cancer models (HepG2 and HepaRG) and in some cases even better than hPCLiS as 
well. Though these results suggest that they exhibit some similarity to in vivo liver, 
there are still significant hurdles to overcome before iPSC-derived hepatic progeny 
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reach a high similarity to real hepatocytes. Different strategies to improve HLC 
differentiation may include chemical engineering of the culture media [60], the use 
of 3D organoid cultures and microfluidic systems to recreate the in vivo hepatocyte 
niche and to allow the manipulation of oxygen gradients and the delivery/removal 
of specific factors [61, 62]. In addition, as several TFs are highly differentially 
expressed between iPSC-HLCs and in vivo liver, another way to improve iPSC-HLCs 
maturation could be by up/downregulation of these misregulated TFs (Suppl. Fig. 
5f) [16, 31]. It is important to consider that these results were obtained from 
baseline comparisons and, while analyzing or deriving hypothesis from these 
results, it should be kept in mind that their response to stress and/or exposure to 
chemicals still has to be elucidated. 
 
Data availability 
The raw data can be assessed from ENA: In vivo liver: PRJEB35350/ERP118386, 
PHH: PRJEB23590/ERP105351, iPSC-HLC: PRJEB23620/ERP105382, 3D liver 
microtissues: PRJEB24482/ERP106310, HepG2: PRJEB24466/ERP106294 and 
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Typical RNA-Seq analyses are performed either at the gene level by summing all 
reads from the same locus, assuming that all transcripts from a gene make a protein 
or at the transcript level, assuming that each transcript displays unique function. 
However, these assumptions are flawed, as a gene can code for different types of 
transcripts and different transcripts are capable of synthesizing similar, different, 
or no protein. As a consequence, functional changes are not well illustrated by 
either gene or transcript analyses. We propose to improve RNA-Seq analyses by 
grouping the transcripts based on their similar functions. We developed FuSe to 
predict functional similarities using the primary and secondary structure of 
proteins. To estimate the likelihood of proteins with similar functions, FuSe 
computes two confidence scores: knowledge (KS) and discovery (DS) for protein 
pairs. Overlapping protein pairs exhibiting high confidence are grouped to form 
‘similar function protein groups’ and expression is calculated for each functional 
group. The impact of using FuSe is demonstrated on in vitro cells exposed to 
paracetamol, which highlight genes responsible for cell adhesion and glycogen 
regulation which were earlier shown to be not differentially expressed with 
traditional analysis methods. 
 
Availability: The source code is available at https://github.com/rajinder4489/FuSe. 
Data for APAP exposure are available in the BioStudies database 
(http://www.ebi.ac.uk/biostudies) under accession numbers S-HECA143, S-
HECA(158), and S-HECA139 
 




With the evolution of RNA sequencing (RNA-Seq), an immense amount of high-
quality transcriptomics data has been generated; identifying and quantifying each 
gene transcript/isoform with high precision. Transcriptomics data are often studied 
to identify the changes in gene or transcript expression between different 
conditions and treatments. The ones exhibiting the highest perturbation at the 
lowest statistical error are then mapped to pathways and ontologies to illuminate 
the functional consequences of the alteration. However, the typical data analysis 
pipelines to assess gene expression from RNA-Seq dataset are not perfect. The 
expression level of a given gene is usually obtained by the summation of expression 
(read count) of all the different spliced variants (isoforms/transcripts) mapping the 
gene locus. These spliced variants are identified using the sequence identity to the 
genome and chromosomal locus. These isoforms can be protein coding (same or 
different proteins), non-coding, nonsense mediated decay, or else. Considering the 
level of expression of a gene as the summation of all reads from these different 
types of isoforms is misrepresentative as it considers all of them as coding for the 
same protein. 
Alternatively, analyzing RNA-Seq data at the level of isoform can also be performed 
by keeping an individual read count for every single transcript. Keeping each 
isoform separated would assume that there are no functional overlaps between 
different transcripts. Currently, most of the tools available to quantify RNA-Seq 
data like RSEM [1], StringTie [2], Sailfish [3], Salmon [4], Kallisto [5], and HT-Seq [6] 
along with others, focus chiefly on gene or transcript (isoform) expression. Cuffdiff 
[7], another read counts quantifying tool, groups different transcripts from the 
same transcription start site (TSS) to identify genes that are differentially regulated 
at the transcriptional or post-transcriptional level. None of these tools captures the 
functional similarity of the proteins coded by different transcripts. However, we 
know that closely related proteins are capable of exhibiting same functions and 
these proteins might be derived from different genes (paralogs) or from the same 
gene locus via alternative RNA splicing. Different histones [8] – HS1.1, HS1.2, HS1.3, 
HS1.4, HS1.5 originating from same family of genes HIST1H1A-E, respectively, share 
functional similarities. Another well studied case is the ubiquitin-conjugating 
enzymes [9] – E2D1, E2D2, E2D3, E2D4 which originate from UBE2D1-4 genes, 
respectively. 
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There is no denying that functional overlap between proteins, derived from 
different genes and transcripts, exists and analyses focused on individual genes or 
transcripts would fail to translate to actual functional changes. A paradigm shift has 
to take place to move from gene/transcript-based to function-based analyses. To 
assess the importance of a given function, the actual amount of all proteins able to 
perform this function would need to be quantified. However, quantifying the 
proteins using the state of the art proteomics technologies do not allow to have the 
exhaustive panel of expressed proteins [10] and hence, mRNA quantification data 
(using RNA-Seq) is a better alternative for establishing functional analyses. Indeed, 
all proteins’ primary structure can be predicted from their corresponding mRNA, a 
multitude of tools such as Translation Tool [11], EMBOSS Transeq [12] or 
TranslatorX [13] are developed to accomplish this task using the knowledge of 
codon to an amino acid relationship, translation start or ORFs (Open reading 
frames). Moreover, considering the limitation of the proteomics, the quantified 
mRNA expression from the RNA-Seq experiments can provide a surrogate 
evaluation of protein expression at steady state [14] and can be quantified using 
RNA to protein conversion factors otherwise [15]. 
Comparing the protein function and ontology profiles would provide the list of 
highly similar proteins; however, this would require a comprehensive protein-
function-ontology knowledgebase which is not available. Around ~20k SwissProt 
and ~168k TrEMBL entries on Uniprot (date accessed: 20/04/2019) are available for 
humans [16]. In the absence of such information, protein structure (tertiary and 
quaternary) seems a reliable option, as the function is chiefly defined by the 
structure. The lack ofhigh-resolution structures, ~3.5k proteins with less than 1.5 Å 
and ~13.5k with 1.5 - 2.0 Å for humans on PDB (date accessed: 20/04/2019) [17], 
and the unavailability of pure state protein structures due to protein stability poses 
a hindrance in defining the structure-function relationships. Different artificial 
intelligence and machine learning approaches have been employed to predict the 
protein structures [18] but with limited precision and success because of multiple 
attraction and repulsion forces in action. 
The only extensive high-quality information on the proteins available is the 
nucleotide sequence of their corresponding mRNAs. A comparison of these mRNAs 
is unsuited to find the similarity between them because of the presence and 
differences in intronic regions, UTRs (3’ or 5’), and CDS. Moreover, comparing the 
nucleotide sequences does not take into account the degeneracy (redundancy) of 
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the genetic codon. Hence the amino acid (primary protein) sequence of these 
proteins is taken for comparison. The primary sequence is readily available but in 
the case of unknown proteins, it can be achieved from the mRNA sequences. Their 
comparison can illustrate the local and global sequence identities but it is not 
enough to predict the functional similarity of the proteins. To supplement the 
comparison, data on the secondary structures are added to the comparison. A 
specific order of these structures gives rise to supersecondary structures and these 
can be used in envisaging the structural and functional features of the protein [19]. 
Rather than defining gene expression that groups together the transcripts from the 
same chromosomal locus, we developed FuSe (Functional grouping of transcripts 
for RNA-Seq analyses) with an aim to group protein coding transcripts based on the 
predicted similarity of their protein function. For this, we used the available primary 
structure of proteins and predicted the secondary, super secondary structures, and 
protein families from it. For establishing the similarity from the protein primary 
sequence, BLAST+ [20] was used to identify sequence identity, coverage, and gaps 
in the alignment. While sequence identity establishes the similarity between the 
proteins, the coverage provides information if the two sequences match globally or 
locally. The gaps further help in checking the presence of any insertions or deletions 
and hence provide information about the alignment continuity. Interpro is an 
ensemble of 14 different tools developed using state of the art algorithms and 
knowledgebase to find and predict the domains, motifs, and protein families [21]. 
On the foundations of this information, two types of confidence scores: knowledge 
(KS) and discovery (DS), are calculated for all protein pairs. KS is stringent and 
predicts highly similar protein pairs whereas DS is lenient and predicts the proteins 
with local similarity as well. Based on the confidence score, ‘similar function protein 
groups’ (SFPGs) are formed from the overlapping protein pairs and are used for 
recalculating the RNA-Seq expression. To assess the approach and illustrate the 
changes in functional inferences between the chromosomal locus and function-
based grouping, mRNA data from hepatic cell models exposed to acetaminophen 
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Methods 
All the protein coding transcripts for human were downloaded from Ensembl 




To find the similarity between the protein sequences, BLAST+ (v.2.8.0) was used 
and data was generated in tabular format 6 of BLAST+. Then, to find and predict 
the presence of structural and functional domains in the proteins, Interpro (v.5.31-
70.0) was used. The data were obtained in the “.tsv” format. 
The output from Interpro was a list of functional and structural domains obtained 
from various tools embedded in Interpro. Using in-house developed scripts, for 
each protein, these domains are first ordered based on their position on the amino 
acid sequence per tool. These ordered domains were then compared for similarities 
between the protein pairs. The similarity between the ordered domains was 
labeled for each tool per protein pair as STONM (same type, order, and number of 
motifs), STNM (same type and number of motifs), STM (same type of motifs), and 
NM (no match) (Suppl. Fig. 2). STONM defines the highest level of similarity. 
Another term, NP (not present), was assigned to cases where there was no 
prediction by an Interpro tool for at least one of the proteins in the given protein 
pair. Each protein pair will have one term (STONM, STNM, STM, NM, or NP) for each 
of the 14 tools and, from this information, a protein-protein domain profile per tool 
is obtained. 
 
Protein pair confidence scores 
From the BLAST+ and protein-protein domain profile comparison, the protein pair 
confidence scores were calculated using a scoring scheme (Suppl. methods). Two 
types of confidence scores: DS and KS, were calculated; succinct and expanded 




              …Eq. 1 
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𝐾𝑆 = 𝐴𝐼𝑆 + 𝐴𝐶𝑆 + 	𝐴𝐺𝑆 + #0&$∗+,,
-./	#0&$
             …Eq. 2 
where 
AIS: Alignment Identity score 
ACS: Alignment Coverage score 
AGS: Alignment Gap score 






















                                                        




































   
    …Eq. 4 
 
The DS relies only on the sequence similarity attributes obtained from sequence 
alignment such as identity, coverage, and gaps. While identity and coverage score 
have a positive value, they illustrate the similarity between the protein pair, the 
Gap score has a negative value and demonstrates their dissimilarity. The score 
obtained is then normalized to 100 using the maximum possible alignment identity 
score. In the case of KS, the final score is a result of sequence similarity attributes 
and ordered secondary structure similarity given as STONM, STNM, STM, NM, or 
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NP. To avoid penalizing protein with missing prediction information for one (or 
more) of the 14 Interpro tools (Suppl. Fig. 3), we then normalize the ITCS to the 
maximum possible ITCS score. 
 
Similar function protein groups (SFPGs) 
Confidence scores were calculated from all possible protein pairs as described in 
the previous step. To identify the proteins which are similar in function, a 
confidence score cutoff (CSC) was used with a default value of KS≥95. The CSC can 
be any positive integer ≤100. A lower CSC would result in the formation of SFPG 
with false positives. It is important to establish here that a given transcript can be 
a member of one or more SFPGs, as it can have certain a sufficient amount of 
similarity (above the assigned DS or KS threshold) with transcripts belonging to 
different SFPGs. 
 
Calculating SFPG expression 
This step is divided in two parts: first the normalization of the raw reads followed 
by the calculation of the SFPG expression. For the normalization, the raw read 
counts of the transcripts and their effective length were used as calculated by 
RSEM. 
(1) Normalization: For the calculation of the SFPG expression, the read counts need to 
be both in-sample and across-samples normalized. While FPKM is in-sample 
normalized, it is not comparable across different samples. Additionally, while the 
normalized read counts generated using one of state of the art method (such as 
DESeq2 or, edgeR) focuses on normalizing for library depth and genes densities to 
compare the same transcript among different treatment groups, it does not allow 
the absolute comparison of transcripts of a different length. To address these 
concerns, we combined these two normalization approaches and generated 
expression which is in-sample and across-samples normalized. We first normalized 
the raw read counts for the transcripts using the DESeq2 default normalization 
method and then, using the effective length of the transcripts as given by the RSEM, 
converted these normalized read count into FPKM (c.f. normalized_fpkm module 
on FuSe’s GitHub repository). 
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(2) Expression of SFPGs: Using the normalized FPKM and SFPGs formed in step 3, SFPG 
expression is then calculated. The calculation of the SFPG expression can be 
achieved using one of two proposed approaches available in FuSe: (a) equal 
distribution (ED) or (b) group size distribution (GD) available under 
“recal_expression” module. In the case of equal distribution, the expression of the 
transcript is equally divided between all the SFPGs of which it is a member 
(equation 5), thus giving equal importance and weight to all individual members of 
all SFPG.  For the group size distribution, the expression of the SFPGs is based on 
the number of members present in each SFPG (equation 6) (Suppl. Fig. 4). If the 
equal distribution is used, each function, as defined by a SFPG, is given equal 
importance whereas group size distribution is based on the concept of genetic 
redundancy [23], giving higher importance to bigger groups. Group size distribution 
is illustrated in Suppl. Fig. 5. 
 












6C+    
   …Eq. 6 
 
Using the GRCh38 for humans from Ensembl, we have created the data object 
(bi_do; BLAST Interpro data object) which can be used for further analyses. For 
using the future updates to Ensembl protein sequences, BLAST+ or/and Interpro, 
create a new bi_do using the steps mentioned on FuSe’s Github repository. The 
data object provided is generated using the protein coding transcripts only 
however, if the user intends, other types of transcripts can also be used for instance 
nonsense mediated decay, polymorphic pseudogene, non-stop decay, etc. refer 
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Assessment of FuSe 
To illustrate the significance of using FuSe, we used a RNA-Seq dataset obtained 
from a 3D human hepatic cell model (Primary Human Hepatocytes + Kuepfer cells 
Spheroids from InSphero®) exposed to APAP. Ribo-depleted libraries were 
generated from these cell models and sequenced on an Illumina Hiseq2000 (Suppl. 
Methods) at an average of 41.3 million reads per sample in 100bp paired-end 
(Suppl. Fig. 6). There were four sets of samples: control untreated (ConUNTR), 
control exposed to DMSO (ConDMSO), exposed to therapeutic dose (Ther), and 
exposed to toxic dose (Tox). ConUNTR and Ther had five time points: 0, 2, 8, 24, 
and 72 hours, and ConDMSO and Tox had four time points: 2, 8, 24, and 72 hours. 
Each time point had three replicates, totaling 54 samples. The therapeutic dose was 
calculated based on PBPK (physiologically based pharmacokinetic) modeling using 
human kinetic data, and the toxic dose was obtained from IC20 [24]. Data are 
available in the BioStudies database (http://www.ebi.ac.uk/biostudies) under 
accession numbers S-HECA143, S-HECA(158), S-HECA139. Reads above Q30 for 
ConUNTR, ConDMSO, Ther, and Tox samples constituted 85.19%, 88.43%, 94.5%, 
and 94.2% of all reads, respectively. FPKM for transcripts was calculated using 
RSEM and from its expression for SFPGs was calculated using FuSe. PCA (principal 
component analysis) and hierarchical clustering were done for top 500 expressed 
transcripts using R packages: prcomp() and hclust(), respectively, for isoform FPKM 
and recalculated SFPG expression to compare them. Then differentially expressed 
transcripts (DETs) were evaluated using Anova package in R for all dose vs control 
samples: ConUNTR v/s The, ConUNTR v/s Tox, ConDMSO v/s The, ConDMSO v/s Tox 
and Ther v/s Tox samples. Significant cutoff was set to p-value<0.01 and 
|log2FC|>1. Changes in the DETs between the original FPKM and recalculated 
expression were also established. 
 
Results 
In order to move from a loci-based transcriptomics analysis to a function-based 
analysis, we first need to identify all protein coding transcripts from the human 
genome. For this, a total of ~107k proteins were retrieved from Ensembl, of which 
719 proteins were discarded which originated from transcripts annotated as 
nonsense mediated decay, polymorphic pseudogene, T-cell receptor genes, and 
immunoglobulin genes. From the remaining transcripts, protein pairs were formed 
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and two confidence scores (KS and DS) were calculated to estimate the likelihood 
of similar functions. Taken individually, both scores are used to make the protein 
pairs and a confidence score cutoff (CSC, here used: 85, 90, and 95 for both KS and 
DS) is introduced to discard the protein pairs with low similarity. While both DS and 
KS show a steep increase in the number of pairs with the lowering of CSC, a steep 
increase for DS can be seen (Fig. 1A). The protein pairs can be divided into four 
categories depending on the origin of the transcripts, namely: same gene, same 
gene family, different gene, or undefined (Fig. 1B). A considerable amount of 
protein pairs originated from the same or different gene families at KS and DS ≥95. 
Moreover, a surge can be witnessed with decreasing CSC. 
With the protein pairs at different CSC, SFPGs are formed and a similar trend of 
increase in the group size (Fig. 1C), the sum of group sizes per CSC and maximum 
group size for a SFPG (Suppl. Fig. 5(A)) with decreasing CSC can be seen. The median 
for the group size per CSC remains low (Suppl. Fig. 5(B)), implying that most groups 
are small. The increase in group size for the biggest group per CSC was also 
apparent (Suppl. Fig. 5(C)). For KS and DS at ≥95, the largest group size was 84 and 
111 which rose to 216 and 229 at ≥85, respectively. 
To evaluate the impact of SFPG on biological interpretation, we applied FuSe on an 
in vitro transcriptomics dataset obtained from a hepatic cell model exposed to 
different doses (therapeutic and toxic) of APAP for variable time duration and 
corresponding controls (untreated and DMSO). The dataset was analyzed by locus-
based and our function-based method. For this, SFPGs at KS≥95 were taken to 
particularly consider the highly similar protein pairs predicted using maximum 
available knowledge. The expression for the SFPGs was calculated from the 
normalized FPKM using both methods, namely, ‘ED’ and ‘GD’ (c.f. section 2.4, 
Calculating SFPG expression). Differences in the recalculated expression from ED 
and GD are discussed in the Supplementary Results, Suppl. Fig. 7. The primary 
analyses shown in this paper makes use of the recalculated expression obtained 
using the ‘GD’ method to give a higher importance to bigger SFPGs, implying that 
important biological processes are conserved. The term recalculated expression 
from here on designate the recalculated expression from ‘GD’. The normalized 
FPKM and recalculated expression (GD) from FuSe were then compared.  










































































































































































































































































































PCA bi-plots and clustering (Fig. 2, Suppl. Fig. 8 (A-E)) were done to show that FuSe 
preserves the inter-sample variation and global profile of the samples. The highest 
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Furthermore, differentially expressed transcripts (DETs) were calculated for the 
FPKM and recalculated expression obtained using FuSe, individually for all control 
v/s dose samples. Lesser number of DETs were observed after applying FuSe (Fig. 
3, Suppl. Table 1). We also observed many transcripts that were significantly 
differentially expressed in FPKM but non-significant after using FuSe and vice-versa 
(Fig. 3, blue bars and green bars, respectively). With loci based analyses, the 
differences were computed at the transcript level while using FuSe the changes at 
the functional level were captured. Using FuSe, the expression levels were correctly 
quantified as a result of the expression of other similar function proteins. In the 
case of ConUNTR v/s Tox and ConDMSO v/s Tox, this is illustrated by protein coding 
transcripts from many genes responsible in cell adhesion and tight junction such as 
PKP2-201 (Plakophilin-2), CHCHD3-203 (MICOS complex subunit), CHCHD3-201 
(MICOS complex subunit MIC19), IMMT-205 (MICOS complex subunit MIC60), 
AGRN-201 (Agrin), WDR1-205 (WD repeat-containing protein 1), CTNNA1-243 
(Catenin alpha-1), ZBTB33-202 (Transcriptional regulator Kaiso), ASPH-201 and 
ASPH-207 (Aspartyl/asparaginyl beta-hydroxylase). All these transcripts, not 
considered differentially expressed by the standard analysis method, were found 
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More importantly, some transcripts displaying a significant regulation (up or down) 
using the conventional analysis method were found to be significantly regulated in 
the opposite direction after using FuSe (Fig. 4, Suppl. Fig. 9). The highest number of 
switches was seen for ConUNTR v/s Ther. A total of 79 unique transcripts changed 
their direction of regulation (from upregulated to downregulated and vice-versa), 
and 3727 changed from differentially expressed to not differentially expressed (and 
vice-versa) across all comparisons.  As an example, PPP1R14B-203 (Protein 
phosphatase 1 regulatory subunit 14B) and GBE1-205 (1,4-alpha-glucan-branching 
enzyme), which are protein coding transcripts, demonstrated a change in the 
direction of regulation. While for PPP1R14B-203, the change could be seen for 
ConDMSO v/s Ther and ConDMSO v/s Tox, for GBE1-205, the switch was witnessed 
for ConUNTR v/s Tox and ConDMSO v/s Tox. 
 
 
Figure 4: Number of DETs changing the direction of regulation. The figure illustrates the 
number of transcripts for which the change in the direction of regulation of the DETs 
(basemean>10 and pval<0.01 and |log2FC|>1) was observed. The comparison was made for 





Figure 5: Effect of using FuSe. Several DETs changed their direction of regulation (up or down 
regulated); here illustrated using two cases. (A) PPP1R14B-203 was upregulated with the 
standard method but, after the functional grouping based analyses, it was shown to be down 
regulated for (i) ConDMSO v/s APAP Ther and (ii) ConDMSO v/s APAP Tox. (B) Similarly in the 
case of GBE1-205, for (i) ConUNTR v/s APAP Tox and (ii) ConDMSO v/s APAP Tox, it was 
exhibited as downregulated regulated after applying FuSe. 
 
FuSe also demonstrated how gene expression based analyses sometimes lead to 
incorrect results. As there are multiple different protein coding transcripts for a 
gene, to compare the expression of the gene to the transcripts we selected the 
longest protein coding transcripts for the comparison. Moreover, for the APAP 
study, there were ~59% genes where the longest protein coding transcript was the 
highest expressed transcript; making them a suitable candidate for the comparison. 
The differences between the gene and SFPG expression can be illustrated here 
using two cases, POLR2J2 (RNA polymerase II subunit J2) from ConUNTR v/s Tox 
and UBE2D4 (Ubiquitin-conjugating enzyme E2 D4) from ConUNTR v/s Ther (Fig. 6). 
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While the gene expression of POLR2J2 is contributed by two transcripts (both 
protein coding), the expression of SFPG (POLR2J2-202) is attributed by four similar 
protein coding transcripts (KS = 98.02). The expression of the longest protein coding 
isoform follows the pattern of the gene expression, however, the SFPG expression 
shows the opposite. For UBE2D4, the gene expression comprises of expression of 
11 transcripts (one retained intron, one processed transcript, seven nonsense 
mediated decay, and two protein coding), the SFPG expression of the longest 
protein coding transcript from the gene (UBE2D4-201) is contributed by 18 similar 
protein coding transcripts (KS = 96.05). The longest protein coding transcript 




Figure 6: Expression of the gene, the longest protein coding isoform, and SFPG from FuSe. 
The typical gene expression analysis is obtained by summing all the transcripts (protein 
coding and non-coding) from the locus whereas in our proposed functional grouping, only the 
transcripts making the same protein are grouped and expression is calculated for the SFPG. 
The longest protein coding isoform from the gene was chosen as a representative of the gene 
to be compared directly with SFPG. (A) POLR2J2; the gene expression is the result of two 
protein coding transcripts whereas the SFPG is constituted by four similar protein coding 
transcripts. (B) UBE2D4; the gene expression is the result of 11 transcripts (two protein coding 
and nine non-coding transcripts) whereas the SFPG is constituted by 18 similar protein coding 




Biological research aims to find the functional properties and changes in the 
biological system, which makes us question the very fabric of our current RNA-Seq 
analyses strategies that focuses on changes in individual genes or transcripts. While 
the information of each gene or transcript is informative, however at the system 
level, contribution by each element should be viewed in terms of functional change. 
Elevating the analyses of the RNA-Seq to the functional level will increase our 
understanding of the biological systems and their underlying processes. Due to the 
limitations in quantifying the whole panel of expressed proteins and limited 
knowledge of protein tertiary and quaternary structure, and functions identifying 
the proteins having similar functions is challenging. Here, we focused on the 
primary and secondary structure of the proteins to establish their functional 
similarity. 
The hypothesis that similar primary sequence and secondary structures make the 
proteins possessing similar functional properties can be challenged at various 
levels, however, it is an acceptable hypothesis [26] and holds true for most cases 
as shown by studies of homologs and paralogs [27]. Protein trees calculated from 
sequence similarity often have the same topologies as those calculated from 
structural similarity. While some cases might be overlooked for instance a point 
mutation, which can result in a different conformation of the protein, they will not 
have a significant influence on the sequence alignment and secondary structure 
prediction (if not present in the prediction region). Moreover, other external 
factors such as molecular crowding or macro-molecular environment cannot be 
accounted for while taking into account only the primary and secondary structures. 
Even though primary and secondary structures exhibit some limitations to predict 
similar proteins, they allow us to group similar function proteins and form SFPGs. 
FuSe uses amino acid sequences of the proteins thus eliminating all non-coding 
transcripts from the analyses. While many non-coding transcripts have been 
associated with a specific function, not enough data are available at this stage to 
allow a generic in silico grouping of non-coding RNA sharing a similar biological 
function. Moreover, the transcripts annotated as nonsense mediated decay, 
polymorphic pseudogene, T-cell receptor genes, and immunoglobulin genes were 
removed from the formation of SFPGs. Nonsense mediated decay transcripts were 
removed because they are destined to be decayed before entering the ribosomal 
Beyond Gene Expression 
 88 
machinery for protein synthesis. In the case of the polymorphic pseudogenes, they 
have lost their functional properties over evolution and may result in non-
functional proteins. T-cell receptor and immunoglobulin genes are very selective 
for their targets and even if they share high similarity among them, they have 
different affinities for their targets and hence cannot be considered as a similar 
functional entity. Even though these transcript types are removed from the 
creation of SFPGs, they are retained with their original expression in the 
recalculated expression. 
The SFPGs are hence formed of only the protein coding transcripts. The similarity 
of the proteins is established using the two score types: DS and KS. DS makes an 
over-prediction because it relies only on the amino acid sequence, providing little 
information on the final structure and hence function(s) of the protein. KS is more 
conservative and takes into account other available knowledge to establish 
similarity. The lenient nature of DS makes it a powerful tool to find novel protein 
pairs whereas KS, being stringent, under-estimates and limits the ballooning of the 
groups by keeping only highly similar proteins together. DS can be used in finding 
the local similarities in proteins and thus allows the discovery of a subset of 
common functions between two proteins whereas KS thrives for global functional 
similarity. 
It is worth noting here that a SFPG is made for each protein coding transcript that 
has other similar protein coding transcripts, in order to preserve the specialized 
protein functions. It resulted in redundancy, as some transcripts can be a member 
of multiple SFPGs and these SFPGs might then be semi- or fully- overlapping. If such 
SFPGs were merged, it would result in the formation of false-positive SFPGs 
(decreased specificity) and the consecutive loss of some specialized protein 
functions. As some transcripts were shared between many groups, for the 
calculation of expression of the SFPGs, two methods are made available. First, 
equally dividing the expression of member transcripts between all the overlapping 
SFPGs and the other where the expression is divided between the SFPGs based on 
the group size of each SFPG, giving higher expression to bigger groups. While the 
first method is conservative giving equal importance to all SFPGs, the second is 
biased towards the bigger SFPGs, establishing that the important functions are 
more preserved. The quantification of the SFPG expression using FuSe requires in-
sample normalized data because it needs to compare the transcripts within the 
sample for its calculation. Moreover, the expression should also be normalized 
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across samples to compare it across samples. We calculated the FPKM from the 
normalized expression which was obtained using DESeq2. As a consequence, SFPGs 
are advised to be studied in relative analysis comparing a given SFPG between two 
biological conditions rather than for evaluating their absolute expression level 
among the different SFPGs. 
The results from the comparison of FPKM and expression of SFPGs using FuSe from 
the hepatic cell model established that the changes in the expression of the 
transcripts acquired using FuSe do not change the overall look of the samples, 
though the changes at the level of SFPGs were apparent and pointed towards 
different functional inferences. For instance, genes responsible for cell adhesion 
and tight junctions that were initially shown to be not differentially expressed. 
However, the application of FuSe completely changes the biological interpretation 
of this signal, confirming the documented APAP effects [28, 29].  
There were also cases of transcripts that were differentially expressed in the 
opposite direction after correction using FuSe, e.g. PPP1R14B-203 (ConDMSO 
versus Ther) and GBE1-205 (ConUNTR versus Tox) (Fig. 4). The correction by FuSe 
reversed the direction of perturbation and hence completely changed the 
inferences drawn from the results. PPP1R14B is responsible for inhibition of 
PPP1CA, which is involved in different processes such as cell division, regulation of 
glycogen metabolism, muscle contractility, and protein synthesis via 
dephosphorylation [30, 31]. For the therapeutic dose of APAP, the upregulation of 
PPP1R14B as shown by FPKM based differential expression would imply all these 
processes to be inhibited. Similarly, GBE1 was shown to be upregulated under APAP 
toxic dose, implying that the glycogen accumulation in the liver has increased. 
However, APAP is known to induce glycogen depletion and is considered as one of 
the early biomarkers of acetaminophen-induced hepatotoxicity [32]. Using FuSe, 
the GBE1 function is shown to be down regulated. The use of SPFGs also 
demonstrated why studying gene expression to attain differentially expressed 
genes can be miss leading, as in the case of UBE2D4 (gene expression: down 
regulated; SFPG expression: upregulated) and POLR2J2 (gene expression: 
upregulated; SFPG expression: down regulated). UBE2D4 is involved in 
ubiquitination [33] and POLR2J2 is an important component of RNA polymerase II. 
The downregulation of POLR2J2 would result in a decrease in transcription while 
the upregulation of UBE2D4 implies more ubiquitination leading to increased 
protein degradation. This suggests a decrease in protein levels in the cell, and hence 
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the disruption of cell processes, which is consistent with the knowledge on APAP 
overdose.  
FuSe showed how moving from loci-based to function-based analyses changed the 
inferences derived from the RNA-Seq data. It illustrated functional changes that 
could not be captured using the conventional RNA-data analyses. Moreover, FuSe 
is forward compatible and new data that will be available in the future for 
transcripts’ protein sequences and secondary structures can be integrated into the 
analysis by following the steps mentioned for ‘Creating your own BLAST Interpro 
data object’ under the Methodology section. Lastly, the transcripts coding for the 
same protein and originating from overlapping chromosomal locations but 
annotated to different genes have to be studied further to understand the 
processes and signals responsible for guiding different genes to make similar 
proteins. In the future, we will look to fine-tune the calculation of CSC using other 
inherent features of the proteins such as molecular weight, charge, electrophoretic 
properties, active sites, or hydrophobic-hydrophilic properties. Furthermore, to 
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Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in the 
world owing to limitations in its prognosis. The current prognosis approaches 
include radiological examination and detection of serum biomarkers, however, 
both have limited efficiency and are ineffective in early prognosis. Due to such 
limitations, we propose to use RNA-Seq data for evaluating putative higher 
accuracy biomarkers at the transcript level that could help in early prognosis.  
 
Method 
To identify such potential transcript biomarkers, RNA-Seq data for healthy liver and 
various HCC cell models were subjected to five different machine learning 
algorithms: random forest, K-nearest neighbor, Naïve Bayes, support vector 
machine, and neural networks. Various metrics, namely sensitivity, specificity, 
MCC, informedness, and AUC-ROC (except for support vector machine) were 
evaluated. The algorithms that produced the highest values for all metrics were 
chosen to extract the top features that were subjected to recursive feature 
elimination. Through recursive feature elimination. the least number of features 
were obtained to differentiate between the healthy and HCC cell models. 
 
Results 
From the metrics used, it is demonstrated that the efficiency of the known protein 
biomarkers for HCC is comparatively lower than complete transcriptomics data. 
Among the different machine learning algorithms, random forest and support 
vector machine demonstrated the best performance. Using recursive feature 
elimination on top features of random forest and support vector machine three 
transcripts were selected that had an accuracy of 0.97 and kappa of 0.93. Of the 
three transcripts, two were protein coding (PARP2-202 and SPON2-203) and one 
was a non-coding transcript (CYREN-211). Lastly, we demonstrated that these three 
selected transcripts outperformed randomly taken three transcripts (15000 
combinations), hence were not chance findings, and could then be an interesting 




Using RNA-Seq data combined with machine learning approaches can aid in finding 
novel transcript biomarkers. The three biomarkers identified: PARP2-202, SPON2-
203, and CYREN-211, presented the highest accuracy among all other transcripts in 
differentiating the healthy and HCC cell models. The machine learning pipeline 
developed in this study can be used for any RNA-Seq dataset to find novel transcript 
biomarkers. 
Code: www.github.com/rajindeer4489/ML_biomarkers  
Beyond Gene Expression 
 96 
Introduction 
The liver, one of the largest organ in the body, performs various important 
functions, such as filtering harmful substances from the blood to be then excreted 
from the body, producing bile to help in the digestion of fats from food, or storing 
glycogen (sugar) that will be used for energy. Due to its continuous exposure to 
harmful substances, it is prone to the amplitude of diseases which can eventually 
cause liver failure and/or liver cancer. Cirrhosis, long term infection with hepatitis 
B virus, and hepatitis C virus, alcoholic liver disease, and nonalcoholic fatty liver 
disease (NAFLD) are leading risk factors for primary liver cancer [1]. Moreover, 
cancer can develop in the liver at any stage in the progression of various liver 
diseases. As published in independent reports by World Health Organization (WHO) 
[2] and the US Center for Disease Control and Prevention (CDC) [3], liver cancer is 
among the top causes of cancer death worldwide, of which hepatocellular 
carcinoma (HCC) is the most common type of primary liver cancer, accounting for 
~80% liver cancers. 
Reducing the global burden of HCC is, therefore, a primary concern and it can be 
achieved by improving early detection and management [4]. Currently, the 
employed prognosis for HCC includes radiological examinations and assessment of 
serum markers. Radiological examinations are limited for early diagnosis as the 
performance of the imaging techniques begins to degrade substantially below a 
lesion size of 2 cm and have only modest accuracy below a lesion size of 1 cm  [5]. 
In the case of biomarkers, currently, there are ~20 biomarkers (Table 1) in research, 
and out of these only α-fetoprotein (alpha-fetoprotein or AFP) has a clinical 
application; even though it is ineffective for detecting early lesions [1, 6-8]. Of the 
other markers used in research, none have reached the standard level of clinical 
practice so far [6, 9]. However, in various studies, it has also been demonstrated 








Table 1: Currently used serum biomarkers in the prognosis of hepatocellular carcinoma 
(HCC). 
Used 













AFP[10] Alpha-fetoprotein Increased, a sign of liver cancer 
DCP[10] des-gamma-carboxy prothrombin 
Increased, a sign of 
liver cancer 
GPC3[16] Glypican-3  GPC3 is overexpressed in HCC 
GP73[17] Golgi glycoprotein 73 High expression of GP73 in primary HCC 
MDK[18] Midkine  Overexpressed in tumors 
OPN[19] Osteopontin  Overexpressed 
SCCA[14] Squamous cell carcinoma antigen 
SCCA1, SCCA2 
overexpressed 
ANXA2[20] Annexin A2 Increased in  HCC 
Annexin A7[21] Annexin A7 
Increased expression 
inhibits HCC lymph 
node metastasis 
CD44[22] Cluster Differentiation 44  Increased 
CD90[22] Cluster Differentiation 90 Increased 
CD133[23] Cluster Differentiation 133 or prominin-1 
CD133 protein 
expression levels of 
HCC in both the 
cytoplasm and nucleus 
were significantly 
higher than adjacent 
normal liver tissue. 
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and EpCAM positivity 
were associated with 
tumor recurrence 
TGF-β (1,2,3)[25] Transforming growth factor beta Highly activated 
FGF[26] Fibroblast growth factor 
Expression was only 
detected in the liver 
tissues of patients 
with chronic hepatitis 
type C and HCC 
HGF/SF[27] Hepatocyte growth factor receptor 
HGFA and Matriptase 




















reactive fraction of alpha-
fetoprotein, des-gamma-
carboxy prothrombin 
Increased, a sign of 
liver cancer 




GPC3 with CK19 and 
AFP 
GPC3, HSP70, GS 
[12] 
Glypican 3, Heat shock 
protein 70, Glutamine 
synthetase 
All increased, show a 
better diagnosis 
TLN1, MDK [13] Talin-1, Midkine 
Talin-1 decreased, 
MDK increased in 
serum 
SCCA-AFP [14] 







1α, vascular endothelial 
growth factor  
HIF-1α 




Though the combinations of various biomarkers are better predictors than the 
individual biomarkers, sensitivity or specificity is still low for all biomarker 
combinations [10-15]. While proteins are the major functional element, the 
corresponding transcripts can be an easier surrogate to detect and quantify. The 
cancer-specific mRNAs can leak into the serum as a result of passive processes (such 
as necrosis) and active processes (such as tumor cell apoptosis and active release 
in microvesicles by tumor cells) [28-31]. Though non-invasive, the lack of 
transcriptomics data for circulating cell-free mRNAs for HCC poses a limitation in 
undertaking a comprehensive in silico study to find novel biomarkers in serum. Only 
one study was found where the extracellular mRNAs for three HCC cell models, 
namely HepG2, Huh7, and immortalized normal liver PH5CH cells were profiled 
[32]. On the other hand, exhaustive transcriptomics data is available for HCC 
tissue/cell models (c.f. Methods) and hence, we concentrated on such data to find 
novel HCC biomarkers. 
Using RNA-Sequencing (RNA-Seq), the whole transcriptome can be quantified. 
Moreover, different types of transcripts (protein coding and non-coding) can also 
be identified. Most transcriptomics analyses focus on gene expression by 
aggregating the expression of all transcripts for the given gene. However, in this 
study, we will focus on the transcripts because alternative-splicing defects in cancer 
are well documented [33-35] and dysregulation of splicing variants’ expression has 
recently emerged as a novel cancer hallmark [35]. Moreover, using the RNA-Seq 
data at the transcript level will also allow us to investigate the potency of non-
coding transcripts to be used as biomarkers. 
Machine learning (ML) is a multidisciplinary field that makes use of computer 
science, artificial intelligence, computational statistics, and information theory to 
build algorithms that learn from existing data and make predictions on new data 
[36]. It has found application in diverse domains of biomedicine, including, but not 
limited to, image analysis [37], cancer prediction from heterogeneous data [38], 
robust phenotyping [39], gene discovery [40], differential network analysis [41], 
biomarker discovery [42], and transcriptional regulated genes [43]. The application 
of machine learning for the biomarker discovery from the RNA-Seq data is mainly 
focused on genes, however, recent studies have demonstrated that transcript 
based analyses outperformed gene-based analyses using ML [44, 45]. To assess if 
transcript biomarkers have better prediction accuracy, we analyzed various HCC 
cell models and healthy liver RNA-Seq data. Several HCC cell models were taken for 
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this study (Table 2) to ascertain that their biological heterogeneity is accounted for 
while building the ML models. Various ML algorithms, namely random forest (RF), 
K-nearest neighbors (KNN), support vector machines (SVM), Naïve Bayes (NB), and 
Neural networks (NNET), which are extensively used in the field of biomedicine, 
were applied to build the models and identify novel putative transcript biomarkers 
for HCC. 
From the transcriptomics data, three datasets were assembled: all transcripts, 
protein coding only and non-coding only. The goal of making these three datasets 
was to see if one of them provides a better prediction. Consecutively, the efficiency 
of the known protein biomarkers (Table 1) was also assessed by taking the 
transcripts for their corresponding genes. The mapped genes also comprised of 
protein coding and non-coding transcripts and they were also made into three 
datasets (as given above). The results from the complete transcriptomics data and 
known protein biomarkers (for all datasets) were compared to establish which 
dataset(s) performs better. 
 
Methodology 
The overview of the methodology is presented in Figure 1 and detailed steps are 
given below. 
1. Data collection 
a. HCC cell models: The list of all HCC human cell models was obtained from 
Cellosaurus [46] (Suppl. Table 1). 
b. RNA-Seq data: Using the names and synonyms of these cell models, RNA-Seq 
datasets were searched on the European Nucleotide Archive (ENA) and were 
filtered for baseline expression, instrument model (Illumina HiSeq 2000 or HiSeq 
2500 or NovaSeq 6000) and paired-end library layout (Table 2). The samples were 
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Study Id Run accession 





































SNU-398 HCC 1 
SRR8615311 SNU-387 HCC 1 
SRR8615387 Li-7 HCC 1 
SRR8615471 SNU-878 HCC 1 
SRR8615472 SNU-886 HCC 1 
SRR8615483 JHH-1 HCC 1 
SRR8615650 SNU-475 HCC 1 
SRR8615654 SNU-423 HCC 1 
SRR8615655 SNU-449 HCC 1 
SRR8615661 HuH-7 HCC 1 
SRR8615664 HuH-1 HCC 1 
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SRR8615682 SK-HEP-1 HCC 1 
SRR8615914 JHH-7 HCC 1 
SRR8615918 JHH-2 HCC 1 
SRR8615919 JHH-4 HCC 1 
SRR8615920 JHH-5 HCC 1 
SRR8615921 JHH-6 HCC 1 














HKCI-1 HCC 1 
SRR873427 HKCI-4 HCC 1 
SRR873428 HKCI-7 HCC 1 
SRR873429 HKCI-9 HCC 1 
SRR873430 HKCI-11 HCC 1 




































Beyond Gene Expression 
 104 
HepG2 HCC 7 
*There were a total of 27 samples but three samples from children or infants were removed 
 **There were a total of 12 replicates for PHH, one was removed for low library depth during 
filtration for quality. 
 
c. Known biomarkers: Concurrently, a list of all known biomarkers for HCC was 
collected through an exhaustive literature review (Table 1). These biomarkers were 
mapped to their corresponding Ensembl gene ids using Biomart and manual 
curation. In instances where there was more than one gene mapping to the protein 
biomarker, all instances were taken. For all the Ensembl genes that were mapped 
to the biomarkers, all of them had multiple isoforms/transcripts, comprising of both 
protein coding and non-coding transcripts.  
2. Data preprocessing: The raw RNA-Seq data (fastq files) were first trimmed of their 
adapter sequences using Trimmomatic [47],  mapped onto the human genome 
(version 84) from Ensembl [48] using Bowtie2 [49], and quantified using RSEM [50]. 
Isoform read counts were then normalized for different studies using DESeq2 [51]. 
3. Machine learning: 
a. Preparing different datasets: We analyzed the known protein biomarkers and 
complete data (named as all data) separately. Furthermore, the transcriptomics 
data consists of protein coding and non-coding transcripts and it provided the 
opportunity to investigate the efficiency of different types of transcripts in 
identifying healthy and HCC cell models. We made three datasets, namely all 
transcripts (protein coding and non-coding), protein coding only, and non-coding 
only for both – all data and known protein biomarkers (Fig. 1). 
b. Machine learning algorithms: On these six datasets (Fig. 1), machine learning 
algorithms from the caret package in R [52] were applied. We used five different 
algorithms, namely random forest (RF), K-nearest neighbors (KNN), support vector 
machines (SVM), Naïve Bayes (NB), and Neural networks (NNET) with ten-fold 
cross-validation for ten times. All further steps are applied to all six datasets 
individually. The seed was fixed to have reproducible results. 
The data was first divided into 70:30 for training and testing, respectively. A 
separate validation set was not created because we used k-fold cross-validation to 
tune the model’s hyper-parameters. In the case of datasets (all transcripts, protein 
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coding only, and non-coding only) from all data, all transcripts that had a  total 
expression for all samples below 10000 were removed. This expression filter was 
applied to take into account only the highly expressed transcripts. However, in the 
case of known biomarkers, no such filter was used since we wanted to retain all 
information. Furthermore, using the ‘findCorrelation’ feature form the Caret 
library, highly correlated transcripts (>0.75) were identified and removed, except 
one (the first, a random transcript). Each algorithm’s performance is assessed on 
all datasets by evaluating various metrics, namely sensitivity, specificity, accuracy, 
Matthew's correlation coefficient (MCC), and informedness (equations 1-4) using R 
library ‘MLeval’ [53] (Table 3). Additionally, the time taken by each algorithm to run 
is also provided. 
Based on the results from these metrics, the best algorithm and dataset were 
selected and the top 20 important features (transcripts) were extracted using 
“varImp” from the Caret library. Then to find the minimum set of features to 
differentiate between healthy and HCC cell models, “RFE” (Recursive Feature 
Elimination) from the Caret library was applied using the method cross-validation 
(CV). 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦	𝑜𝑟	𝑇𝑃𝑅	 = 	 0R
0R%UD
     …Equation 1 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦	𝑜𝑟	𝑇𝑁𝑅	 = 	 0D
0D%UR
     …Equation 2 
𝑀𝐶𝐶	 = 	 0R.0D>UR.UD
X(0R%UR)(0R%UD)(0D%UR)(0D%UD)
   …Equation 3 
𝐼𝑛𝑓𝑜𝑟𝑚𝑒𝑑𝑛𝑒𝑠𝑠 = 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦	 + 	𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 − 1  …Equation 4 
where 
TP is true positive 
TN is true negative 
FP is false positive 
FN is false negative 
MCC is Mathew’s correlation coefficient 
4. Re-training the model: The features (transcripts) selected using RFE were used to 
train the final model. Taking these features, exhaustive k-fold cross-validation was 
run by setting the repeats to 100 and number to 10; implying 1000 instances will 
be evaluated. 
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5. Chance findings: There were a total of ~200k transcripts and to establish that the 
features (transcripts) selected using RFE were not chance findings, 15000 iterations 
were performed taking three random transcripts out of the highly expressed 
transcripts to compare their prediction accuracy. The results from randomly taken 
transcripts were compared to the selected features (transcripts from RFE). 
 
Results 
To obtain an exhaustive list of all HCC in vitro cell models, Cellosaurus [46] was used 
(accessed on 27/08/2019). It houses data for 250 HCC cell models for humans 
(Suppl. Table 1). RNA-Seq data for all 250 cell models were searched on ENA using 
the application programming interface (API), taking the data generated using 
Illumina’s HiSeq platforms or newer and library layout as paired-end. Furthermore, 
it was manually checked if the data were obtained at baseline. A total of 51 samples 
from 6 studies comprising of 33 cell models from ENA passed the filters and manual 
curation (Table 1). Samples from the EU-ToxRisk project were also taken; healthy 
in vivo liver (24 samples) and all other samples (32 samples from 5 cell models) 
were sequenced on NovaSeq 6000 and HiSeq 2500, respectively (Table 1). 
The samples’ quality was assessed using FastQC, and it was observed that all 
samples passed the “Per base sequence quality” metric.  However, one sample 
(PHH_024_1) did not pass the library size filter and was discarded. The samples 
passing the filters were then processed and the transcript expression was 
normalized using DESeq2 for different studies. 
We first investigated the expression patterns of the known biomarkers at the 
transcript level to see if the protein coding transcripts demonstrate a similar 
expression pattern as known protein biomarkers. Each gene can have multiple 
protein coding transcripts, only the ones mapped to manually annotated and 
reviewed Uniprot identifiers were considered and their expression pattern was 
examined (Suppl. Figure 1). VEGFA-223, HSP90AB1-203, FGF5-201, ANXA7-201, and 
SPP1-201 were the most down-regulated and CD44-206, HSP90AB1-201, SPP1-202, 
ANXA2-202, and CD44-209 were the most upregulated transcripts. 
We then investigated the accuracy of the known biomarkers (all three datasets, 
namely all transcripts, protein coding only, non-coding only) and all data (all three 
datasets), in predicting the correct labels for the cell models. We focused only on 
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highly expressed transcripts and hence, to remove the lowly expressed ones, an 
expression filter was introduced (total expression across all samples > 10000 reads) 
(Table 3). However, in the case of known biomarkers, no such filter was used 
because we wanted to preserve any information, if present, held by even the lowly 
expressed transcripts. Furthermore, all transcripts having a high correlation (>0.75) 
were discarded to remove redundancy except the first (random) transcript in the 
list. To the remaining transcripts in each dataset, ML algorithms were applied, 
individually. While KNN and SVM were the fastest to run (a few seconds), NNET 
took the longest time for all datasets (most for all data-all transcripts: ~19 hours 44 
minutes) (Table 3). 
 
























Number of transcripts 
after expression filter; 
biomarkers no filter, all 
data > 10000 
410 262 149 16173 13688 2724 




177 98 37 12047 9866 1970 
Number of transcripts 
after removing highly 
correlated features 
234 165 113 4127 3823 755 
Time to run 
(in seconds) 
RF 10.77 8.09 6.44 196.2
5 
169.31 32.60 
NB 12.34 9.38 6.63 297.8
1 
280.27 46.05 
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KNN 1.03 1.10 1.11 5.63 5.62 1.78 
SVM 2.25 1,07 1.05 7.51 7.48 2.72 









The results obtained from the algorithms show that the area under the curve-
receiver operating characteristics (AUC-ROC) values were the highest for RF and the 
lowest for KNN, across all datasets (Fig. 2). AUC-ROC values for SVM cannot be 
obtained because it is a discrete classifier. For other metrics (sensitivity, specificity, 
informedness, and MCC) for all datasets, SVM illustrated the highest values (Fig. 3). 
In the case of known biomarkers, RF demonstrated high values comparable to SVM 
in some cases for all datasets. NB also illustrated high values for all metrics for all 
data-all transcripts. We were also interested to see if protein coding or non-coding 
individually could give a better prediction. However, it was noted that predictions 
were less accurate when using them separately, as compared to all transcripts. The 
confidence intervals for sensitivity and specificity were the smallest in the case of 



















































































































































































































































































































































































































































Based on the values of different metrics used to assess the performance of the 
algorithms on various datasets, RF and SVM performed the best for all datasets; 
primarily for all transcripts, protein coding transcripts, and non-coding transcripts 
datasets for all data. To further get the least number of features required to 
differentiate between the healthy and HCC cell models, the top 20 important 
features (transcripts) from RF and SVM when applied to all data-all transcripts were 
taken (Fig. 5A). There was a total of 32 unique features (transcripts), with an overlap 
of eight features between the two algorithms (Suppl. Figure 2). Furthermore, 
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number of features required to differentiate between healthy and HCC samples. 
With the application RFE, three features (transcripts) were identified (Fig. 5B), 
namely PARP2-202 (protein coding transcript), SPON2-203 (protein coding 
transcript), and CYREN-211 (non-coding transcript) with an accuracy of 0.97 and 
kappa of 0.93. These three transcripts were present in both algorithm’s top 
important features. While PARP2-202 was upregulated (log2 fold change: 2.368), 
SPON2-203 and CYREN-211 were both down-regulated (-5.421 and -2.771, 
respectively) (Fig. 5C). 
 
 
Figure 5: (A) Top 20 important features extracted from all data-all transcripts dataset 
obtained using (i) SVM and  (ii) RF. (B) Recursive feature elimination (RFE) used with the top 
20 features from (A) to extract a list of least number of features required to differentiate 
between healthy and HCC cell models. Three features were selected having an accuracy of 
0.97 and kappa of 0.93 (C) Average expression of three features (transcripts), across healthy 
liver and HCC cell models, chosen in (B). 
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A direct relationship of these genes (or transcripts) could not be established to HCC 
through literature review. However, an investigation of the gene ontology terms 
(biological process) obtained using DAVID [54] highlighted that CYREN-211 is 
involved in double-strand break repair via non-homologous end joining 
(GO:0006303) and PARP2-202 had a known function in DNA repair (GO:0006281), 
base-excision repair (GO:0006284) and DNA ligation involved in DNA repair 
(GO:0051103). In the case of SPON2-203, multiple ontologies for immune 
responses were obtained – GO:0002448 (mast cell mediated immunity), 
GO:0008228 (opsonization), GO:0032755 (positive regulation of interleukin-6 
production), GO:0032760 (positive regulation of tumor necrosis factor production), 
GO:0043152 (induction of bacterial agglutination), GO:0045087 (innate immune 
response), GO:0050832 (defense response to fungus), GO:0051607 (defense 
response to virus), GO:0060907 (positive regulation of macrophage cytokine 
production), GO:0071222 (cellular response to lipopolysaccharide), GO:0001530 
(lipopolysaccharide binding), and GO:0003823 (antigen binding). 
To assess its strength, the model was re-trained using these three features but with 
an increased number of cross-validations (repeats = 100, number = 10; implying 
1000 iterations). High values for all metrics were observed with RF and SVM 
(sensitivity: 0.968 and 0.944 (RF and SVM), specificity: 1 and 1, MCC: 0.973 and 
0.936, informedness: 0.968 and 0.944, and AUC-ROC: 0.99 (RF only)). Moreover, 
the confidence interval for sensitivity and specificity in the case of RF was 0.84-0.99 
and 0.92-1, respectively. Finally, to establish that these transcripts (PARP2-202, 
SPON2-203, and CYREN-211) were not chance findings, random combinations of 
three transcripts (highly expressed) were made and their efficiency was assessed 
and compared to the three transcripts selected using RFE. It was observed that out 
of 15000 combinations created, none of the combinations exhibited higher or equal 
values for the metrics for RF and only 0.12% cases (18 cases) demonstrated higher 
or equal value for the metrics in the case of SVM (Suppl. Table 2). 
 
Discussion 
Hepatocellular carcinoma (HCC) has a huge global burden and the challenge lies 
primarily in its early detection owing to the limited accuracy of serum biomarkers 
and inefficiency of radiological examinations. With advancements made in machine 
learning over the last few years, we investigated if it can assist in finding better 
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biomarkers for HCC. We took RNA-Seq data from HCC and healthy liver cell models 
and used various machine learning algorithms to highlight key features that can 
differentiate between the healthy and HCC cell models with high accuracy. A set of 
three transcripts were identified, namely PARP2-202, SPON2-203, and CYREN-211; 
proposed as novel putative transcript biomarkers. 
Though widely studied, RNA-Seq data for HCC at baseline is not abundantly 
available. Out of 250 HCC cell models listed in Cellosaurus, data could only be 
obtained for 33 cell models. Many studies were discarded in the process of 
selection due to single-end library layout, low coverage, exposure to drugs various 
treatments, and insufficient metadata. For the 33 cell models taken in this study, 
28 had only one replicate. This could have been a limiting factor if these were to be 
analyzed per cell model, however, in this study the focus was on HCC and all cell 
models were combined to define the transcriptome profile of HCC. Using the 
transcriptome profile, the cell type and/or condition (healthy/disease/treatment) 
can then be accurately assessed [55] and then comparing these profiles, distinct 
features for these profiles can be established. 
For HCC, many biomarkers are extensively studied (Table 1), AFP being one of the 
most studied biomarker. Although these biomarkers have been established 
through studies of serum, most of them are predominantly secreted by the liver 
[56]. In an attempt to compare the efficiency of these known biomarkers and all 
data with respect to their ability to discriminate between the healthy and HCC cell 
models, we observed that all data out-performed known biomarkers’ datasets. The 
comparatively lower accuracy obtained using known biomarkers can be attributed 
to fewer features (transcripts) in the dataset. While all data constituted of ~200k 
transcripts, known biomarkers amounted for ~400 features only. The 
transcriptomics data also provided an opportunity to investigate if protein coding 
or non-coding transcripts could individually be enough to classify healthy and HCC 
cell models. A loss of information can be witnessed in both instances compared to 
both types of transcripts taken together (all transcripts datasets) in case of known 
biomarkers and all data. This exhibits that the non-coding transcripts are equally 
important as the protein coding transcripts. Moreover, in recent studies, the 
dysregulation of long non-coding RNA in HCC has been studied [57] and their use 
as biomarkers has also been investigated [58]. 
Multiple machine learning algorithms (RF, NB, SVM, KNN, and NNET) were used to 
analyze the data and all exhibited high efficiency.  It was surprising to see how well 
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these algorithms performed, despite significant variations in the sample and library 
preparation by different labs.  Though all exhibited high efficiency, we observed 
some differences among them across all datasets as illustrated by various metrics 
calculated for them (Fig. 2 and 3). The reason for the varying performance of these 
algorithms on the same datasets can be explained by how their hyper-parameters 
are set. For instance, in the case of RF, the hyperparameters can be the number of 
samples required to split a node or tree depth; for KNN it can be the number of 
iterations to form k-groups or clusters; for NNET it can be node weights. 
The highest values for all metrics were demonstrated by RF and SVM on all data-all 
transcripts dataset and the confidence intervals were smallest for RF for the 
mentioned dataset. NB also exhibited high values for all metrics for all data-all 
transcripts dataset however it performed poorly for other datasets and hence was 
not considered for further analyses. Hence top 32 important features were 
extracted from the algorithm-dataset combination (RF and SVM with all data-all 
transcripts) to find the least number of features using RFE. RFE employs a backward 
selection of the predictors, starting with all and removing the ones with the least 
importance in the model. Three transcripts were identified having maximum 
accuracy and kappa (Fig. 5B). None of these three transcripts were the ones that 
were taken randomly from correlated transcripts (c.f. Methodology 3b) and hence 
no transcript was discarded (correlation >0.75) that could have provided the same 
prediction accuracy. One of the chosen transcript was a non-coding transcript 
(CYREN-211). While many studies have emphasized the role of non-coding 
transcripts in the initiation, progression, and metastasis of HCC [59-62], their 
identification as key features to differentiate HCC and healthy liver is highlighted in 
only a handful of recent studies [63, 64].  
Re-training the model using the three selected transcripts by applying exhaustive 
cross-validation helped in establishing their potency in discriminating the healthy 
from the HCC cell models. A final comparison with randomly selected highly 
expressed transcripts further established that these three transcripts were not 
chance findings; with values for all metrics always higher than the random 
combinations for RF and only 6 cases exhibited higher values for SVM. The three 
selected transcripts are involved in DNA repair pathways (CYREN-211 and PARP2-
202) and immune response (SPON2-203). The DNA repair pathways are known to 
be affected in most cancers [65, 66] and in recent studies, immune dysfunction in 
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HCC and immunomodulation as a major factor in HCC development have been 
highlighted [67, 68]. 
Though these transcripts are validated through in silico approaches, an extensive 
validation in the HCC patients still needs to be done. If established, such an 
approach can also be used to identify transcript level biomarkers for various 
diseases and conditions, thus providing us an opportunity to look beyond proteins 
and maybe help in the identification of the disease or the condition at an early 
stage. One drawback of the current study was that the data was taken from the 
liver and to predict HCC, an invasive approach has to be taken to extract the sample. 
To look for transcript biomarkers for HCC that are non-invasive, data from HCC 
patient’s blood serum/plasma will be required. At this moment, the scarcity of such 
data limits us from exploring the circulating mRNAs from HCC to find novel and 
potent biomarkers through in silico approaches. A thorough follow up study would 
be required to look for non-invasive/circulating transcript biomarkers in the blood 
of the HCC patients, by generating and analyzing the data as discussed in this study. 
 
Conclusion 
In our investigation of the healthy liver and various HCC cell models to find novel 
biomarkers, we analyzed RNA-Seq data using machine learning. Comparing the 
known HCC biomarkers with all other possible transcripts, we first concluded that 
using the exhaustive transcript list displayed better accuracy, thus implying that 
better biomarkers exist. Similarly, between all existing transcripts, protein coding 
transcripts only or non-coding transcripts only, it was illustrated that all 
transcriptomics data improved also the overall accuracy. From this observation, it 
can be concluded that both protein coding and non-coding transcripts hold 
important information and are regulated under internal and/or external stimuli. 
This is further supported by the identification of two protein coding (PARP2-202 
and SPON2-203) and one non-coding (CYREN-211) transcript as novel and potent 
biomarker for HCC. However, the findings would have to be validated in vivo. 
The pipeline developed in this study to identify transcript level biomarkers for HCC 
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Abstract 
Protein complexes are the multi-molecule machinery of the biological system that 
are crucially involved in biological structures and functions. Moreover, the 
assembly of the complexes is an intricate process and is well regulated, however, it 
is less understood. Though functionally and structurally imperative to the biological 
system, they are not contemplated while assessing different biological systems 
and/or conditions. In this work through time-series RNA-Seq data, we first present 
the calculation of the protein complex expression and as an application of dynamic 
Bayesian networks, the prediction of assembly order of protein complexes. We 
show that the lowest expressed subunit at different time points can be the same or 
different subunit and it defines the expression of the complex at the given time 
point. For instance, the expression of SMAD2-SMAD3-SMAD4 complex (CPX-1) was 
shown to be determined bya different subunit of the complex during the time 
series. Furthermore, from the expression of individual subunits over different time 
points, dynamic Bayesian networks were generated and, analyzing the edges over 
consecutive time points, the order of assembly was predicted. For an arbitrarily 
chosen complex, Laminin211-nidogen complex (CPX-1282), analyzing the network 
suggested that the initial interaction happened between LAMB1 and NID1, 
followed by LAMC1 with LAMA2, and finally, LAMB1 and LAMC1 bind to each other. 
The information of protein complexes (expression and protein-complex assembly 
order) is imperative in assessing the biological function and identification of 




Various proteins, macromolecules, metabolites, nucleic acids, and other 
biomolecules are produced within or transported inside the cells for its function 
and conformation structure. This crowded environment of the cell results in 
continuous interaction of all these biomolecules. Many interactions are non-
specific [1, 2]; however, others form the basis for a variety of biological processes 
including, but not limited to, cell cycle regulation, differentiation, protein folding, 
translation, transcription, post-translational modifications, gene expression, 
enzyme inhibition, and antibody-antigen interactions [3, 4]. These bound molecules 
that possess important functions are termed protein complexes. The interactions 
between the subunits of a complex can be either short-lived, for instance in the 
case of molecules involved in signaling networks, or stable over time such as 
filaments. Moreover, the binding affinity, given by the dissociation constant (Kd), 
between the proteins varies and is influenced by various factors, such as cellular 
conditions, mutations in the protein, and protein folding. Several databases [5-11] 
and in silico [12-21] approaches are available to assess this binding affinity. 
The complexes can also be classified as homomultimeric (homomeric) and 
heteromultimeric (heteromeric) protein complexes, according to their composition 
of the same or different biomolecules. Complexes can vary in their function and 
composition depending on the tissue type, developmental stage, and biological 
process, for instance, the lactate dehydrogenase (LDH) enzyme is a tetramer made 
of two different subunits, the H-form and the M-form. It assembles into five 
different complexes across various tissues in humans. LDH1 (4H; homomer) is 
found in the heart, LDH2 (3H1M; heteromer) in the reticuloendothelial system, 
LDH3 (2H2M; homomer) in the lungs, LDH4 (1H3M; heteromer) in the kidney, and 
LDH5 (4M; homomer) in the liver and striated muscle [22]. These five assemblies of 
the LDH differ in their electrophoretic mobility, with LDH1 being the fastest and 
LDH5 being the slowest. 
While a complex can be homomeric or heteromeric, the number of units of the 
participating biomolecules can vary. This distribution of the number of 
biomolecules in a complex is known as stoichiometry and is an important aspect 
while studying the complexes. Most heteromeric complexes have an equal number 
of molecules of the subunits, known as even stoichiometry; however, a significant 
minority have uneven stoichiometry, implying differing numbers of each subunit 
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type. The DNA polymerase epsilon complex in Saccharomyces cerevisiae 
demonstrates even stoichiometry and has one chain of each DNA polymerase 
epsilon subunit A, B, C, and D. An example of the uneven stoichiometry is SMAD1-
SMAD4 complex in humans, where SMAD1 has a stoichiometry of two and SMAD4 
has one. Recent studies have demonstrated increased translational efficiency for 
the higher stoichiometry subunits within a complex [23, 24]. It has been shown that 
the most common uneven stoichiometry that exists are 2:1 (including 2:1, 4:2, 6:3, 
and similar) and 3:1 (includes 3:1, 6:2, 9:3, and similar) [25]. 
Using various approaches, namely, X-ray crystallography, nuclear magnetic 
resonance (NMR), various mass-spectrometry techniques such as native, cross-
linked (CX or XL), ion mobility, and protein microarray [26]; the three-dimensional 
structures of thousands of protein complexes have been determined [27]. 
Additionally, there are also some computational methods available for protein 
complex prediction, these can be mainly divided into three categories: network-
based, biological-context-aware, and specialized methods; reviewed extensively in 
[26]. This information on the three-dimensional structure and conformation of the 
complexes has a broad impact on our understanding of biological function and 
evolution [28]. In a recent paper on the organizing principles of the protein 
complexes, it has been shown that the assembly of the homomeric protein 
complexes can be classified into three basic types: dimerization, cyclization, 
fractional transition, and into two basic types for heteromeric complexes: 
heteromeric subunit addition, and non-stoichiometric transition [29]. The paper 
further develops all possible topologies of the homomeric and heteromeric protein 
complexes and develops a periodic table for them. Such information on the 
topologies of the complexes can help in understanding the evolution of the protein 
complexes. Moreover, it can help in predicting the quaternary structure of the 
complex hence formed from the given stoichiometry; highlighting potential 
constraints for multi-subunit docking and hybrid methods. Lastly, it can be helpful 
in bioengineering the complexes. 
There are multiple databases available for the protein complexes [26] but many of 
them are not maintained anymore. The two major protein complex databases that 
are annotated manually and updated regularly are CORUM [30] and Complex portal 
[31]. They have 2417 (non-redundant) (CORUM) and 779 (Complex portal) protein 
complexes listed for humans, respectively (assessed on 14/08/202). While CORUM 
houses more complexes than Complex Portal, information of the stoichiometry of 
Chapter 5 
 125 
the subunits is given as text in the description which makes it difficult to extract it. 
While this could be achieved with Natural Language Processing (NLP) tools, it is a 
time-consuming process. The information of the stoichiometry is important in 
assessing the expression of the complex. Complex Portal houses complexes for 25 
organisms (assessed on 14/08/2020) and has stoichiometry defined for the listed 
protein complexes. These protein complexes include protein-only complexes as 
well as protein-small molecule (Chemical Entities of Biological Interest, ChEBI [32]) 
and protein-nucleic acid complexes. All complexes are derived from physical 
molecular interaction evidence extracted from the literature and cross-referenced 
in the entry, or by curator inference from information on homologs in closely 
related species or by inference from a scientific background. All complexes are 
tagged with Evidence and Conclusion Ontology codes to indicate the type of 
evidence available for each entry [31]. 
Various important aspects of the protein complexes such as half-life, binding 
affinity, stoichiometry, organizing principles, and conformations have already 
provided valuable information. However, the estimation of the expression and 
assembly order of the complexes would be required to further increase our 
understanding. The knowledge of the expression of the protein complex can be 
useful in establishing if the function of the complex is up- or downregulated. The 
expression-determining subunit for the protein complex is the lowest expressed 
subunit, after adjusting for the stoichiometry. 
Furthermore, the knowledge of the assembly order of the protein complexes can 
provide us the opportunity to find novel binding sites for the drugs to control and 
treat various diseases. During the assembly of a protein complex, binding affinity 
and conformations change. The knowledge of these attributes can be beneficial. 
Moreover, the assembly order information can also help in understanding 
evolution by mapping gene fusion events [33]. Currently, using mass spectrometry 
techniques, the knowledge of subunits and their connectivity is illustrated [34]. 
However, due to the use of destabilizing solutions used for mass spectrometry, it is 
not an ideal system for assessing the assembly order. Moreover, at any given time, 
there will be multiple conformations of each complex and assessing one complex 
at a time is a time-consuming process. Through an in-silico approach, preliminary 
predictions can be made that can then be validated in lab. 
We hypothesized that the expression of the subunits of a protein complex at 
multiple time points can provide information on the assembly of the complex 
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through the generation of probabilistic networks. To generate the probabilistic 
networks, dynamic Bayesian networks (DBN) were used on a time-series RNA-Seq 
dataset. A DBN is a Bayesian network (BN) that establishes the relationship/edges 
between the variables/nodes within the same and across different time steps. The 
edges are never directed from a later time point to an earlier time point, however, 
the forward prediction is possible. We used RNA-Seq data for this study instead of 
proteomics data because it has been shown that the protein complexes assemble 
co-translationally [35-37]. Additionally, the complexes are formed in a step-wise 
manner and the time-series data capture such information. The subunits that are 
required earlier will be formed first and then the other subunits will follow based 
on their requirement in the protein complex assembly. The RNA-Seq data were 
obtained from a baseline 3D human hepatic cell model (Primary Human 
Hepatocytes + Kuepfer cells Spheroids from InSphero®). The protein complex data 
(subunits and their respective stoichiometry) were taken from Complex Portal. 
For this study, transcript expression is used instead of gene expression because of 
the heterogeneity of gene expression. However, since each gene can generate 
multiple transcripts, to choose the principal transcript (or isoform) from the given 
gene, we used the APPRIS annotation [38] (Box 1). APPRIS uses structural and 
functional features of the protein-coding genes together with cross-species 
conservation information to annotate the splice isoforms. However, when 
unavailable, the longest protein-coding transcript of the gene was selected as the 
principal transcript. From the expression of these transcripts, the subunit 
expression was calculated. The assembly order was then predicted using DBNs and 
analyzing the connections between the nodes over consecutive time points, the 
assembly order was predicted. The knowledge of the protein complex expression 
and the assembly order of the complex would add another dimension to the study 




Protein complexes are taken from Complex Portal [31]. The total number of protein 
complexes obtained from the Complex Portal was 779 (as of 14/08/2020). Mainly, 
the protein complexes are made up of proteins; however, some may also include 
nucleic acids and/or small molecules. The Complex Portal gives the data for the 
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complexes as proteins defined by Uniprot identifiers, nucleic acids given as 
RNAcentral identifiers [39], and small molecules given as ChEBl identifiers [32]. 
We used transcriptomics data to calculate the expression of the protein complexes 
and their order of assembly. The RNA-Seq data were obtained from a baseline 3D 
human hepatic cell model (Primary Human Hepatocytes + Kuepfer cells Spheroids 
from InSphero®). Ribo-depleted libraries were generated from these cell models 
and sequenced on an Illumina Hiseq2000 in 100bp paired-end. Data are available 
in the BioStudies database (http://www.ebi.ac.uk/biostudies) under accession 
number S-HECA143. Eight-time points were analyzed: 0, 2, 8, 24, 72, 168, 240, and 
336h and each time point had three replicates, making the total samples to 24. The 
quality assessment of the data has already been performed in one of our other 
study [40]. All samples passed the quality assessment. FPKM (Fragments Per 
Kilobase of transcript per Million mapped reads) was taken for calculation and 
prediction of the complex assembly order to normalize the expression for the 
length of the transcripts. All scripts and results are made available on 
https://github.com/rajinder4489/protein_complexes. 
 
Filtration and mapping 
The protein complexes were subjected to multiple steps of filtration (Fig. 1). First, 
the protein complexes having nucleic acid and/or small molecule as a subunit were 
discarded. In the transcriptomics data, small molecules (ChEBI) are not quantified; 
hence, the complexes that have small molecules as subunits (which are not 
quantified by a standard RNA sequencing libraries)  are removed from further 
analyses. Similarly, complexes with non-coding RNAs were discarded because their 
functional annotation is limited. 
 





















































While the protein complexes from the Complex Portal are represented as protein 
subunits (along with other molecules) given by Uniprot identifiers [41], the RNA-
Seq data is quantified in terms of Ensembl genes and transcripts identifiers [42]. To 
map these identifiers, Biomart [43] was used. When no transcript was mappable to 
a subunit, the protein complex was discarded. On the contrary, when more than 
one transcript mapped to the subunit, all mapped transcripts were retained for 
further processing. Additionally, there were cases where multiple transcripts from 
one gene mapped to the given subunit, which were addressed as described ahead. 
 
Subunit expression 
To resolve the cases of multiple transcripts from a gene mapping to one subunit, 
the transcript with the highest APPRIS annotation (Box 1) was selected. If more than 
one transcript from the same gene exhibit the same highest APPRIS annotation, all 
those transcripts were considered. Transcripts from different genes mapped to the 
same subunit and from all such genes, the highest APPRIS annotated transcript was 
taken. When no APPRIS annotation was available, the longest mapped transcript 
per gene was selected (or all the longest transcripts in case of several equally long 
transcript). 
 
Protein complex expression 
The protein complexes where at least one subunit was not detected in more than 
50% of the samples, based on the RNA seq data, were discarded from further 
analysis. This step was performed to avoid making calculations using insufficient 
data. For the remaining protein complexes, the expression of each subunit was 
calculated per time point by averaging the expression of replicates for each time 
point. Furthermore, the expression was adjusted for the subunit stoichiometry by 
dividing the expression of the subunit by the corresponding stoichiometry. If the 
stoichiometry was unknown, it was set to one. Finally, the protein complex 
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Order of assembly 
Only heteromers should be taken for the prediction of the order of assembly 
because, in the case of homomers, only a single subunit is present and thus it 
cannot be used to define the order. DBNs were applied to the subunit expression 
before adjusting for the stoichiometry. The unadjusted subunit expression was 
used because the subunits with higher stoichiometry are produced at a higher 
amount to form the complex and the stoichiometry adjustment would reduce their 
impact in the DBN calculation. The R library bnstruct [44] was used to build the 
DBN, using the default parameters (‘mmhc’ algorithm and ‘BDeu’ (Bayesian-
Dirichlet equivalent uniform) scoring function). The number of parents was limited 
to one and the edges between the same subunits over different time points were 
discarded. From the remaining network, the assembly order of the complexes was 
inferred by aligning the nodes/subunits over time using Cytoscape [45] and then 
analyzing the edges between the subunits over consecutive time points (t → t+1). 
If the connection between all subunits could not be established by analyzing the 
consecutive time points, then the connections from t → t+2 are analyzed and it is 
further expanded in a stepwise manner until the assembly order of all subunits 
could be predicted. 
 
Results 
Complex Portal houses 779 human protein complexes. The distribution of 
stoichiometry for these protein complexes was: 559 even, 122 uneven, and 98 
undefined. For the complexes where this information was undefined, the 
stoichiometry was set to one for all subunits, labeling them as protein complexes 
with even stoichiometry. The protein complexes were subjected to various steps of 
filtration. First, the protein complexes comprising of only protein subunits were 
taken Then the protein complexes which had unmapped identifiers between 
Uniprot (protein complex subunits) and Ensembl (transcript identifiers) were 
removed from further analyses and finally the transcripts that were not expressed 






Table 1: Protein complexes through various steps of filtration and processing 
Step Number of protein complexes (discarded) Action performed 
Downloaded from 








nucleic acids and/or 
small molecules 
681 (98)  - 
Uniprot identifiers for 
all subunits mapped to 
at least one Ensembl 
transcript identifier 






Transcripts for all 
subunits selected by 
APPRIS annotation  
426 
Transcripts for all 
subunits selected by 
Longest transcript  
2 
Transcripts for some 
subunits selected by 
APPRIS and for others by 
Longest transcript 
17 
Homomers removed 384 (61) - 
Mapped transcripts 
detected in more than 
50% of samples 
At least one mapped 







Protein complex expression 
After removing the complexes where the subunits were other than proteins and 
when a subunit could not be mapped to an Ensembl identifier, 445 protein 
complexes were obtained for calculation of the protein complex expression. The 
protein complex expression was determined by the lowest expressed subunit of the 
complex, after adjusting for the stoichiometry. In the case of the homomers (426), 
the expression of the complex was given by the expression of the subunit adjusted 
for the stoichiometry. As in the case of ANPR-A receptor complex (CPX-35) where 
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the stoichiometry of its subunit NPR1 was two, the complex expression was half of 
the expression of the lowest expressed subunit (figure not shown). 
For 203 complexes out of 445 (45.62%), the complex expression was defined by a 
single subunit across all time points and for others (54.48%) by different subunits 
at different time points. Two examples are presented here, one where the 
stoichiometry of the subunits was one and the other where it was two, illustrating 
the impact of stoichiometry on the expression of the complex. First, for SMAD2-
SMAD3-SMAD4 complex (CPX-1) all had a stoichiometry of 1 for all its subunits 
(SMAD2, SMAD3, and SMAD4) and the expression of the complex was defined by 
different lowest expressed subunits at each time point (Fig. 2A). SMAD2 was the 
lowest expressed subunit at time points 2, 8, 240, and 336 hours; SMAD3 at 168 
hours, and SMAD4 for 0, 24, and 72 hours. Comparing the expression of the 
individual subunits exhibit higher perturbation than the protein complex and fail to 
present the functional perturbation. While SMAD2-SMAD3-SMAD4 complex had 
stoichiometry of one for all subunits, SLX4-TERF2 complex (CPX-484; subunits: SLX4 
and TERF2 ) stoichiometry was two for both of its subunits (Fig. 2B). After adjusting 
for the stoichiometry, the expression of the complex was calculated and was given 
by SLX4 at time points 2, 8, 24, 168, and 336 hours and by TERF2 for 0, 72, and 240 
hours. Out of 445 protein complexes, the complex was predicted to not expressed  
(expression = 0)for 185 complexes at all time-points because at least one of the 
subunits was not detected at the corresponding time points. Out of 185 complexes, 
167 were heteromers and only 12 were homomers. 
Furthermore, the expression profile of the complexes with respect to the subunits 
was evaluated using R library Genefilter [46]. The euclidean distance along with z-
score scaling was used to calculate the distance between the expression profile of 
the subunits and the complex. For 252 (56.63%) complexes, the expression profile 
of the complex was similar to the expression profile of at least one subunit 
(Euclidean distance < 0.5) and for others, it was different from all subunits (193, 
43.37%). The Laminin-521 complex (CPX-1780) has three subunits: LAMA5, LAMB2, 
and LAMC1; and the Euclidean distance between these three subunits and the 
complex was 0.49, 5.8, and 0.37, respectively. The smaller the Euclidean distance, 
the more is the similarity in the expression profile. As here LAMC1 has the closest 



































































































































































































































































































































































































































































































On the other hand, AP-2 Adaptor complex, alpha2 variant (CPX-5150), there was no 
similarity between the expression profile of the complex and the subunits (Fig. 3B). 
The Euclidean distances for the four subunits to the complex were AP2A2: 1.44, 
AP2B1: 1.28, AP2M1: 1.98, and AP2S1: 6.64. The Euclidean distance for all subunits 
to their respective complexes is given in Suppl. Table 1. 
 
Order of assembly 
The protein complexes are formed by binding of the subunits in a phased manner. 
The subunits binding first make suitable conformational changes for the next 
subunit to bind to the nascent complex  [47-49]. We predicted the assembly order 
using the DBNs. Only heteromers for which the transcripts were expressed in at 
least 50% of samples were taken, resulting in 69 complexes that were taken for 
assembly order prediction. Among the 69 protein complexes, only three complexes, 
namely SMAD1-SMAD4 complex (CPX-54), Collagen type I trimer (CPX-1650), and 
PDGF receptor beta - PDGF-AB complex (CPX-2886) had uneven stoichiometry of 
2:1, 2:1, and 2:1:1 respectively. For these 69 complexes, DBNs were computed 
using bnstruct [44] and adjacency matrices are provided for all of them in Suppl. 
Table 2. The edges between the same subunits over different time points should be 
removed while predicting the order of assembly and the remaining network should 
be analyzed to assess earlier and later interactions. 
In the case of an arbitrarily chosen complex - Laminin211-nidogen complex (CPX-
1282) (Fig. 4), the protein complex consisted of four subunits: LAMA2, LAMB1, 
LAMC1, and NID1. The analyses of the DBN for consecutive time points (t → t+1) 
predicted that LAMB1 (0h) interacts with NID1 (2h) and LAMC1 (2h) interacts with 
LAMA2 (2h and 8h). However, since no interactions were predicted between 
LAMB1-LAMA2, LAMB1-LAMC1, NID1-LAMA2, or NID1-LAMC1, the analyses of the 
DBN was expanded to t → t+2. It was then predicted that LAMB1 (0h) interacts with 
LAMC1 (8h). Hence, DBN predicts that the overall assembly of this complex could 
be the initial formation of two nascent complexes: LAMB1-NID1, and LAMC1-
LAMA2, followed by LAMB1 and LAMC1 binding to each other. This binding 
between LAMB1 and LAMC1 can be between the nascent complexes formed. 
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Figure 4: Protein-complex expression order prediction for a multimeric heteromer. The 
protein complex Laminin211-nidogen complex (CPX-1282) constitutes of four subunits: 
LAMA2, LAMB1, LAMC1, and NID1. (A) The DBN computed from the expression data for the 
subunits using R library bnstruct. The highlighted nodes and edges were deleted because they 
connect the same subunits over different time points (B) The order of assembly was predicted 
by analyzing the edges/connections between the nodes over consecutive time points (t → 
t+1). The nodes over initial consecutive time points are highlighted. They show that LAMC1 
interacts with LAMA2 and LAMB1interacts with NID1. (C) The time points analyzed were 




Protein complexes are the functional and structural machinery of the biological 
system. The knowledge of their expression can be advantageous in studying 
biological functions and structures. Through this work, we presented an approach 
to calculate the expression of the protein complexes using the RNA-Seq time-series 
data. To circumvent the heterogeneity in the gene expression calculation, we used 
transcript expression for the calculation of expression of the protein complexes. 
Furthermore, as hypothesized, the probabilistic models generated from time-series 
expression data can help in predicting the assembly order of the protein complexes. 
We demonstrated a DBN-based approach to infer the assembly order of the protein 
complexes from time-series RNA-Seq data (eight time-points). The protein 
complexes are formed in a well-ordered manner and each binding subunit causes 
conformational changes in the nascent complex [47-49]. This creates favorable 
conditions for the next subunit to bind and helps the complex in attaining its 
structure and function. 
We demonstrated that for ~54% of the complexes, the complex expression 
determining subunit is different at different time points. As illustrated for SMAD2-
SMAD3-SMAD4 complex (CPX-1) and SLX4-TERF2 complex (CPX-484), the 
expression of the complexes were defined by different subunits over different time 
points. While the individual subunits exhibited higher rates of perturbation across 
various time points, the comparison of the complex expression helped in 
eliminating the false inferences derived from the subunit expression comparison. It 
has been shown that the complexes are formed co-translationally [35-37] and 
hence the higher changes in the expression of the subunits can be due to their 
demand in the complex assembly.  
The expression of the complex was different from the subunits in various instances 
however, the expression profiles over time were similar as shown in Fig. 3A for 
Laminin-521 complex. In such cases, the analyses of the subunits can also be used 
to infer the functional properties of the biological system. The significance of 
complex expression analyses arises when the subunit and the complex expression 
profiles are different as presented in Fig. 3B for AP-2 Adaptor complex, alpha2 
variant. The changes in the expression of the subunit might not be related to its 
function, rather to its demand in complex assembly. 
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The protein complex expression computed from the RNA-Seq cannot give the 
absolute expression of the protein complex in the biological system. However, it 
can be used as a comparative metric for estimating the functional changes. Multiple 
processes and steps of regulation are involved in the journey of a protein-coding 
transcript to form a protein. Moreover, there are also other limiting factors such as 
the amount of ribosomes, the half-life of transcripts and proteins, translational 
efficiency, and Spatio-temporal availability. The protein half-life of the different 
subunits could be different [50, 51]. The amount and saturation of the mRNA by 
ribosomes can indeed be a limiting factor in the amount of protein expressed [52]. 
In a study evaluating the half-lives of 803 proteins, it was shown that the median 
half-life of the proteins was 8.7 hours [53]. Moreover, the translational efficiency 
for different transcripts might be variable [54-56]. 
Another important aspect of the protein complexes is their order of assembly. It 
was computed using DBNs because they allow only the nodes from the earlier time 
points to be the parent of nodes in the same or later time points. No node from a 
later point can be a parent to a node in the earlier time point; hence the 
relationship moves forward in time. The analysis of the DBNs by studying the edges 
helped in establishing earlier and later connections between the subunits. The 
distribution of time points of RNA-Seq time-series data is based on PBPK modeling, 
however, RNA-Seq data collected at smaller and equal intervals may better exhibit 
the assembly of the protein complex. The correct prediction of the protein complex 
assembly might help in finding novel drug targets, as the binding of the subunits to 
the nascent protein complex results in conformational changes. These 
conformational changes occur to allow the presentation of the binding sites for 
incoming subunits and exposing the functional domains of the complex. Knowledge 
of what subunits bind and when they bind may help in assessing the conformational 
changes and hence their role as drug targets. 
The current approach can be improved by identifying the nascent protein complex 
being formed as an individual entity in the computation of the network and 
assembly order prediction. Currently, only subunits are considered for the creation 
of DBNs. The expression of the forming complex can be given by the bound subunits 
at the given time point. Other options to explore the protein complex assembly 
order can be using the Bayesian networks for individual time points and then 
analyzing the high probability edges over each timepoint individually. This will be 
different from the DBN because there will not be any connections between the 
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nodes over different time points. Additionally, other temporal network prediction 
approaches can be used; some packages available in R to perform temporal analysis 
are sna [57], ndtv [58], and tsna [59]. To further enhance the creation of the 
networks, additional information can be added such as protein-protein 
interactions, ontology, and known functions. 
In addition to advancing the computational approaches to predict the assembly 
order of the protein complexes, approaches to extract nascent protein complexes 
and investigating them through X-ray crystallography and mass spectrometry 
experiments to validate the in silico findings are equally important. Such a 
validation step would provide proof of the hypothesis and help in defining the order 
of assembly in other complexes. 
 
Conclusion 
The knowledge of the protein complex expression and their assembly order can 
pave the way for better quantification of the biological systems’ functional 
capability and capturing the perturbations in protein complex assembly. Moreover, 
the conformational changes in the forming complex can be studied for their use as 










high to low) 
Explanation 
Principal1 
Transcript(s) expected to code for the main functional isoform 
based solely on the core modules in the APPRIS. 
Principal2 
Where the APPRIS core modules are unable to choose a clear 
principal variant (approximately 25% of human protein coding 
Beyond Gene Expression 
 140 
genes), the database chooses two or more of the CDS variants 
as "candidates" to be the principal variant. 
Principal3 
Where the APPRIS core modules are unable to choose a clear 
principal variant and there more than one of the variants have 
distinct CCDS identifiers, APPRIS selects the variant with lowest 
CCDS identifier as the principal variant. The lower the CCDS 
identifier, the earlier it was annotated. 
Principal4 
Where the APPRIS core modules are unable to choose a clear 
principal CDS and there is more than one variant with a distinct 
(but consecutive) CCDS identifiers, APPRIS selects the longest 
CCDS isoform as the principal variant. 
Principal5 
Where the APPRIS core modules are unable to choose a clear 
principal variant and none of the candidate variants are 
annotated by CCDS, APPRIS selects the longest of the candidate 
isoforms as the principal variant. 
Alternative1 
For genes in which the APPRIS core modules are unable to 
choose a clear principal isoform, the alternative1 is the 
candidate transcript(s) models that is conserved in at least 
three tested species. 
Alternative2 
For genes in which the APPRIS core modules are unable to 
choose a clear principal isoform, the alternative2 is the 
candidate transcript(s) models that appear to be conserved in 
fewer than three tested species. 
 
References 
1. Johansson H, Jensen MR, Gesmar H, Meier S, Vinther JM, Keeler C, Hodsdon ME, Led JJ: Specific and 
nonspecific interactions in ultraweak protein-protein associations revealed by solvent paramagnetic 
relaxation enhancements. J Am Chem Soc 2014, 136(29):10277-10286. 
2. Johnson ME, Hummer G: Nonspecific binding limits the number of proteins in a cell and shapes their 
interaction networks. Proceedings of the National Academy of Sciences 2011, 108(2):603-608. 
3. Srihari S, Leong HW: A survey of computational methods for protein complex prediction from protein 
interaction networks. Journal of bioinformatics and computational biology 2013, 11(02):1230002. 
4. Ramyachitra D, Banupriya D: Protein Complex Detection: A Study. International Journal of Computer 
Science and Information Technology & Security (IJCSITS) 2014, 4(4). 
5. Thorn KS, Bogan AA: ASEdb: a database of alanine mutations and their effects on the free energy of 
binding in protein interactions. Bioinformatics 2001, 17(3):284-285. 
6. Kumar MS, Gromiha MM: PINT: protein–protein interactions thermodynamic database. Nucleic Acids 
Res 2006, 34(suppl_1):D195-D198. 
7. Moal IH, Fernández-Recio J: SKEMPI: a Structural Kinetic and Energetic database of Mutant Protein 
Interactions and its use in empirical models. Bioinformatics 2012, 28(20):2600-2607. 
8. Vreven T, Moal IH, Vangone A, Pierce BG, Kastritis PL, Torchala M, Chaleil R, Jiménez-García B, Bates PA, 
Fernandez-Recio J: Updates to the integrated protein–protein interaction benchmarks: docking 




9. Liu Z, Li Y, Han L, Li J, Liu J, Zhao Z, Nie W, Liu Y, Wang R: PDB-wide collection of binding data: current 
status of the PDBbind database. Bioinformatics 2015, 31(3):405-412. 
10. Jankauskaitė J, Jiménez-García B, Dapkūnas J, Fernández-Recio J, Moal IH: SKEMPI 2.0: an updated 
benchmark of changes in protein–protein binding energy, kinetics and thermodynamics upon 
mutation. Bioinformatics 2019, 35(3):462-469. 
11. Jemimah S, Yugandhar K, Michael Gromiha M: PROXiMATE: a database of mutant protein–protein 
complex thermodynamics and kinetics. Bioinformatics 2017, 33(17):2787-2788. 
12. Moal IH, Agius R, Bates PA: Protein–protein binding affinity prediction on a diverse set of structures. 
Bioinformatics 2011, 27(21):3002-3009. 
13. Moal IH, Jiménez-García B, Fernández-Recio J: CCharPPI web server: computational characterization of 
protein–protein interactions from structure. Bioinformatics 2015, 31(1):123-125. 
14. Yugandhar K, Gromiha MM: Protein–protein binding affinity prediction from amino acid sequence. 
Bioinformatics 2014, 30(24):3583-3589. 
15. Dehouck Y, Kwasigroch JM, Rooman M, Gilis D: BeAtMuSiC: prediction of changes in protein–protein 
binding affinity on mutations. Nucleic Acids Res 2013, 41(W1):W333-W339. 
16. Berliner N, Teyra J, Çolak R, Lopez SG, Kim PM: Combining structural modeling with ensemble machine 
learning to accurately predict protein fold stability and binding affinity effects upon mutation. PloS 
one 2014, 9(9):e107353. 
17. Brender JR, Zhang Y: Predicting the effect of mutations on protein-protein binding interactions through 
structure-based interface profiles. PLoS Comput Biol 2015, 11(10):e1004494. 
18. Petukh M, Dai L, Alexov E: SAAMBE: webserver to predict the charge of binding free energy caused by 
amino acids mutations. International journal of molecular sciences 2016, 17(4):547. 
19. Li M, Simonetti FL, Goncearenco A, Panchenko AR: MutaBind estimates and interprets the effects of 
sequence variants on protein–protein interactions. Nucleic Acids Res 2016, 44(W1):W494-W501. 
20. Pires DE, Ascher DB: mCSM-AB: a web server for predicting antibody–antigen affinity changes upon 
mutation with graph-based signatures. Nucleic Acids Res 2016, 44(W1):W469-W473. 
21. Rodrigues CHM, Myung Y, Pires DEV, Ascher DB: mCSM-PPI2: predicting the effects of mutations on 
protein–protein interactions. Nucleic Acids Res 2019, 47(W1):W338-W344. 
22. Dzoyem JP, Kuete V, Eloff JN: 23 - Biochemical Parameters in Toxicological Studies in Africa: 
Significance, Principle of Methods, Data Interpretation, and Use in Plant Screenings. In: Toxicological 
Survey of African Medicinal Plants. Edited by Kuete V: Elsevier; 2014: 659-715. 
23. Quax TE, Wolf YI, Koehorst JJ, Wurtzel O, van der Oost R, Ran W, Blombach F, Makarova KS, Brouns SJ, 
Forster AC et al: Differential translation tunes uneven production of operon-encoded proteins. Cell 
Rep 2013, 4(5):938-944. 
24. Li G-W, Burkhardt D, Gross C, Weissman JS: Quantifying absolute protein synthesis rates reveals 
principles underlying allocation of cellular resources. Cell 2014, 157(3):624-635. 
25. Marsh JA, Rees HA, Ahnert SE, Teichmann SA: Structural and evolutionary versatility in protein 
complexes with uneven stoichiometry. Nature communications 2015, 6(1):1-10. 
26. Zahiri J, Emamjomeh A, Bagheri S, Ivazeh A, Mahdevar G, Tehrani HS, Mirzaie M, Fakheri BA, 
Mohammad-Noori M: Protein complex prediction: A survey. Genomics 2019. 
27. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein 
Data Bank. Nucleic Acids Res 2000, 28(1):235-242. 
28. Marsh JA, Teichmann SA: Structure, dynamics, assembly, and evolution of protein complexes. Annu 
Rev Biochem 2015, 84:551-575. 
29. Ahnert SE, Marsh JA, Hernández H, Robinson CV, Teichmann SA: Principles of assembly reveal a periodic 
table of protein complexes. Science 2015, 350(6266). 
30. Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G, Frishman G, Montrone C, 
Mewes H-W: CORUM: the comprehensive resource of mammalian protein complexes—2009. Nucleic 
Acids Res 2009, 38(suppl_1):D497-D501. 
31. Meldal BHM, Forner-Martinez O, Costanzo MC, Dana J, Demeter J, Dumousseau M, Dwight SS, Gaulton 
A, Licata L, Melidoni AN et al: The complex portal - an encyclopaedia of macromolecular complexes. 
Nucleic Acids Res 2014, 43(D1):D479-D484. 
32. Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, 
Steinbeck C: ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic 
Acids Res 2015, 44(D1):D1214-D1219. 
33. Marsh JA, Hernández H, Hall Z, Ahnert SE, Perica T, Robinson CV, Teichmann SA: Protein complexes are 
under evolutionary selection to assemble via ordered pathways. Cell 2013, 153(2):461-470. 
Beyond Gene Expression 
 142 
34. Gingras AC, Gstaiger M, Raught B, Aebersold R: Analysis of protein complexes using mass spectrometry. 
Nat Rev Mol Cell Biol 2007, 8(8):645-654. 
35. Mayr C: Protein complexes assemble as they are being made. In.: Nature Publishing Group; 2018. 
36. Williams NK, Dichtl B: Co-translational control of protein complex formation: a fundamental pathway 
of cellular organization? Biochemical Society Transactions 2018, 46(1):197-206. 
37. Wells JN, Bergendahl LT, Marsh JA: Co-translational assembly of protein complexes. Biochemical 
Society Transactions 2015, 43(6):1221-1226. 
38. Rodriguez JM, Rodriguez-Rivas J, Di Domenico T, Vázquez J, Valencia A, Tress ML: APPRIS 2017: principal 
isoforms for multiple gene sets. Nucleic Acids Res 2017, 46(D1):D213-D217. 
39. RNAcentral: a comprehensive database of non-coding RNA sequences. Nucleic Acids Res 2016, 
45(D1):D128-D134. 
40. Gupta R, Schrooders Y, Verheijen M, Roth A, Kleinjans J, Caiment F: FuSe: A tool to move RNA-Seq 
analyses from chromosomal/gene loci to functional grouping of mRNA transcripts. Bioinformatics 
2020. 
41. The_UniProt_Consortium: UniProt: a hub for protein information. Nucleic Acids Res 2015, 43(Database 
issue):27. 
42. Frankish A, Vullo A, Zadissa A, Yates A, Thormann A, Parker A, Gall A, Moore B, Walts B, Aken BL et al: 
Ensembl 2018. Nucleic Acids Res 2017, 46(D1):D754-D761. 
43. Smedley D, Haider S, Durinck S, Pandini L, Provero P, Allen J, Arnaiz O, Awedh MH, Baldock R, Barbiera 
G et al: The BioMart community portal: an innovative alternative to large, centralized data 
repositories. Nucleic Acids Res 2015, 43(W1):20. 
44. Franzin A, Sambo F, Di Camillo B: bnstruct: an R package for Bayesian Network structure learning in 
the presence of missing data. Bioinformatics 2017, 33(8):1250-1252. 
45. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T: Cytoscape 2.8: new features for data integration 
and network visualization. Bioinformatics 2011, 27(3):431-432. 
46. Gentleman R, Carey V, Huber W, Hahne F, Maintainer MBP, AnnotationDbi I: Package ‘genefilter’. 2013. 
47. Ito Y, Ikeguchi M: Mechanism of the αβ conformational change in F1-ATPase after ATP hydrolysis: free-
energy simulations. Biophys J 2015, 108(1):85-97. 
48. Chu W-T, Chu X, Wang J: Binding mechanism and dynamic conformational change of C subunit of PKA 
with different pathways. Proceedings of the National Academy of Sciences 2017, 114(38):E7959-E7968. 
49. Garton M, MacKinnon SS, Malevanets A, Wodak SJ: Interplay of self-association and conformational 
flexibility in regulating protein function. Philosophical Transactions of the Royal Society B: Biological 
Sciences 2018, 373(1749):20170190. 
50. Yang E, van Nimwegen E, Zavolan M, Rajewsky N, Schroeder M, Magnasco M, Darnell JE, Jr.: Decay rates 
of human mRNAs: correlation with functional characteristics and sequence attributes. Genome Res 
2003, 13(8):1863-1872. 
51. Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MSH: Database for mRNA half-life of 19 977 
genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem 
cells. DNA Res 2009, 16(1):45-58. 
52. Lin J, Amir A: Homeostasis of protein and mRNA concentrations in growing cells. Nature 
communications 2018, 9(1):4496-4496. 
53. Chen W, Smeekens JM, Wu R: Systematic study of the dynamics and half-lives of newly synthesized 
proteins in human cells. Chemical science 2016, 7(2):1393-1400. 
54. Mead EJ, Smales CM: 1.29 - mRNA Translation and Recombinant Gene Expression from Mammalian 
Cell Expression Systems. In: Comprehensive Biotechnology (Second Edition). Edited by Moo-Young M. 
Burlington: Academic Press; 2011: 403-409. 
55. Neves D, Vos S, Blank LM, Ebert BE: Pseudomonas mRNA 2.0: Boosting Gene Expression Through 
Enhanced mRNA Stability and Translational Efficiency. Frontiers in Bioengineering and Biotechnology 
2020, 7(458). 
56. Cenik C, Cenik ES, Byeon GW, Grubert F, Candille SI, Spacek D, Alsallakh B, Tilgner H, Araya CL, Tang H et 
al: Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation 
across humans. Genome Res 2015, 25(11):1610-1621. 
57. Butts CT: Social network analysis with sna. Journal of statistical software 2008, 24(6):1-51. 
58. Bender-deMoll S: Package Vignette for ndtv: Network Dynamic Temporal Visualizations (Version 0.13. 
0). 2019. 







Beyond Gene Expression 
 144 
Gene expression is omnipresent with transcriptomics data analysis. However, gene 
expression data is heterogeneous, as it is obtained by summing the expression of 
all the transcripts it codes. Through this thesis, a transcript-based analysis of the 
RNA sequencing (RNA-Seq) data is presented and novel methods for data analysis 
and their applications are proposed. To test the novel methodologies developed in 
this thesis, the liver was chosen because of its significance in the human body and 
its predominance in the toxicology field. RNA-Seq data from various in vitro liver 
cell models generated under the aegis of EU-ToxRisk project and available through 
public databases formed the basis of this thesis. 
 
In vitro cell models – the dilemma  
Multiple challenges and limitations with animal testing for the drug efficacy and 
toxicity studies have highlighted the need for finding better testing models [1, 2]. 
The in vitro cell models have merged as a viable alternative to animal testing. A 
major problem with the in vitro cell models is their abundance. Various cell models 
for different tissues, cells, and conditions (such as cancer, knockdown) have been 
developed. The problem of plenty poses a challenge in selecting the best cell model 
for a study or research question. The selection is primarily based on prior 
knowledge and literature review, however, the literature is biased towards a well-
studied set of genes, proteins, or processes. There is a gap in the knowledge to 
assess the cell models. 
To be able to make an informed decision while selecting the cell models for a study, 
a thorough investigation of the in vitro liver cell models using the RNA-Seq data was 
performed in Chapter 2. Various in vitro cell models from the liver ranging from 
cancer derived (HepG2, HepaRG, hPCLiS (human precision cut liver slices)), iPSC 
derived, microtissues, PHH, and healthy in vivo liver were taken for this study. The 
healthy in vivo liver samples were used as control. 
A global comparison was performed using correlation and CellNet [3], highlighting 
the similarity of the transcriptome profile to in vivo human liver through various 
metrics. First, through correlation, it was established that all cell models exhibited 
high similarity among themselves and to the in vivo liver. There was an even higher 
similarity between the replicates from the cell models. Overall, all cell models 
presented a spearman’s correlation greater than 0.8 (range 0-1). Furthermore, 
using CellNet, various aspects of the cell models were compared – the similarity of 
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the overall transcriptome profile defined by C/T (Cell/Tissue) score, the 
conservation of the gene regulatory networks (GRN) given by GRN score, and the 
network influence score (NIS) of the transcription factors (TFs). The C/T score 
presents how similar the given cell model’s RNA-Seq data is to various cells or 
tissues in the CellNet’s consensus profile. As expected, the samples directly derived 
from the liver (healthy liver (PHH, 3D liver microtissues), and cancerous liver 
(hPCLiS)) illustrated a high C/T score while cancer- (HepG2, HepaRG 3D) and iPSC-
derived (iPSC-HLC) models had a comparatively lower score with the liver; 
highlighting their extent of similarity with liver (c.f. Chapter 2 Fig. 2). 
Similarly, the GRN score was used for comparing the cell models for the 
conservation of gene regulatory networks (c.f. Chapter 2 Suppl. Fig. 3) and NIS score 
evaluated the influence of perturbed TFs on the cell models (c.f. Chapter 2 Suppl. 
Fig. 5a-g). The identification of the perturbed TFs provides an opportunity to 
regulate their expression to make the cell models similar to the target cell/tissue 
type. For all cell models, the most perturbed TF was ATF5; moreover, in all cell 
models except PHH, it was shown that ATF5 was downregulated. With the current 
data, it was not possible to investigate the reason why ATF5 was perturbed in 
opposite direction as compared to other cell models. However, investigation of the 
culture conditions and/or protocols may elucidate the cause. Anyhow, the 
identification of the TFs that are perturbed and their degree of perturbation helps 
in developing the cell models to look and behave similarly to the target cell/tissue. 
Especially, in the case of iPSC cell models, the identification of the TFs that have 
different expression patterns as compared to target cell/tissue helps in adjusting 
their differentiation protocols and hence improving further their similarity to in vivo 
liver. 
Furthermore, a comparison on the gene-level was achieved by analyzing 
differentially expressed genes (DEGs) and non-DEGs. While a higher number of 
DEGs corresponds to high dissimilarity, more non-DEGs demonstrate the similarity 
between the two cell models. The number of DEGs (most: HepG2, ~9900; least: 3D 
liver microtissues 0h, ~5200) and non-DEGs (most: 3D liver microtissues 0h, 
~10200; least: HepG2, ~5700) only provides an overview of resemblance and fails 
to convey what processes are affected. To investigate the changes in the processes 
and pathways, the DEGs and non-DEGs were mapped to the KEGG human pathways 
and the extent of coverage illustrated whether the particular pathway was 
perturbed or not. On a total of ~420 human KEGG pathways [4], the list of genes 
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(DEGs and non-DEGs) from each cell model was mapped. Through this exercise, the 
pathway coverage for all human KEGG pathways was achieved and illustrated the 
extent of similarity/perturbation in each pathway for each cell model. Among the 
important liver pathways (c.f. Fig. 5 and Fig. 7, Chapter 2), the highest similarity was 
predominantly exhibited by PHH and 3D liver microtissues. The DNA-repair 
pathways were highly conserved in HepG2, HepaRG 3D, and hPCLiS. Surprisingly, 
iPSC-HLC demonstrated higher similarity than HepG2 and occasionally better than 
HepaRG 3D and hPCLiS. These analyses will help in selecting the appropriate cell 
models for studying a process and/or set of genes. 
 
Beyond the genes – transcript expression 
For transcriptomics data analyses, the convention has been to assess the gene 
expression and study its perturbation across conditions or samples. However, the 
heterogeneity in the gene expression, due to multiple transcripts originating from 
a gene, makes it a less reliable metric to assess. We explored the opportunities in a 
transcript-based analysis. Usually, the transcripts are studied for their differential 
expression (DET: differentially expressed transcripts, similar to DEGs) or usage 
(DTU: differential transcript usage). In DET analyses, the change in the amount of 
expression of the transcript between two conditions is compared while in DTU the 
change in the fraction of the transcript expression in the gene expression is 
calculated. Irrespective of DET or DTU analyses, the resulting transcripts cannot be 
mapped to biological databases (pathway, ontology, or function) as the databases 
are gene- and/or protein-based. To counter this challenge, we derived non-
DEGsDTU- (non-differentially expressed genes without differential transcript usage) 
by taking the non-DEGs and then removing the genes for which transcripts 
exhibited differential transcript usage. The resulting list of genes (non-DEGsDTU-) 
comprised of the genes that were not differentially expressed on the gene and 
transcript level. Non-DEGsDTU- could then be mapped to pathways and processes 
across various biological databases. In comparison to the pathway coverage by non-
DEGs, non-DEGDTU- exhibited a lower coverage for all pathways, however, it 
followed a similar trend as non-DEGs across all cell models. 
Analyses of the transcript usage highlighted that, for many genes, the main protein-
coding transcript from the gene is replaced by another protein-coding transcript or 
by a non-coding transcript. For instance, in the case of POLR2F, which is a 
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component of RNA polymerases I, II, and III and plays an important role in 
transcription [5], the main protein-coding transcript constituted ~50% in healthy in 
vivo liver but was completely replaced by other protein-coding and non-coding 
transcripts in all in vitro systems. Another example was GOLGA8B (Golgin subfamily 
A member 8B), for which non-coding transcripts in the cell models replaced the 
major protein-coding transcript (~ 60% in healthy in vivo liver), predominantly. 
Importantly, both these genes were not differentially expressed on the gene level, 
however, presented differential transcript usage. Numerous such cases were 
identified, thus highlighting the added benefits of performing a transcript-based 
analysis. 
The PHH and 3D liver microtissues exhibited high similarity to the in vivo liver in 
most analyses performed. Each cell model demonstrated high similarity across 
certain pathways, e.g. HepG2 for DNA repair pathways. However, no cell model 
(among the cell models tested) could be presented as the “go-to” option for all 
studies. Through this study, an extensive data resource of differentially expressed 
genes, differential usage transcripts, pathway coverage for DEGs, non-DEGs, and 
non-DEGsDTU- has been created that could be used to make a selection for 
processes, pathways, or genes of interest. In addition, the selection of the cell 
model for a study might also be influenced by various other factors such as cost, 
maintenance, and availability of expertise. 
 
Different transcripts-same function 
A gene can code for multiple transcripts due to the presence of various 
transcription start sites and alternative splicing [6, 7]. The analyses of the 
transcriptomics data have evolved predominantly centering the gene and only 
lately, the transcripts. While the gene-centered approaches mask any changes 
occurring on the transcript level, the transcript-based analysis overlooks the 
functional similarities of the transcripts. Functional similarity for the protein-coding 
transcripts being their ability to produce the same or similar proteins (and hence 
perform the same functions) and for the non-coding transcripts being their ability 
to bind the same targets and trigger the same/similar responses. Functionally 
similar transcripts might originate from the same or different genes and possess a 
similar coding sequence (CDS). From the similar CDS, courtesy of degeneracy of the 
codon, functionally similar proteins are translated. 
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When multiple transcripts are capable of coding for the same or similar proteins, 
an ensemble of expression of all such transcripts should be used to define the total 
amount of function, rather than analyzing individual transcripts or genes. In 
Chapter 3, this notion of different protein coding transcripts capable of coding for 
the same or similar proteins was explored and, to study its impact on RNA-Seq data, 
resulted in the development of FuSe (Functional grouping of RNA-Seq data). FuSe 
is a command-line based tool that allows the user to search for protein-coding 
transcripts that would code for the same protein. For finding the functionally similar 
protein-coding transcripts, their amino acid sequence, secondary and super 
secondary structures were compared and a scoring scheme was developed to score 
the features. Two different scores were designed: a discovery score (DS, lenient) 
and a knowledge score (KS, stringent). Using these scores, flexibility is provided to 
search for transcripts with a certain amount of similarity and the features to be 
considered while calculating the similarity. It was also observed that the transcripts, 
which code for the same or similar proteins, originated from distinct genes as well 
(at KS≥95, ~78.5% from the same gene, ~15.5% from same gene family, ~2% from 
different gene family, and ~4% from genes with undefined family). For 60% of 
genes, the longest protein-coding transcript was the main form and the smaller 
protein-coding transcripts exhibited a different function, emphasizing that the 
major (known) function of a gene is not its only function. 
FuSe was applied to liver cell models exposed to APAP (acetaminophen, therapeutic 
and toxic doses) and its equivalent controls (untreated and DMSO). It was seen that 
some of the important characteristics of APAP exposure were captured by FuSe 
while being completely missed by conventional RNA-Seq data analyses. One of the 
important examples was the GBE1 expression. With conventional analyses, at the 
toxic APAP dose, GBE1 was shown to be upregulated, implying that the glycogen 
accumulation in the liver has increased. However, glycogen depletion is considered 
as one of the early biomarkers of acetaminophen-induced hepatotoxicity [8] and 
through the application of FuSe, the expression of GBE1 was correctly quantified 
by accommodating other transcripts coding for the same protein. 
 
Transcript biomarkers – a potent tool 
Biomarkers are an important aspect of biomedical research. The different classes 
of biomarkers are used to address various aspects of a disease, for instance, 
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susceptibility, presence, progression, effects of treatment, or chances of 
reoccurrence. Predominantly, proteins are used as biomarkers, however, with the 
advancements in NGS technologies, the search for gene biomarkers has also 
accelerated [9-11]. The transcriptome landscape changes rapidly under exposure 
to drugs, alterations in the external environment, and lifestyle changes. The 
subsequent changes in the proteome are delayed due to the intermediate 
processes of translation and post-translational modifications of the protein. At the 
same time, as previously mentioned, the heterogeneity in gene expression makes 
them a poor choice for biomarkers. To address these challenges, we investigated 
transcript expression in Chapter 4 to demonstrate if transcripts can project as 
better biomarkers. The RNA-Seq data for hepatocellular carcinoma (HCC) cell 
models was analyzed using machine learning to find transcript biomarkers. The HCC 
cell models selected for this study presented distinct genome-scale variations, for 
instance, HuH7.5.1 is homozygous for TP53 p.Tyr220Cys [12, 13], HKCI-4 has lost 
chromosome Y and aberrations in chromosome 10 [14], and PLC/PRF/5 contains at 
least 7 copies of integrated HBV genomes [15]. It was important to make a 
collection of such cell models to accommodate all possible variations in HCC. 
From the analysis of the HCC cell models, three transcripts (two protein coding: 
PARP2-202 and SPON2-203 and one non-coding: CYREN-211) were selected 
through recursive feature elimination with an accuracy of 0.97 and kappa of 0.93. 
Consequently, it was also demonstrated that when the transcriptomics data were 
analyzed separately for protein-coding and non-coding transcripts, a comparatively 
lower accuracy was observed compared to when they were taken together (AUC-
ROC, sensitivity, specificity, MCC, and informedness were all ~1 for the random 
forest, Naive Bayes, and Support vector machine). Additionally, the comparison of 
classical serum biomarkers (on the transcript level) was also performed and a 
comparatively lower accuracy was observed for them. 
From the analyses of the whole transcriptomics data, protein-coding and non-
coding transcripts were identified as HCC biomarkers. At the same time, 
comparatively lower accuracy for the split data (protein coding only, or non-coding 
only) establishes that both protein-coding and non-coding transcripts possess 
important biological information. Moreover, their expression changes under 
internal and external influences. This work is purely computational and no known 
relationship of the identified biomarkers (PARP2-202, SPON2-203, and CYREN-211) 
to the HCC could be found in the literature. Hence, before advancing further, these 
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results need to be validated in the lab. Regardless, the machine-learning pipeline 
developed in this study can be applied to any RNA-Seq data study aimed at finding 
transcript biomarkers. 
 
Protein complexes – the multi-molecule machineries 
Protein complexes are the multi-molecule machineries of the biological system. 
They are involved in several functions and are part of various cellular structures. 
Complex Portal, one of the manually curated protein complex database, currently 
holds information on 779 complexes. However, the knowledge and understanding 
of the protein complexes are limited. To enhance our understanding of these 
protein complexes, the protein complex expression and their assembly order were 
investigated in Chapter 5, using time-series RNA-Seq data from untreated liver 
spheroids in vitro cell models. 
In this study, RNA-Seq data from eight-time points after initiating the cell culture 
for baseline liver microtissues was used. The subsequent time points represent the 
growth of the cell/tissue culture at baseline. For the calculation of the protein 
complex expression, the lowest expressed subunit was identified after adjusting 
the expression of the subunits for their respective stoichiometry. It was observed 
that at different time points, different subunits of the complex represented the 
lowest expressed subunit. For instance, SMAD2-SMAD3-SMAD4 complex (CPX-1) 
expression is defined by SMAD2 for time points 2, 8, and 240hours, SMAD3 for 168 
hours, and SMAD4 for 0, 24, 72, and 336 hours. If the expression of the individual 
subunits was compared, up or downregulation was observed, however, the 
complex expression showed insignificant perturbation. A higher upregulation for 
SMAD3 was observed at time point 72 and 240 hours as compared to other time 
points. Similarly for SMAD4, 168 hours exhibited upregulation compared to all 
other time points. If only these subunits were compared, as for SMAD3 that is an 
intracellular signal transducer and transcriptional modulator [16], it would imply an 
increase in transcription. Similarly, the upregulation of SMAD4 implies an escalation 
in the TGF-mediated signaling [17]. However, the complex demonstrated 
insignificant perturbation in expression over time, thus implying that none of these 
functions were upregulated as shown by subunits. It is important to mention that 
the complex expression calculated from the RNA-Seq data is not an absolute 
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measure of the final assembled complex in the biological system, and it only 
provides a metric to compare the functional changes. 
Furthermore, the protein complexes are formed in a stepwise manner, binding one 
or a few subunits at each step. A stepwise binding allows the forming complex to 
change in confirmation and to expose hidden binding regions for other incoming 
subunits. By means of  the application of the dynamic Bayesian networks (DBN) on 
the RNA-Seq time-series data, the order of assembly of the protein complexes was 
predicted by analyzing the interaction over consecutive time points. An important 
feature of the DBN is that the nodes only have children in further time points i.e. a 
node from time point ‘t’ will only have a child in time point t+1, t+2, … t+n but not 
in t-1, t-2, … t-m (t: time point, n, m: positive integers). The subunits that exhibit 
interaction at the initial time points would come together earlier as compared to 
subunits that show interaction at later time points. The order of assembly for 
Laminin211-nidogen complex (CPX-1282) was predicted from analyzing the edges 
(interactions) between the nodes (subunits) over consecutive time points. 
The elucidation of the order of assembly may create opportunities to develop novel 
drug targets. The binding of the subunits creates and opens up hidden binding sites 
due to conformational changes in the formation of the protein complex [18, 19]. 
The conformational changes occur to achieve the minimum energy state. These 
conformational changes can thus present new binding sites for the drugs. 
 
Challenges 
The major challenge in the transcript-based analyses of the data is the unavailability 
of transcript-function databases. Currently, biological databases (for GO, pathways, 
function, interaction, etc.) predominantly store and present data in terms of genes 
and/or proteins. The transcripts are un-mappable on several databases or are 
mapped with significant loss of data. We addressed this issue by identifying the 
changes at the transcript level (DTU) and then refining the list of non-DEGs by 
removing the genes that have a transcript exhibiting differential usage. Through 
this approach, we were able to capture the changes at the transcript level and study 
the function at the gene level. However, the non-existence of an exhaustive 
transcript-function database limited the outcome of the study. Additionally, we 
encountered multiple challenges making the editor and the reviewers agree on the 
transcript-based analyses presented in Chapter 2. However, various RNA-Seq 
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studies have illustrated the significance of transcript-oriented analyses; the major 
proportion of the RNA-Seq community still prefers gene-expression based analyses. 
Furthermore, while working to find the transcripts that code for the same or similar 
proteins, the selection of the features of the proteins to be used was a major 
challenge. The complete and purified 3D structure of many human proteins is not 
available [20] and hence could not be used to compare the proteins. We resorted 
to amino acid sequence and secondary structures of the proteins for establishing 
similarity between the proteins. However, due to the lack of any pre-existing 
approach to assemble results from sequence and secondary structure similarities, 
novel approaches were developed. 
Finally, for the work on the protein complexes, we realized that only a handful of 
protein complexes are known (Complex Portal: 779 [21]) and out of them, one-third 
of the complexes do not have defined stoichiometry. The stoichiometry is 
important to know for the calculation of the complex expression, so it was assumed 
that the stoichiometry of such complexes was one for all subunits. This work would 
improve our understanding of the biological interpretation of the RNA-Seq data; 




In Chapter 2, the comparison is based on baseline expression of the cell models and 
hence it cannot illustrate the response when exposed to certain drugs, culture 
conditions, and other controllable or uncontrollable parameters. However, the 
study presents the response of the cell models concerning certain processes and 
can be used as the base for future research and interpretations. Further in Chapter 
3, while FuSe identifies transcripts coding for the same or similar proteins, it does 
not cover the non-coding transcripts. The involvement of the non-coding 
transcripts in various regulation processes is well established [22-25] and hence 
would need an analogous similarity finding tool or utility. Next in Chapter 4, the 
identification of the transcript biomarkers for HCC using various machine-learning 
algorithms is illustrated. However, the predicted biomarkers illustrate high 
accuracy in their ability to distinguish the healthy and HCC cell models through 
computational approaches, their validation in the HCC patients is yet to be done. A 
study thoroughly investigating the predicted biomarkers in HCC patients is required 
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to establish confidence in the in silico findings. Lastly, the work on the prediction of 
the protein complex expression and its assembly order could not be verified due to 
the unavailability of wet-lab findings. 
 
Future work 
In this thesis, across the various research chapters, multiple ideas have been 
explored and developed, for instance finding the transcripts coding for the same or 
similar proteins (Chapter 3), identification of transcript-based biomarkers for HCC 
as an application of a novel ML-based approach (Chapter 4), and prediction of 
protein complex order of assembly using DBN (Chapter 5). For each of these 
research objectives, there is immense scope for further development of the idea 
and investigating the outcomes. 
As in Chapter 3, the identification of the similar protein coding transcripts was done 
using the amino acid sequence, secondary and super-secondary structures. 
However, various other attributes of the proteins could also be added to this 
comparison to make it comprehensive. Some of the features of the proteins that 
should be included in the comparison are charge of the proteins, stability, 
degradation, and half-life. The protein charge can be calculated from the 
assessment of the charged amino acids in the protein and will play a vital role in the 
function of the protein by allowing or preventing certain interactions [26, 27]. 
Protein stability is another important feature that can contribute to assessing the 
similarity between the proteins. Through various computational approaches, 
protein stability can be predicted [28-30]. The degradation and half-life of the 
transcripts and proteins can further add important information on their life span in 
the cell and hence could be used to predict the expression at a given time [31, 32]. 
The functionality comparison could also be developed for the non-coding 
transcripts to assess the similarity of function across various non-coding transcripts. 
The similarity in function of the non-coding transcripts could be achieved by 
analyzing their share binding target motifs. 
Furthermore, the identification of the biomarkers from the transcriptomics data 
using ML for HCC is an in-silico study (Chapter 4) that needs a follow-up validation 
study. A population study to sequence healthy and HCC patients’ liver samples 
needs to be done. Targeted RNA-Seq such as TempO-Seq or Targeted Enrichment 
RNA-Seq should be performed to target the specific transcripts that are identified 
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as HCC biomarkers. Such a study would establish if the predicted transcript 
biomarkers for HCC are efficient in distinguishing the healthy and diseased states 
in the real-world scenario as well. 
Lastly, the work on the prediction of the protein complex’s assembly order as 
discussed in Chapter 5 can be developed further, first by refining the selection of 
the protein-complexes based on the information of stoichiometry, identifier 
mapping, and expression of the transcripts. Additionally, the use of FuSe, the tool 
developed in Chapter 3, to calculate the expression of the transcripts coding for the 
same or similar proteins, could further enhance the prediction of the protein 
complex's assembly order. Additionally, the current generation of the DBNs is 
based on connections between individual subunits over consecutive time points 
and these should be changed to the nascent protein complex that is defined by the 
subunits bound at each time point as predicted by DBN. It would mean that the 
DBNs should be computed iteratively by eliminating the first time point in each step 
and replacing the bound subunits with the nascent protein complex. These in-silico 
predictions should be made the basis for the electrospray mass spectrometry, co-
purification, co-crystallization, Yeast2Hybrid, and genetic interactions experiments 
to study the binding of proteins and hence the order of assembly of the complexes. 




Novel analyses and applications of the transcript expression data from RNA-Seq 
have been illustrated in this thesis. These studies provide an opportunity to further 
explore and understand biological complexities. Through the transcript-based 
analyses, the heterogeneity in the gene expression as obtained from RNA-Seq data 
and the ability of different transcripts to code for the same proteins are addressed. 
A transcript-based biomarker identification approach and a method to predict the 
protein-complex assembly order are presented. This work on transcript-based 
analyses of the RNA-Seq data provides another dimension to the data analyses and 
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The primary goal of the research is to add to the existing knowledge and deepen 
our understanding of a topic. The primary analysis of the RNA-Seq data is gene-
based, however, in this thesis, we showed that a transcript-based analysis approach 
produces better biological interpretations. At the same time, it allows for novel 
analysis of the RNA-Seq data generating new hypotheses and results. 
The study of comparison of different liver cell models through RNA-Seq data 
resulted in the generation of an exhaustive resource outlining the similarities and 
differences of the cell models to liver biopsies, as presented in chapter 2 (1). The 
cell models ex-vivo lose various in-vivo characteristics (2, 3). However, the 
unavailability of a comprehensive comparison restricted the assessment of the 
changes. A thorough study of the liver cell models through RNA-Seq data at the 
gene and transcript level illustrated the need for moving to a transcript-based 
approach. The biological changes in the cell models were highlighted with more 
precision using the transcript expression. The data generated through this 
comparison will be beneficial in selecting the cell models for specific research 
questions – what pathways, processes, and/or traits are of interest? Using the 
comparison data available, informed decisions can be made. This work can be used 
as a template to compare cell models from other tissues and cell types as well. A 
resource of cell models defining how similar or different they are to the in vivo 
systems would be helpful to perform better research. 
The knowledge of different transcripts originating from the same or different genes 
making the same protein always existed (4, 5). However, while analyzing the RNA-
Seq data the focus was always on evaluating the expression of individual genes or 
transcripts. The assimilation of this concept of the same protein from different 
transcripts to the RNA-Seq data analysis resulted in the creation of FuSe (6). 
Through this approach, the RNA-Seq data analysis provided more information on 
the dynamics of the biological system. However, various layers of regulation are 
involved in making a protein from the mRNA, the grouped expression calculation 
gives the preliminary protein expression estimates. This can be used as a starting 
point to accommodate other regulations and reach to the protein expression 
values. The work emphasized that the biological systems try to achieve homeostasis 
by producing different transcripts that code for the same proteins. The changes in 
the type and expression of these transcripts can be attributed to the internal or 
external environment. The identification of such transcripts that are involved in 
coding for the same proteins calls for studying their evolutionary relationships. 
Impact 
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Using machine learning (ML) approaches with the transcript expression data novel 
potent transcript biomarkers were identified (7, 8). The study focused on various 
HCC cell models and presented a group of protein coding and non-coding 
transcripts as the potent biomarkers for detection of HCC. The inclusion of non-
coding transcripts in the biomarker discovery results emphasized their underlying 
role in disease progression. The added advantage of using transcripts is that they 
are produced before the proteins in the system and can help in the early detection 
of the diseases. The identification of the transcripts as biomarkers can have a major 
impact on future of biomarker research. Novel and more potent biomarkers can 
then be identified for diseases where early diagnosis is a major hurdle. 
Lastly, evaluating the expression of the protein complexes from the RNA-Seq data 
provided more functional assessment of the biological system. From an entity-
based analyses (gene or transcript), we could then define the amount of work 
achievable in the biological system. Additionally, the information of the assembly 
of the protein complexes elevated our understanding of the multi-molecule 
machinery and opened new doors for investigating novel drug targets. The 
application of dynamic Bayesian networks to the temporal RNA-Seq data helped in 
generating hypothesis for assembly of protein complexes. Though preliminary, this 
work has the capacity to control and eliminate various diseases occurring due to 
mis-assembly of the protein complexes. Moreover, information on the assembly 
would highlight the evolutionary information. What genes moved apart and what 
came closer over years of evolution (9). 
We demonstrated that the study of RNA-Seq data is no longer limited to evaluating 
genes or transcripts. It can be used to assess the amount of protein that can be 
formed in the biological system, present transcripts as potent disease biomarkers, 
can help elucidate protein complex assembly and more. 
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